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ABSTRACT 
 
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human 
malignancies, with a mean survival of only 6 months. Therefore, novel 
therapeutic approaches are desperately required.  
- dl1520 is a  replication competent adenovirus that, due to lack of a functional 
E1B-55kD gene, can complete its life cycle solely in tumoural cells. We 
previously demonstrated that dl1520 efficiently kills ATC cells, but high 
multiplicity of infection (MOI) are required to obtain a significant 
antineoplastic effect. One of the major limiting factor in the efficient 
adenoviral transduction is the presence on cell surface of CAR receptor. 
Inhibition of the Raf/MEK/ERK pathway up-regulates CAR expression in 
cancer cells, thus improving adenoviral entry and cell killing by adenoviral 
mutants. To enhance its oncolytic activity, we decided to combine dl1520 with 
lovastatin, a drug that, blocking mevalonate synthesis, inhibits Raf/MEK/ERK 
pathway. However, lovastatin does not up-regulate CAR levels but, acting on 
viral genes expression, enhances viral replication. Indeed, lovastatin enhances 
in vitro and in vivo dl1520 effects, thus suggesting its potential role as dl1520 
adjuvant in ATC therapy. 
- A common feature of anaplastic thyroid carcinoma is represented by 
aneuploidy. Aberrant expression of Aurora B occurs in solid tumours and it is 
associated with chromosome instability and carcinogenesis. Therefore, Aurora 
B expression has been evaluated in cell lines and samples from human thyroid 
carcinoma, showing that its expression paralleles the malignant phenotype. To 
establish a molecular target for ATC, Aurora B expression has been inhibited 
by RNAi or a specific inhibitor, showing that Aurora B inhibition blocks cell 
proliferation and cell survival.  
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1. BACKGROUND 
THYROID CARCINOMA 
Thyroid cancers originating from follicular cell epithelium include 
papillary thyroid carcinoma, follicular carcinoma, and anaplastic thyroid 
carcinoma (ATC). Well differentiated thyroid carcinomas (WDTC: papillary 
and follicular) account for 80-85% of all thyroid carcinomas while ATC 
accounts for a small fraction (1-7%). Despite the small percentage, ATC is 
responsible for more than half of the 1200 deaths per year attributed to thyroid 
cancer (Ain et al. 1998).  
At molecular level, papillary carcinoma presents an high percentage of 
rearrangements of RET gene and/or B-RAF mutations (Grieco et al. 1990, Xu 
et al. 2003) while follicular carcinomas frequently show RAS genes activating 
mutations (Suarez et al. 1990) and PAX 8-PPAR-1 rearrangements (Kroll et al. 
2000). Alterations of the p53 tumour suppressor gene and beta-catenin are a 
peculiar feature of anaplastic carcinomas (Ito et al. 1992, Garcia Rostan et al. 
1999, Nikiforov et al. 2004).  
Several studies have documented a series of molecular abnormalities 
associated with the progression of normal to benign to well-differentiated to 
anaplastic thyroid carcinoma. The evidences available so far suggest that the 
early stages of thyroid cancer development may be the consequence of the 
activation of proto-oncogenes or growth factor receptors, such as gsp, ras, ret, 
and the thyrotropin (TSH) receptor. Inappropriate expression of these genes is 
associated with the development of neoplasms ranging from benign toxic 
adenomas (TSH receptor), to differentiated follicular (ras, B-Raf) and papillary 
(met, NTRK, ret, PAX8-PPAR1) carcinomas. In contrast, alterations in tumour 
suppressor genes such as p53 or Rb are solely observed in poorly differentiated 
forms of thyroid cancer, suggesting that they represent relatively late genetic 
events (Segev et al. 2003).  
Usually, thyroid cancer is a well treatable disease with a good 
prognosis. Current therapeutic protocols include surgery to remove the thyroid 
gland in part or totally, followed, if necessary, by application of 131I. This 
radioisotope is accumulated in remnant or even disseminated thyrocytes by the 
thyroidal sodium/iodide symporter (NIS) and destroys them by internal 
radiation. Another widely used therapeutic measure is the administration of 
thyroxine (T4) to suppress the production of the thyrotrophic growth factor 
TSH via hypothalamic and hypophyseal feedback; this aims to reduce the 
proliferation rate of residual thyroid tissue or metastases. In contrast, external 
radiation or chemotherapy, being less potent, are of minor importance 
(Schmultzler and Koehrle 2000). 
These therapeutic measures are so far the only ones with proven 
efficiency and prognostic relevance. They are successfully applied for WDTCs 
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but they are unsuccessful for anaplastic thyroid carcinoma, that is one of the 
most malignant solid tumour in the human body, leading to death within a few 
months after diagnosis.  
 
THERAPEUTIC APPROACHES FOR ATC 
The individual failure of all modalities in the management of anaplastic 
thyroid carcinoma has prompted the application of multimodality regimens, 
with old and new drugs in different combinations, including vascular targeting 
agents (in table 1, VTA), histone deacetilase inhibitors (HDACI), PPARgamma 
agonist (PPARγA), reverse transcriptase inhibitors (RTI) and farnesyl-
transferase inhibitors (FTI). These approaches are summarized in table 1. 
 
Table 1 – Novel therapeutic approaches for anaplastic thyroid carcinoma 
Class of 
drug Drug 1 Drug 2 Drug 3 Effect 
In vitro/ 
in vivo Reference 
VTA anti VEGF2 Irinotecan or Paclitaxel / No potentiation Both 
Kim et al. 2006, 
Gomez-Rivera et 
al. 2007 
VTA anti EGF / / / Both Schiff et al. 2004 
VTA anti EGF anti VEGF Doxorubucin Potentiation Both Prichard et al.  2007 
VTA anti EGF/VEGF Paclitaxel / Synergistic Both Kim et al. 2005 
VTA Combretastatin A4 / / / Both 
Randal et al. 
2000, Dowlati et 
al. 2002 
VTA Combretastatin A4 
Manumicin or 
Carboplatin Paclitaxel Synergistic 
 
Both Yeung et al. 2007 
VTA Combretastatin A4 / / / 
One patient still 
alive after 36 
months 
Randal et al. 2000 
VTA Fumagillin / / / Both Hama et al. 1997, Nahari et al. 2007 
HDACI Trichostatin A / / / In vitro Greenberg et al. 2001 
HDCAI Sodium butyrate / / / In vitro Greenberg et al. 2001 
HDACI Acid valproic Doxorubicin / Potentiation In vitro Catalano et al. 2006 
HDACI Acid valproic Paclitaxel / Potentiation In vitro Catalano et al. 2007 
HDACI SAHA / / / Both 
Mitsiades et al. 
2005, Luong et al. 
2006 
HDACI Depsipeptide (FR901228) P53 gene therapy / Potentiation In vitro 
Kitazono et al. 
2001, Imanishi et 
al. 2002, Furuya 
et al. 2004 
PPARγA RS5444 Paclitaxel / Potentiation Both Copland et al. 2006 
RTI nevirapine / / Differentiation Both Landriscina et al. 2005 
RTI efavirenz / / Differentiation Both Landriscina et al. 2005 
RTI nevirapine / / 
Restore of 
radioiodine uptake in 
distal metastatic 
One patient Modoni et al. 2007 
FTI Manumycin A Paclitaxel / Synergistic Both Xu et al. 2001, Yeung et al. 2007 
FTI Manumycin A Paclitaxel Minocycline Synergistic Both She and Jim 2006 
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Some of these agents have been proposed for different lesions, such as 
vascular targeting agents, that seek to starve the tumour by inhibiting 
angiogenesis, or farnesyltransferase inhibitors, that act on genes (e.g. Ras) 
frequently mutated in tumours. Others agents are more specific for ATC, since 
they seek to redifferentiate thyroid tumours, at least to such a degree that 
established treatment protocols, especially radioiodine therapy, may be 
applicable again. The classification is not so strict, indeed some drugs, initially 
designed as antineoplastic agent, can also induce differentiation, and therefore 
be used to restore sensitivity to radioiodine uptake.  
GENE THERAPY 
Another proposed approach for ATC treatment is gene therapy. Gene 
therapy seeks to treat cancer by introducing genes that will result in destruction 
of the tumour from within or will enhance an immune response against it. 
Viruses are frequently chosen as vehicles for such genes because they have 
evolved very efficient mechanisms of gene transfer (transduction) and 
expression. For safety reasons, such virus vectors are generally replication-
defective but, unfortunately, this limits the efficacy of treatment by restricting 
the number of cells the therapeutic gene is delivered to (reviewed by Walther 
and Stein 2000). For this reason, the use of replication-competent viruses has 
been proposed. There are 3 general mechanisms used to achieve tumour 
selective viral replication: 
1) deletion of viral genes that are dispensable upon infection of neoplastic 
cells but are critical for viral replication in non neoplastic cells, 
2) placement of tumour specific promoters upstream of viral genes that are 
critical for efficient viral replication, 
3) delivery of virus entry into cells based on the expression of antigens 
that are unique or overexpressed on the tumour cell surface. 
It is worth to note that the replication of these viruses results in lysis of the host 
cells with amplification of the “input dose”, since the infection continues until 
abrogated by an immune system response or a lack of susceptible cells. 
Consequently, oncolytic viral therapy is capable of increasing the therapeutic 
index between tumour cells and normal cells when viral replication proceeds 
preferentially in tumour cells.   
The role of immune system is controversial. Oncolytic viruses can be 
administered locally, by direct intratumoural inoculation, or systemically, by 
intravascular administration. The immune system could antagonize the 
effectiveness of oncolytic viruses administered intravascularly by limiting viral 
delivery to the tumour while, on the other hand, once the virus has reached its 
target and begins replicating within and destroying tumour cells, the immune 
response can theoretically augment tumour reduction by redirecting the 
cytotoxic T lymphocytes response from viral antigens to tumour antigens, also 
against distal metastasis. In fact, viruses administered by direct intratumoural 
inoculation elicit a systemic immune response that prevents tumour formation 
and causes regression of existing tumours at distant sites (Todo et al. 1999). 
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These data suggest that the best targets for replication competent viruses are 
locally advanced cancers, such as glioblastoma, ovarian cancer, head and neck 
cancer and anaplastic thyroid carcinoma. 
Gene therapy for anaplastic thyroid carcinoma  
Several approaches of gene therapy have been studied for poorly 
differentiated and anaplastic thyroid carcinomas, such as differentiating 
therapy to restore radioiodine uptake (see Spitzweg and Morris 2001), suicide 
therapy, replication selective viruses.  
In suicide gene therapy, gene transfer is used to introduce into the 
tumour a vector coding for a `sensitising enzyme'. A chemotherapeutic agent is 
then applied as a non-toxic prodrug, which is activated only in those cells that 
express the sensitising enzyme. The most widely used system for suicide 
therapy is the prodrug ganciclovir (GCN) together with herpes simplex virus 
type 1 thymidine kinase (HSV1-TK). GCN is a nucleotide analogue, and 
HSV1-TK, in contrast to normal mammalian TK, preferentially phosphorylates 
GCN. Monophosphorylated GCN is then converted to its triphosphate by 
cellular kinases and interferes with cell propagation by competition with 
normal nucleotides during replication. Growing cells will be destroyed 
preferentially, which limits the side effects on normal tissue. As the thyroid 
gland is a very slowly growing tissue, gene therapy using GCN and the TK 
gene might be a method of choice in this case. In 2005, Barzon et colleagues 
published the first report of gene therapy for ATC using suicide therapy. Two 
patients with end-stage anaplastic thyroid carcinoma were treated by direct 
intratumour injection of retroviral vector producer cells followed by 
ganciclovir. The retroviral vector carried the human IL-2 gene and the suicide 
gene thymidine kinase of herpes simplex virus type 1. Treatment was safe and 
associated with only mild adverse events. Radiological evaluation of injected 
tumour masses demonstrated local tumour necrosis.  
The most used replication defective viruses are adenoviral mutants; to 
better understand their function, I will briefly summarize their life cycle. 
The Ad genome is composed of a linear double-stranded DNA molecule of 
approximately 36 kb. Adenoviral infection of permissive cells involves two 
distinct virus–cell interactions. Cell surface attachment is mediated by binding 
of the knob domain of the viral fiber protein to the cellular coxsackie–
adenovirus receptor (CAR) (Bergelson et al. 1997; Tomko et al. 2000). 
Internalization, via receptor-mediated endocytosis, involves interactions 
between the Arg-Gly-Asp peptide sequence of the viral penton protein with the 
cellular avb3 and avb5 integrin receptors. Ad genes are transcribed in a 
complex temporal manner and have been divided into three groups: early, 
intermediate, and late (Fields 1996). Early viral gene expression commences at 
the E1 locus and includes gene products that promote entry into cell cycle. E1A 
binds members of the cellular pRb family. This interaction results in the 
displacement of Rb-bound E2F family members, that are then free to activate 
transcription of E2F-responsive genes involved in stimulating cell cycle 
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progression. The expression of E1A induces an apoptotic cellular antiviral 
response through p53-dependent and independent pathways. To circumvent 
premature cell death during viral replication, the viral E1B-55kD protein binds 
to and inhibits p53 (Yew and Berk 1992) while the E1B-19kD protein 
functions as a viral homolog of the cellular antiapoptotic factor Bcl2 (White 
1992). The remaining early regions encode proteins involved in viral DNA 
synthesis (E2), modulation of host immune response and cell lysis (E3), and 
regulation of viral gene expression, mRNA transport, DNA replication, and 
apoptosis (E4). The intermediate and late gene products encode viral structural 
proteins and proteins involved in virion assembly. 
A well designed replication competent virus is HILMI. As already 
mentioned, a sizable fraction of undifferentiated or poorly differentiated 
thyroid cancers were shown to contain mutations in beta-catenin, an oncogenic 
protein involved in the aetiology of cancers of many tissues. Abbosh et al. 
(2007) developed HILMI, a conditionally replicative adenovirus that, by virtue 
of TCF response elements, drives E1A and E1B expression and replicates 
specifically in cells with an active Wnt/beta-catenin pathway. Several thyroid 
cancer cell lines, derived from undifferentiated or anaplastic tissues, were 
susceptible to cell killing by HILMI. Furthermore, viral replication in ATC 
cells as xenograft tumours in nude mice was observed, and prolonged survival 
of mice with ATC tumours was observed following administration of the 
HILMI therapeutic vector. Clinical trial are now necessary to establish its 
therapeutical effect. 
Already studied in clinic is dl1520, the first replication competent 
adenovirus described. dl1520 (also called ONYX-015) contains alterations in 
the E1B-55kD gene, that result in complete abrogation of E1B-55kD protein 
expression (Bischoff et al. 1996). E1B-55kD binds and inhibits the p53 tumour 
suppressor protein, thereby inhibiting p53-dependent apoptosis and enabling 
the cell to enter the S phase of the cell cycle, a requirement for efficient 
replication of viral DNA. dl1520 lacks the ability to inactivate p53 and 
therefore it was expected to replicate only in cells lacking functional p53. This 
has generated considerable hopes for its clinical use, because more than 50% of 
tumours have a mutant TP53 gene and even more possess defects in one of the 
genes that modulate p53 expression (White 2006, Fulci et al. 1998, Fulci and 
Van Meir 1999). In spite of this early enthusiasm (Bischoff et al. 1996; Heise 
et al. 1997; Rogulski et al. 2000), there have been reports contradicting the 
mechanism of dl1520 selectivity based on findings that cells with a normal 
TP53 gene support its replication.  Recently, it has been shown that E1B-55K 
mediates late-viral RNA transport and dl1520 tumour-selective replication is 
determined by a unique property of tumour cells to efficiently export late viral 
RNA in the absence of E1B-55kD. Thus, loss of E1B-55kD-mediated late viral 
RNA export, rather than p53 degradation, is the major determinant of dl1520 
selective replication in neoplastic cells (Parato et al. 2005). 
The safety and antitumour efficacy of dl1520 have been tested in 
numerous phase I and II clinical trials with multiple tumour types and several 
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routes of administration (for a review, see Nemunaitis et al. 2007). In all cases, 
safety was demonstrated, with the most common associated toxicity being 
flulike symptoms. Although preclinical cancer models have demonstrated the 
antitumour capabilities of dl1520, there are few examples of complete tumour 
eradication. A multimodal cancer therapy approach utilizing oncolytic viruses 
in conjunction with chemotherapy or radiotherapy was the next logical step. 
Several studies in vitro and in vivo, utilizing various human tumour models, 
have demonstrated enhanced to synergistic effects of dl1520 in combination 
with different drugs (see table 2). Several mechanism can explain the 
augmented therapeutic effects of combined treatment:  
• the virus may be increasing the cell-killing effects of the drug 
sensitising cells to antineoplastic agents,  
• the drug may enhance virus replication, 
• the two different therapies may be acting on different cell populations 
within the tumour.  
dl1520 has also been used in conjunction with chemotherapeutic agents in 
clinical trials with evidence for potential synergistic antitumour activity (see 
table 2). It is worth to note that in all tested clinical approaches there is not a 
significant increase in toxicity compared with single treatment.  
 
                   Table 2- dl1520 plus chemotherapy  
Drug Effect/Comment Tumour type 
In vitro/ 
in vivo/ 
clinical trial 
Reference 
Cisplatin + 
paclitaxel Synergistic NSCLC In vitro You et al. 2000 
Doxorubicin Synergistic Thyroid In vitro Portella et al. 2002 
Paclitaxel Synergistic Thyroid In vitro Portella et al. 2002 
5-fluorouracil Enhanced HNSCC In vivo Heise et al. 1997 
5-fluorouracil Enhanced Colon In vivo Heise et al. 1997 
Cisplatin Enhanced HNSCC In vivo Heise et al. 1997 
5-fluorouracil 
+ cisplatin Enhanced HNSCC In vivo Heise et al. 2000 
5-fluorouracil 
+ cisplatin Enhanced Ovarian In vivo Heise et al. 2000 
5-fluorouracil 
+ cisplatin 
Enhanced, with no 
improved toxicity HNSCC Phase II 
Khuri et al. 2000, 
Lamont et al.  2000 
leucovorin and 
5-fluorouracil 
Enhanced, with no 
improved toxicity 
gastrointestinal carcinoma 
metastatic to the liver Phase II Reid et al. 2002 
gemcitabine Enhanced, with no improved toxicity 
unresectable pancreatic 
carcinoma Phase I/II Hecht et al. 2003 
 
Finally, in November 2005, China approved world’s first oncolytic 
virus therapy for cancer treatment, with Shanghai Sunway Biotech’s 
genetically modified adenovirus H101.  This virus is considered the Chinese 
version of dl1520, being the only difference between the two viruses a slightly 
larger deletion in H101’s E3 gene, which affects immune response. In its phase 
III trial, Sunway reported a 79% response rate for H101 plus chemotherapy, 
compared with 40% for chemotherapy alone (Yu and Fang  2007). 
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We have previously demonstrated an antineoplastic activity of dl1520 
against ATC cell lines (Portella et al. 2002, Portella et al. 2003). It is worth to 
note that high multiplicity of infection (MOI) were used in these previous 
studies, highlighting the need to enhance viral transduction in order to obtain a 
significant killing effect. CAR receptor is a major limiting factor in the 
efficient transduction of tumour cells, since it is not ubiquitously expressed and 
many tumour types exhibit variable levels of CAR expression (Bergelson et al. 
1997; Fechner et al.  1999; Tomko et al. 2000). Moreover, recent observation 
suggest that expression of this receptor, that physiologically participates in 
formation of cell-cell adhesion, is frequently reduced in highly malignant 
cancer cells. This raises the possibility that those tumours representing the 
greatest therapeutic challenge might be the least susceptible to infection with 
oncolytic adenovirus. It has been reported that treatment of cells with histone 
deacetilase inhibitors up-regulates CAR and αv integrin levels, increasing the 
number of infected cells and the antitumour effect of the replicant selective 
adenovirus OBP-301 (Kitazono et al. 2001, Goldsmith et al. 2003, Watanabe et 
al. 2006). Anders et al. (2003) showed that inhibition of the Raf/MEK/ERK 
pathway up-regulates CAR expression in cancer cells, thus improving 
adenoviral entry and cell killing by dl1520. To enhance viral transduction, we 
decided to combine dl1520 with lovastatin, a statin that, acting on mevalonate 
pathway, behaves as Raf/MEK/ERK pathway inhibitor. 
Statins as antineoplastic drugs 
Increasing evidences suggest that statins might be useful for cancer 
treatment. Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors, are commonly-used drugs for the treatment of 
hypercholesterolemia. They act inhibiting the rate-limiting step of the 
mevalonate pathway, that is the conversion of HMG-CoA to mevalonate, 
catalyzed by HMG-CoA reductase. They have a marked beneficial action on 
the lipid profile but also have effects unrelated to lipid reduction, since 
mevalonate is precursor not only of cholesterol but also of dolicol, ubiquinone 
and prenylic groups (geranyl-geranylpyrophospate GPP and 
farnesylpyrophosphate FPP). Geranylgeranyl transferase and farnesyl 
transferase use GPP and FPP, respectively, for posttranslational modifications 
of cellular proteins. These include Ras, nuclear lamins, and many small GTP-
binding proteins such as members of the Rab, Rac, and Rho families. Indeed, 
to be active, some proteins must first undergo prenylation to properly associate 
with the plasma membrane. This association is achieved by the addition of a 
farnesyl (e.g., Ras) or a geranylgeranyl moiety (e.g., Rho) to the COOH 
terminus of the proteins. Blockade of mevalonate pathway results in decreased 
levels of all its downstream products and, thus, may have significant influences 
on many critical cellular functions, such as cell proliferation, differentiation 
and migration (Chan et al. 2003). Indeed, in vitro and in vivo studies have 
demonstrated that statins inhibit tumour growth, induce apoptosis or decrease 
metastatic potential in a variety of tumour cells, including melanoma 
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(Shellman et al. 2005), glioma (Koyuturk et al. 2004), neuroblastoma (Girgert 
1999), leukemia (Dimitroulakos et al. 2000), breast  (Koyuturk et al. 2007) and 
pancreatic cell lines (Kusama et al. 2001). Additionally, several clinical trials 
have also assessed the antitumour activity of statins (for a review, see Hindler 
et al. 2006). Moreover, increasing evidence suggest that statins might enhance 
the antitumour activity of various chemotherapeutic agents (see table 3).  
 
Table 3 – Statin for the treatment of cancer: summary of human clinical trials 
Drug No. of patients Type of cancer Result Reference 
Fluvastatin 12 Pediatric tumours 
22 months’ survival of two patients 
with anaplastic astrocytoma 
Lopez-Aguilar 
et al. 1999 
Pravastin + 
fluorouracil 91 
Advanced 
hepatocellular 
carcinoma 
Median survival rate: 18 months in 
the statin group vs. 9 months in the 
control group (p < .006) 
Kawata et al. 
2001 
Lovastatin 1 
Acute 
myeloblastic 
leukemia 
Statin therapy leads to an apparent 
control of the leukemic blast cells 
Minden et al. 
2001 
Pravastastin 58 Hepatocellular carcinoma 
Median survival rate: 7.2 months in 
the statin group vs. 5 months in the 
octreotide group and 3.5 months in 
the gemcitabine group 
Lersch et al. 
2004 
Statin and 
neoadjuvant 
chemoradiation 
349 Non metastatic rectal cancer 
Complete response rate: 30% in the 
statin group vs. 17% in the control 
group (p= .10) 
Katz et al. 
2005 
Lovastatin 26 HNSCC Stable disease in 23% of the patients Knox et al. 2005 
 
It is important to note that recent study by Wang et al. (2003) has 
shown that at a higher dose (50microM) lovastatin induces apoptosis of ATC 
cells, whereas at a lower doses (10-25microM) it promotes 3-D 
cytomorphological differentiation and increases secretion of thyroglobulin, a 
differentiation marker of thyrocytes. These data have further encouraged us to 
evaluate the effects of the combined treatment . 
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To treat anaplastic thyroid carcinoma it is also important to identify novel 
therapeutic targets. To this purpose, we focused our attention on Aurora B 
kinase, that belongs to Aurora kinase family genes.  
AURORA KINASES  
Mitosis is an extraordinary complex biological process, by which a 
complete copy of the duplicated genome is precisely segregated into two 
daughter cells. All mitosis phases are strictly controlled by phosphorylation 
events performed by several evolutionary conserved serine/threonine kinases, 
known as mitotic kinases, such as cyclin-dependent kinases, NIMA-related 
kinases and Aurora-Ipl1 related kinases. Three paralogues of Aurora kinases 
are present in mammals: Aurora A, Aurora B and Aurora C. These are very 
similar in sequence, in particular within the carboxyterminal catalytic domain, 
in which human Aurora A and B share 71% identity. However, the three 
Auroras differ in the length and sequence of the amino-terminal domain and 
have very distinct expression patterns, localizations, functions. Aurora-A 
kinases are associated with centrosomes and are involved in their positioning, 
recruitment of components at the forming mitotic spindle and microtubules 
stability while Aurora B and Aurora C are chromosomal passenger proteins. 
Moreover, Aurora A and Aurora B are expressed ubiquitously while Aurora C 
is expressed only in testis.  
The genes encoding the three human Aurora kinases map to regions that 
are affected by chromosomal abnormalities in different cancer types, and 
overexpression of each of the three human Auroras has been detected in 
tumour cell lines (Carmena and Earnshaw 2003). 
Aurora B  
The Aurora B gene lies on human chromosome 17p13 and codifies for a 
41KDa serin-treonin kinase. Aurora B expression and activity in proliferating 
tissues are cell cycle regulated: expressions peaks at G2-M transition and 
kinase activity is maximal during mitosis. 
Aurora B is a one of the component of the Cromosomal Passenger 
Complex. The CPC proteins show a very dynamic localization during mitosis 
that gave them their name (Earnshaw and Bernat, 1991): they initially paint the 
entire chromatin during the onset of mitosis, move from the chromosome arms 
toward the inner centromeric chromatin (in between the kinetochores, the sites 
of microtubule attachment)during prometaphase, relocalize to the microtubules 
of the central spindle at the metaphase–anaphase transition, and finally 
concentrate at the midbody during telophase/cytokinesis. This localization 
correlates with the diverse functions of the CPC during mitosis: modifying 
histones at the chromatin, correcting misattachments while at the centromere, 
and regulating cytokinesis at the central spindle (and later midbody). Given the 
correlation between localization and function, it is apparent that timely and 
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proper localization of the CPC is the key to allowing Aurora-B to exert its 
diverse functions during mitosis (Vader et al. 2006). 
The CPC can be regarded as a complex in which the binding of a 
nonenzymatic protein to its enzymatic partner is essential for functioning of the 
kinase. The CPC contains three nonenzymatic subunits, all of which are 
essential for the activity, localization, stability, and substrate specificity of 
Aurora-B. In human cells, these non enzymatic subunits are Survivin, the inner 
centromere protein (INCENP), and Borealin. Recent evidence suggests that 
two distinct passenger complexes exist during mitosis: one containing all four 
CPC members and another consisting of INCENP and Aurora-B (Gassmann et 
al. 2004). Of these two complexes, the quaternary CPC functions during 
chromosome alignment and cytokinesis, whereas the INCENP–Aurora-B 
complex might be responsible for modifying Histone H3 (Gassmann et al., 
2004). Aurora-B is a histone kinase, a spindle checkpoint kinase and a 
cytokinesis kinase. 
Histone kinase - Aurora-B is responsible for the mitotic phosphorylation of not 
only the celebrated Ser10 residue in the tail of histone H3 but also of Ser28 in 
H3 and of Ser7 in CENP-A. These phosphorylation events are thought to be 
necessary for chromosome condensation, although the only direct evidence 
comes from Tetrahymena. It is quite likely, however, that these 
phosphorylations might only initiate the recruitment of condensation and 
segregation proteins on chromosomes (Goto et al. 2002).  
Spindle checkpoint kinase - Aurora-B phosphorylates, inactivating and targeting 
it to the kinetochores, the microtubule depolymerase MCAK (mitotic 
centromere-associated kinesin). MCAK can then be locally activated by a 
phosphatase, presumably PP1, to correct any incorrect kinetochore attachments 
to the spindle. In the absence of Aurora-B, MCAK does not localize to 
kinetochores and incorrect attachments persist (Andrews et al. 2004).  
A speculative model postulate that the dynamic interplay between Aurora B, 
MCAK and PP1 could constitute a phosphorylation-dependent tensiometer. 
The key to this model is a dynamic, metastable localization of Aurora B. The 
asymmetric localisation of Aurora B on the centromere axis results in 
asymmetric phosphorylation of factors that promote microtubule dynamics, 
such as MCAK, causing asymmetric force production and thus directional 
movement of the chromosome. A force-balanced stationary chromosome can 
occur only transiently, unless Aurora B localization becomes fixed between the 
middle of centromeres or the its kinase activity is inhibited. At anaphase, 
Aurora B leaves the centromere and force generation can proceed unhindered 
(Giet et al. 2005). 
Cytokinesis kinase – Phosphorylation has a dramatic effect on intermediate 
filament stability and some intermediate filaments participating in cleavage 
furrow dynamics, such as vimentin, desmin, myosin II, are Aurora B 
substrates. For instance, Aurora-B phosphorylates Ser72 in vimentin: in the 
absence of Ser72 phosphorylation, the two daughter cells remain associated 
through long bridges of cytoplasm, and cytokinesis fails (Goto et al. 2003). 
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Moreover, Aurora-B also phosphorylates MgcRacGAP, a GTPase-activating 
protein (GAP) required for cytokinesis. Phosphorylation in Ser387 occurs in 
the midbody and activates its GAP activity towards RhoA. MgcRacGAP and 
RhoA seem to regulate cortical movement during cytokinesis (Minoshima et 
al. 2005)  
Aurora B and cancer  
Aurora B is involved in chromosome segregation, spindle-checkpoint 
and cytokinesis, and alteration of each of these steps could induce aneuploidy, 
that is one of main feature and driving force of cancer cells. 
In vitro studies performed with several Aurora B inhibitors/dominant 
negative/RNAi, show that Aurora B deficiency interfere with cell cycle. 
Treated cells cannot divide after mitosis and become tetraploidy, with 2 
centrosomes. Moreover, cells expressing catalytically inactive Aurora B do not 
arrest in mitosis in the presence of nocodazole or taxol, underling a role for 
Aurora B in mitotic checkpoint. These observations concur with Aurora B 
presumed roles: spindle checkpoint suppression let cells go on mitosis, despite 
many of the chromosome are oriented in a syntelic manner (both kinetocore 
attached to the same pole) while the missed fosforilation of clivage furrow 
components prevents the cytokinesis. The effects of longer depletion of Aurora 
B seem to be cell line dependent. Some cells either enter additional cell cycles 
but, because of cell division failure, they become massively  polyploidy, 
whereas others undergo apoptosis or arrest in a pseudo G1 state. These 
different fates are probably not a reflection of differing requirements for 
Aurora-kinase activity in these cell lines, but rather of the status of the p53-
dependent post-mitotic checkpoint (Margolis et al. 2003). Briefly, it seems that 
p53 can also respond to a failed cell division by inducing a G1-like arrest 
following an abnormal mitosis. In this manner, p53 might act as a ‘back-up’ to 
the spindle-checkpoint system to prevent the propagation of cells with an 
abnormal genome. Consistently, p53 is required to prevent endoreplication in 
U2OS cells following exposure to the Aurora inhibitor ZM447439 (Ditchfield 
et al. 2003).  
One report from Ota et al. (2002) strongly suggests a direct link 
between Aurora B and carcinogenesis. The authors transfected Chinese 
hamster embryo (CHE) cells, carrying wild type p53 or a G245S mutation in 
both allele of p53 (CHEp53-/-), with Aurora B. The mutation in p53 abrogates 
the p53-dependent G1 checkpoint. Stable clones overexpressing Aurora B were 
isolated and injected in nude mice. Notably, the authors could use only 
CHEp53-/- tranfected cells, since they could not isolate any stable clone from 
CHE with wt p53. Nontransfected cells induce tumours when injected in nude 
mice, but they don’t metastasize whereas mice injected with Aurora B 
overexpressing CHE p53-/- cells formed more aggressive tumours that, also, 
developed metastases. In a recent paper, Kanda et at. (2005) showed that, 
although Aurora B overexpression is not oncogenic in BALB/c 3T3 A31-1-1 
cells, Aurora-B kinase activity augments Ras-mediated cell transformation, 
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suggesting that the overexpression of Aurora-B may contribute to the 
generation of a transformed phenotype, by potentiating oncogene activity 
during carcinogenesis. 
Aurora B expression has been studied in different human cancer and it 
has been shown that its expression directly correlates with malignancy in 
several human cancers, such as non small cell lung carcinoma (Smith et al. 
2005, Vischioni et al. 2006), mesothelioma (Lopez-Rios et al. 2006), 
glioblastoma (Araki et al. 2004, Zeng et al. 2007), oral cancer (Qi et al. 2007) 
and hepatocellular carcinoma (Kurai et al. 2005). In previous papers, we have 
demonstrated that Aurora B is overexpressed in seminoma (Chieffi et al. 2004) 
and that Aurora B expression directly correlates with Gleason grade in prostate 
cancer (Chieffi et al. 2006). 
Despite the established role of Aurora B in different types of cancers, 
information regarding its expression in normal and neoplastic thyroid are very 
limitate. A recent paper by Ito et colleagues (2003) demonstrated that survivin 
expression is significantly linked to the dedifferentiation of thyroid carcinoma, 
being survivin expression low in normal tissue, stronger in papillary and 
follicular carcinomas and very strong in anaplastic thyroid.  
This observation, the high aneuploidy of thyroid carcinoma and the 
availability of specific inhibitors led us to analyse the expression of  Aurora B 
in  anaplastic thyroid carcinoma. 
Aurora kinases inhibitors represent a novel and interesting class of 
drugs with a broad therapeutic index. Indeed, Aurora kinases are only 
expressed and active during mitosis, therefore non-proliferating cells would not 
be adversely affected by these drugs. Furthermore, cells lacking a p53-
mediated post-mitotic checkpoint are highly responsive to Aurora(s) inhibition. 
Clinical trial will be soon underway to test the effect of Aurora-kinase 
inhibitors in patient with cancer, animal studies suggest that the major side 
effect is neutropenia, dose depending and reversible.  
Anaplastic thyroid carcinoma are characterized by high incidence of 
p53 mutation, therefore Aurora B could represent a novel therapeutic target  for 
the treatments of this dismal disease.  
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2. AIMS OF THE STUDY 
 
Novel therapeutic approaches are desperately required for anaplastic 
thyroid carcinoma, that is one of the most aggressive human neoplasia.  
We have previously demonstrated that the oncolytic adenovirus dl1520 
is active against ATC cells and tumour xenografts, although a high viral 
multiplicity of infection are required. In the present thesis, I have decided to 
evaluate whether the combination of dl1520 with lovastatin, a drug that blocks 
mevalonate pathway, could enhance viral cell killing activity . 
Aneuploidy is a common feature of anaplastic thyroid carcinoma and 
the serine threonine kinase Aurora B is involved in chromosomal instability. 
Therefore, I have decided to evaluate the expression levels of Aurora B in ATC 
cell lines, experimental models of thyroid carcinogenesis and human samples, 
validating Aurora B as potential therapeutic target. 
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3. MATERIALS AND METHODS 
Cell lines  
See Sorrentino et al., 2005 and Libertini et al., 2007 
Plamids, transfections, Aurora B inhibitor  
PCMV-AurB construct was obtained as follows: mRNA from human testis 
(Clontech, USA) was  reverse transcribed using random hexamers as primers 
and MuLV reverse transcriptase (Applied Biosystems, Foster City, CA) to yeld 
cDNA. The forward: 5'CTCTGGATCCATGGCCCAGAAGGAGAAC3'; and 
the Reverse: 5'ACAGGGATCCTCAGGCGACAGATTGAAG3' primers were 
used to amplify the human Aurora B gene (Accession: NM 004217). The PCR 
product was cloned into the Bam H1 site of the pcDNA His-tagged (Invitrogen 
Life Technologies).The pCMV-AurB sense and antisense constructs were 
obtained by inserting the Aurora B cDNA in both sense and antisense 
orientation in the pCMV vector under the trascriptional control of the 
cytomegalovirus promoter. The vector also carries the gene for G418 
resistance. The transfection was performed according to the calcium phosphate 
transfection protocol. After 36 hours, the cells were tripsinized and expanded, 
stable transfectants were generated after selection with 400 µg/ml geneticin 
(G418) (Life Technologies, Italy). Five and six independent clones were 
isolated from pCMV-AurB sense and antisense and from control transfections, 
respectively. The integration of the contruct was confirmed by Southern blot 
assay. In pCMV-AurB antisense transfected clones a decreased synthesis of 
Aurora B protein was confirmed by Western Blot. Clones carrying sense or 
antisense plasmid were then selected for further experiments. 
For the synthesis of Aurora kinase inhibitor was followed the methodology 
described elsewhere. The quinazolin derivative: N-[4-(6,7-dimethoxy-
quinazolin-4-ylamino)-phenyl]-benzamide was dissolved in DMSO  at a 
concentration of 10mM. 1x103 ARO cells were plated in a 96 well plate and 
after 24 hours the cells were treated with 5, 10, 15 μM  of the inhibitor. Cell 
proliferation was evaluated after 24 and 48 hours by using the Cell Titer 96 ® 
Aqueous cell proliferation assay (Promega). Soft agar colony assays were 
performed according to a previously described technique. 
RNA interference and transfection of RNA Oligonucleotides 
For design of siRNA oligos targeting Aurora B, the sequence AAG 
GAGAACUCCUACCCCUGG (RNAi) was selected, corresponding to the 
nucleotides located 67-87 bp of the human Aurora B gene.  As a control of 
siRNA oligo, the following aspecific sequence was used AAG GUC CCC 
AUC CUC AAG AGG (RNAc). The siRNAs were purchased from Pharmacon 
Research (USA). Approximately, 6*10 5cells were plated per 6-well plate in 
media containing 10% fetal bovine serum to give 30–50% confluence. 
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Transfection of the RNA oligonucleotides was performed after 24 hours to 
result in a final RNA concentration of 200nM. Transfections were performed 
by Oligofectamine (Invitrogen, Carlsbad, CA). 
Preparation of adenoviruses and adenovirus infection 
dl1520 (ONYX-015), a gift from Dr. A. Balmain and Dr I. Ganly, is a 
chimaeric human group C adenovirus (Ad2 and Ad5) that has a deletion 
between nucleotides 2496 and 3323 in the E1B region that encodes the 55-kDa 
protein. In addition, there is a C to T transition at position 2022 in region E1B 
that generates a stop codon at the third codon of the protein. Viral stocks were 
expanded in the human embryonic kidney cell line HEK-293 (American Type 
Culture Collection) and purified as previously reported. Stocks were stored at -
70°C after the addition of glycerol to a concentration of 50% vol/vol. Virus 
titre was determined by plaque-forming units (pfu) on the HEK-293 cells. 
Cells were detached, counted, and plated in 6 well plate at 70% cell density. 
After 24 hours cells were infected with AdGFP, a non replicating E1 and E2-
deleted adenovirus encoding green fluorescent protein, diluted in growth 
medium at different MOIs, medium was replaced after 2 hours. Cells were 
washed 24 hours after infection, then trypsinised, washed, and resuspended in 
300μl of PBS and analyzed for GFP expression on a FACS cytometer (Dako 
Cytomation, U.S.A.) and Summit V4.3 software (Dako). 
For the evaluation of lovastatin effects on adenoviral entry and GFP 
expression, the cells were treated for 16h with 10 μM lovastatin and then 
infected for 24 h with AdGFP. Cells were harvested and prepared for FACS 
analysis as previously described. For the evaluation of the cytoxic effects of the 
dl1520 virus, 1 x103 cells were seeded in 96-well plates, and 24 hours later 
lovastatin was added to the incubation medium. After additional 16 hours, 
medium was replaced with a medium containing or not lovastatin plus dl1520 
at different MOIs. After 14 days, the media were fixed with 50% TCA and 
stained with 0.4 % sulforhodamine B in 1% acetic acid. The bound dye was 
solubilised in 200 μl of 10 mM unbuffered Tris solution and the optical density 
was determined at 490 nm in a microplate reader (Biorad). The percent of 
survival rates of treated cells were calculated by assuming the survival rate of 
untreated cells to be 100%. 
Quantitative PCR of dl1520 
To quantify the amount of dl1520 virus genome upon lovastatin treatment, 
ATC cells were treated with 10μM lovastatin for 16 hours and then media 
replaced with a medium containing different MOIs of dl1520 alone or with 
lovastatin. After  24 hours of infection, cell media were collected and viral 
DNA extracted using a QIAamp DNA mini kit (Valencia, CA, USA).  Viral 
DNA  was then  quantified by Real-Time PCR using assay-specific primer and 
probe. A Real Time-based assay was developed using the following primers: 
5'-GCCACCGAGACGTACTTCAGCCTG-3' (Upstream primer) and 5'-TTG 
TAC GAG TAC GC G GTA TCCT-3' (Downstream primer) for the 
 23
amplification of 143 bp sequence of the viral hexon gene (from bp 99 to 242 
bp). For quantification, a standard curve was constructed by assaying serial 
dilutions of dl1520 virus ranging from 0.1 pfu to 100 pfu.  
To quantify the amount of dl1520 virus genome in tumour xenografts, total 
DNA was extracted from 20 mg of each sample using a DNA Purification 
System (Promega Corporation, Madison,WI, USA).  DNA was resuspended in 
200 μL of water and 2 μl used for the Real Time PCR-based assay. For each 
experiment the DNA was extracted from three different samples of each 
treatment group. 
Quantitative RT-PCR of dl1520 gene expression 
Cells were infected with 10 or 100 pfu of dl1520, in the presence or in the 
absence of 10 μM of lovastatin, and harvested at 24 hours post infection.  Cells 
were dissolved in 1 ml Trizol (Invitrogen). RNA quality was evaluated by 
agarose gel electrophoresis, DNAse treatment was performed. 1 μg of total 
RNA was reverse transcribed and the expression of E1A 13 S and Penton genes 
monitored using Real Time PCR with the following specific primers: 
E1A 13 S Forward: 5’-AATGGCCGCCAGTCTTTT-3’  
E1A 13 S Reverse: 5’-ACACAGGACTGTAGACAA-3’ 
Penton Forward: 5’-TAACCAGTCACAGTCGCAAG-3’  
Penton Reverse: 5’-CCCGCGCCTTAAACTTATT-3’.  
To calculate the relative expression levels we used the 2–[delta][delta]Ct method.  
Negative controls, samples without RT PCR or CDNA template were included 
in every PCR run, always resulting negative (data not shown). 
Detection of cell-surface CAR receptor  
Cells were grown in 6-well plates. After 48 hours cells were detached in PBS-
EDTA 10mM, washed with PBS and then incubated 1.5 h in FACS buffer with 
a mouse anti-CAR monoclonal antibody RmcB (1:250). After washing, the 
cells were incubated in FACS buffer containing the secondary antibody 
conjugated to fluorescein isothiocyanate [FITC] (Sigma,1:100) and analyzed 
for CAR expression on a Cyan cytometer (Dako Cytomation, U.S.A.) and 
Summit V4.3 software (Dako). 
Human thyroid tissue samples, semiquantitative RT-PCR, Real Time RT-PCR 
and immunohistochemistry 
Normal and neoplastic human thyroid tissue were obtained from surgical 
specimens and immediately frozen in liquid nitrogen. Thyroid tumours were 
collected at the Laboratoire d’Histologie et de Cytologie, Centre Hospitalier 
Lyon Sud, France and at the Laboratoire d’Anatomie Pathologique, Hospital de 
L’ Antiquaille Lyon, France. The study was approved by the Ethics Committee 
of the Centre Hospitalier Lyon Sud and of the University Federico II Napoli 
and conducted in accordance to the principles of the Declaration of Helsinki as 
revised in 2000. In all cases written informed consent was obtained.  
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Total RNA was isolated and DNAse-digested using the Rneasy mini kit 
(Qiagen, Valencia, CA) according to the manufacturer’s recommendations. 
Three µg of total RNA from each sample were reverse transcribed using 
random hexamers as primers and MuLV reverse transcriptase (Applied 
Biosystems, Foster City, CA) to yeld cDNA. Semiquantitative RT-PCR was 
carried out on cDNA using the GeneAmp PCR System 9600 (Applied 
Biosystems). RNA PCR Core kit (Applied Biosystems) was used to perform 
PCR reactions. The human ß-actin gene primers, amplifying a 109-bp cDNA 
fragment, were used as a control with the following program: 95°C for 10 min; 
25 cycles of 95°C for 30 sec, 60°C for 30 sec and 72°C for 30 sec; 72°C for 5 
min for a final extension.  To amplify the AuroraB mRNA RT-PCR was 
performed using two primers that amplified a 128-bp nucleotide cDNA 
fragment encompassing exons 5 and 6 with the following program: 95°C for 10 
min; 29 cycles of 95°C for 30 sec, 59.5°C for 30 sec and 72°C; final extension 
of 72°C for 5 min. Same primers were used for Real-Time RT-PCR and 
semiquantitative RT-PCR. 
Quantitative PCR was performed in triplicate using iCycler (Bio-Rad, 
München, Germany) with SYBR® Green PCR Master Mix (Applied 
Biosystems) as follows: 95°C 10 min and 40 cycles (95°C 15 s and 60°C 1’). 
For Cxadr mRNA, an amplicon of 93 nucleotides scattered among sixth and 
seventh exon was selected. The primer sequences were:  
Aurora B forward: 5’-CTGGAATATGCACCACTTGGA,  
Aurora B reverse: 5’CGAATGACAGTAAG-ACAGGG;  
ß-Actin-forward,5’-TCGTGCGTGACATTAAGGAG;  
ß-Actin-reverse, 5’-GTCAGGCAGCTCGTA-GCTCT.  
Cxadr forward 5’-ATGAAAAGGAAGTTCATCACGATA-3’;  
Cxadr reverse 5’-AATGATTACTGCCGATGTAGCTT-3’ 
Fold mRNA overexpression was calculated according to the formula 2(Rt-Et)2(Rn-
En), where Rt is the threshold cycle number for the reference gene (β actin) in 
the tumour, Et for the experimental gene in the tumour, Rn for the reference 
gene in the normal sample and En for the experimental gene in the normal 
sample. 
The cellular distribution of Aurora B protein was assessed by immuno-
histochemical analysis. Aurora B expression was evaluated both in non-
neoplastic  and neoplastic thyroid tissues. H&E stained slides were retrieved 
from the files of the Department of Bio-Morphological Sciences at the 
University Federico II of Naples; in all cases the histological diagnosis was 
confirmed on review. Paraffin-embedded sections were obtained from these 
samples and Aurora B expression was evaluated Xylene dewaxed and alcohol 
rehydrated paraffin sections were placed in Coplin jars filled with a 0.01M tri-
sodium citrate solution, and heated for 3 minutes in a conventional pressure 
cooker. After heating, slides were thoroughly rinsed in cool running water for 5 
minutes and then washed in Tris-Buffered Saline (TBS) ph 7.4. 
Aurora B protein was detected by using the polyclonal antibody raised in rabbit 
(n° 611082; BD Transduction Laboratories, USA). The incubation with the 
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primary antibody was followed by incubation with biotinylated anti-mouse 
immunoglobulins, and by peroxidase labelled streptavidine (LSAB-DAKO). 
The signal was developed by using diaminobencidine chromogen as substrate. 
Negative controls were run with normal rabbit serum instead of the primary 
antibody or the antibody was preadsorbed with the cognate peptide (10-6 M). 
Cases were scored by assessing the percentage of labelled cells, percentage of 
positive cells was evaluated by analysing 1000 neoplastic cells in five different 
high power fields.  
Western blot analysis 
See Sorrentino et al. 2005, Libertini et al. 2007 
Tumorigenicity assays  
Experiments were performed in six-week-old male athymic mice (Charles-
River, Italy). All mice were maintained at the Dipartimento di Biologia e 
Patologia Animal Facility, in accordance with accepted standards of animal 
care and with the Italian regulations for the welfare of animals used in studies 
of experimental neoplasia. The studies were approved by Ethic Committee on 
animal care of the University Federico II Napoli. 
Untransfected ARO cells (5*106) or respectively transfected with a plasmid 
containing Aurora B in the sense or antisense orientation were injected into the 
right flank of the mice. The animals were monitored for the appearance of 
tumours and tumour latency evaluated.   
FRO cells (4*106) were injected into the right flank of 80 athymic mice. After 
20 days, when tumours were clearly detectable, the animals were divided into 
four groups (20 animals/group), and tumour volume was evaluated.  
In one experiments, two groups received lovastatin intratumourally, twice a 
week, for 7 weeks, at a final concentration of 10μM. After 16 hours, one of 
these group received dl1520 (5*107pfu) as well. The other groups were media 
or dl1520 alone administrated with same schedule. 
In the second experiment, two groups received lovastatin in the drinking water 
(40mg/1000 ml) and after six days dl1520 (5*107pfu) was injected in the 
peritumoral area in a group treated with lovastatin and in an untreated group. 
Tumour diameters were measured with calipers every second day by two blind 
and neutral observers until the animals were sacrificed. No mouse showed 
signs of wasting or other indications of toxicity. Tumour volumes (V) were 
calculated by the formula of rotational ellipsoid: V= A x B2/2 (A= axial 
diameter, B= rotational diameter). 
The amount of lovastatin administered was chosen considering that the average 
daily water intake for each mouse was 5–7.5 ml and 10 mg/kg/day was the best 
dose of lovastatin for obtaining biological effects in mice. 
To evaluate the genome equivalent copies of dl1520 in tumour xenografts, 3 
animals bearing FRO xenografts received lovastatin in the drinking water (40 
mg /1000 ml) or intratumourally. After six days (per os administration) or 16 
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hours (intratumoural administration), dl1520 (5 x 107 pfu) was injected in the 
peritumoral area of the mice treated with lovastatin and in 3 untreated mice. 
After 48 hours, animals were sacrificed, tumours excised, DNA extracted and 
viral replication evaluated by Real Time PCR. DNA quality was analysed by 
Real Time PCR of β actin gene. 
Statistical analysis 
Comparisons among different treatment groups in the experiments in vivo were 
made by the ANOVA method and the Bonferroni post hoc test using a 
commercial software (GraphPad Prism 4). Assessment of differences among 
rate of tumour growth in mice was made for each time point of the observation 
period; treatment groups were control, dl1520, lovastatin and lovastatin plus 
dl1520. The analysis of the cell killing effect in vitro was also made by 
ANOVA method and the Bonferroni post hoc test. For all the other 
experiments comparisons among groups were made by ANOVA method and t 
test. 
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4. RESULTS 
Lovastatin enhances the cell killing effects of dl1520 
To evaluate whether lovastatin could enhance oncolytic activity of 
dl1520, we infected two anaplastic cell lines, KAT-4 and FRO, characterized 
by a different sensitivity to adenoviral infection. KAT-4 cells were chosen as 
representative of  ATC cells at low sensitivity, FRO cell line was chosen as 
representative of an intermediate infectivity (Libertini et al. 2007). 
In both cell lines, the combined treatment enhanced the cell killing 
activity of dl1520. In FRO cells treated with 10 pfu/cell of dl1520, an additive 
and significant (2.5 μM) and highly significant (5μM) increase in cell killing 
was observed. In KAT-4 cells, a highly significant increase in cell killing was 
induced by lovastatin treatment at all MOIs and drug concentrations used 
(Fig.1).  
 
 
 
Lovastatin slightly enhances adenoviral entry 
Since dl1520 activity is enhanced by lovastatin, we have decided to 
evaluate whether lovastatin enhanced adenoviral entry in ATC cells. For this 
purpose we used AdGFP, a replication defective adenovirus transducing GFP. 
It’s worth to note that we used different treatment conditions for the evaluation 
of lovastatin effects: antineoplastic effects of dl1520 were evaluated in the 
presence of lovastatin, whereas  experiments designed to evaluate the effects of 
the drug on the early phases of viral infection were performed with a short 
treatment time. 
Figure 1 - Lovastatin treatment enhances 
the cell killing effects of dl 1520  
 
FRO and KAT-4 cells were treated for 16 h 
with lovastatin, then medium was replaced 
with a medium containing or not lovastatin 
plus dl1520 at different MOIs. Survival was 
established after 14 days of infection. 
In FRO cells kept in the presence of 
lovastatin, a highly significant increase (**p 
<0.01) in the cell killing activity of 10 
pfu/cell of dl1520 was observed in 
association with 5 μM of lovastatin. In 
KAT-4 cells kept in the presence of 1 and 
2.5 μM of lovastatin, a highly significant 
increase (**p <0.01) in combination with 1 
and 2.5 pfu/cell of dl1520 was obtained.  
Viral concentration able to induce the same 
cell killing in the two cell lines were used.  
The data are expressed as percentages of 
untreated control cells and are the mean of 
five different experiments, the bar represents 
the standard deviation. 
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KAT-4 and FRO cells were pre-treated with a non-cytotoxic 
concentration of lovastatin (10 μM) for 16 hours and then infected with 
AdGFP for other 24 hours at different MOIs. FACS analysis showed that 
lovastatin treatment induced a highly statistically significant increase 
(**p<0.01), albeit modest, in the number positive cells ranging from 3 up to 
10% (Fig.2, upper panel). Both cell lines showed a strong increase (up to 
250%) in fluorescence to cell ratio upon lovastatin treatment (Fig.2, lower 
panel). 
 
 
 
 
Figure 2 - Lovastatin enhances percentage of GFP positive cells and fluorescence to cell ratio  
 
FRO and KAT-4 cells were treated with 10 μM of lovastatin for 16 hours and then infected with Ad 
GFP at different MOIs.  FACS analysis was performed 24 hours after the infection. Lovastatin 
increased the percentage of Ad GFP positive KAT-4 and FRO cells (upper panel). Highly significant 
difference between treated and untreated cells is observed in both cell lines starting from 10pfu/cell 
point. Lovastatin treated cells showed an increase in fluorescence to cell ratio (lower panel). The 
difference is statistically high (**p<0.01) starting from 25 pfu/cell (FRO cells) or 50 pfu/cell (KAT-
4 cells). The data are the mean of five different experiments, the bar represents the standard 
deviation. 
Lovastatin does not change total and membrane CAR levels 
Since adenoviral infection occurs via the attachment of the knob domain 
of the viral fiber protein to the cellular coxsackie–adenovirus receptor (CAR) 
and since pharmacological inhibitors of the Raf-MEK-ERK pathway 
upregulates CAR expression on the cell surface of cancer cells, we have 
analysed CAR expression after lovastatin treatment. By inhibiting Ras 
pathway, HMG-CoA reductase inhibitors act as Raf-MEK-ERK inhibitors. 
Cells at same confluence were treated for 16 or 24 hours with 5 or 10 μM of 
lovastatin, then harvested for proteins extraction or FACS analysis. As shown 
in figure 3A, total CAR expression were not modified by lovastatin treatment. 
Since the virus uses membrane CAR for its entry, we have evaluated CAR 
levels on cell surface by FACS analysis, again showing no differences (fig.3B). 
Moreover, preincubation with neutralizing anti-CAR antibody does not 
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decreased infectivity in lovastatin treated cells (data not shown). Therefore, we 
can affirm that lovastatin does not act on total and membrane CAR levels.  
 
 
 
 
Figure 3 - Lovastatin does not modify total and membrane CAR levels  
 
A-  KAT-4 and FRO cells were treated with 0, 5 or 10 μM of lovastatin for 16 or 24 hours. Proteins 
were subjected to SDS-PAGE (10%). Equal amount of protein were loaded in each lane (50 μg).  
B-  KAT-4 and FRO cells were treated with 0 (control), 5 or 10 μM of lovastatin for 16 or 24 hours, 
then harvested and incubated with anti CAR (RmcB) monoclonal antibody. Background emission 
was assessed by incubating KAT-4 and FRO cells with fluorescein isothiocyanate (FITC)-labeled-
mouse alone (FITC). At all times and lovastatin concentrations used, CAR expression was not 
modified. The figure represents CAR expression after 16 hours of 10μM lovastatin. The data are 
representative of three different experiments 
 
 
It has been shown that lovastatin inhibits the invasiveness of ATC cell 
lines, lowering FAK (focal adhesion kinase) phosphorylation (Zhong et al. 
2005). FAK is a non receptor tyrosine kinase, that plays a crucial role in 
integrins mediated cell adhesion. Integrins act as a coreceptor for Adenovirus 
type 2 (Ad2) and type 5 (Ad5), therefore the slight increase in adenoviral entry, 
observed after lovastatin treatment, could be due to changes in integrins pattern 
on cell surface.  
The modest increase in adenoviral entry (3-10%) is not sufficient to explain 
lovastatin effects on fluorescence to cell ratio (Fig.2) and cell survival (Fig.1), 
therefore we decided not to further investigate this step. 
Lovastatin enhances the expression of viral genes and viral replication 
Increase in fluorescence to cell ratio suggests that lovastatin treatment 
could enhance viral gene expression. To monitor this step, we selected two 
genes, whose expression is correlated with different stages of the adenoviral 
life-cycle: E1A 13 S, representing genes transcribed from the immediate early 
region, and Penton, representing genes expressed from the late region. FRO 
and KAT-4 cells were infected, respectively, with a MOI of 100 and 10 pfu of 
dl1520 in the presence or in the absence of lovastatin (10 μM). The expression 
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levels of E1A 13 S and Penton gene were measured by Real Time RT-PCR at 
24h. Co-treatment with lovastatin significantly (*p<0.05) enhanced the 
expression levels of E1A 13 S and Penton gene in both cell lines (Fig.4).  
 
 
 
Figure 4 - Lovastatin increases viral gene expression in ATC cells  
 
FRO and KAT-4 cells were treated with 10 μM of lovastatin, after 16 h cells were infected with 
dl1520. For FRO cells a MOI of 100 pfu was used, KAT-4 cells were infected with 10 pfu. After 24 
h, the levels of expression of the early gene E1A 13 S and of late gene Penton were measured by 
Real Time RT PCR. The result is normalized to β-actin gene expression. 
Lovastatin treatment significantly enhanced the expression levels of both genes. In FRO cells, a four 
fold increase of E1A 13 S expression levels and sixteen fold increase of Penton gene were obtained.  
In KAT-4 cells, a five fold increase of E1A 13 S expression levels and twelve fold increase in Penton 
expression levels were observed. The data are the mean of three different experiments, the bar 
represents the standard deviation. 
 
Next, we quantified the amount of dl1520 virus genome by Real Time 
PCR in FRO and KAT-4 cells untreated, treated with lovastatin for 16 hours 
(lovastatin 16h) before infection, or kept in the presence of lovastatin after the 
infection (lovastatin) and infected with different MOIs (Fig.5). 
In FRO cells infected at 10 pfu/cell, both lovastatin treatments induced an 
highly significant (**p<0.01) increase in viral replication, while at 1 pfu/cell 
no significant differences were observed. KAT-4 cells kept in the presence of 
lovastatin also showed a highly significant increase in viral replication 
(**p<0.01), whereas 16 hours pre-treatment did not modified viral replication. 
These results suggest that the increase in viral replication observed treating 
ATC cells with lovastatin is viral dose or lovastatin treatment time dependent. 
Therefore, it is possible that higher MOIs of dl1520 in combination with a 16 h 
lovastatin pre-treatment could result in enhanced viral replication in KAT-4. In 
conclusion of this part, we can affirm that lovastatin enhances viral gene 
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expression and, consequently, viral replication. Other drugs have been reported 
to enhance dl1520 activity, such as cisplatin and 5-fluorouracil, which 
potentiate the dl1520 virus without changing viral replication (Heise et al. 
2000) or paclitaxel, that increases adenoviral entry and viral gene expression 
(AboulEl Hassan et al. 2006). Recent studies suggest that the stage of the cell 
cycle may influence the outcome of Ad infection (Seidman et al. 2001). It has 
been demonstrated that adenoviral binding is optimal during M phase, since 
both CAR and αv integrin expression showed increased cell surface expression 
at M phase. Statins induce apoptosis or a G1 arrest but not a G2 arrest (Sala et 
al. 2007, Sivaprasad et al. 2006) in neoplastic cells. We have shown that 
lovastatin does not change CAR levels, therefore other mechanisms are 
responsible for lovastatin effects on viral life cycle. 
 
 
 
Lovastatin per os in combination with dl1520 reduced the growth of ATC 
tumour xenografts 
In order to demonstrate that the combined treatment lovastatin and 
dl1520 could potentially yield improved clinical efficacy, we have evaluated 
the effects of lovastatin treatment in vivo. We performed two different 
experiments: in the first one, lovastatin was given within the tumour, whereas 
in the second one was added in the drinking water. FRO cells (4*106) were 
injected into the right flank of athymic mice, and after 20 days, when tumours 
were clearly detectable (T=0), animals were randomised into four groups. In 
figure, tumour growth is expressed as a percentage of growth relative to the 
volume observed at T=0. 
In the first experiment (Fig.6A), one group received dl1520 (5*107 pfu) 
or lovastatin (10μM) or both within the tumour. Animals that received both 
Figure 5 - Lovastatin treatment 
enhances the replication of the dl1520 
 
FRO and KAT-4 cells were treated with 
lovastatin (10μM) for 16 hours and then 
infected with a medium containing 
dl1520 (lovastatin 16 h) or dl1520 plus 
lovastatin (lovastatin). Cells were 
harvested after 24 hours of infection. 
FRO cells at 10 pfu/cell showed a highly 
significant increase (**p<0.01) of dl 
1520 replication in both groups. KAT-4 
cells at 5 and 10 pfu/cell showed a highly 
significant increase (**p<0.01) of dl 
1520 replication only in the group kept in 
the presence of lovastatin.  
The data are the mean of three different 
experiments, the bar represents the 
standard deviation. 
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treatments were treated one day with lovastatin and with virus after 16 hours, 
twice a week. The control group received same volume (100μl) of media. The 
treatment was performed for 7 weeks, twice a week.  
In the second experiment (Fig.6B), after the randomisation, lovastatin 
was added in the drinking water of two groups and the animals received 
lovastatin until the end of the experiment. After six days, dl1520 was injected 
within the tumour (T=6), twice per week, for 6 weeks.  
 
 
Figure 6 - Tumour growth  
A- Intratumoral administration of lovastatin doesn’t affect oncolytic activity of dl1520 
Groups received twice a week intratumoral injection of 100 μl of media (control), dl1520 alone, 
lovastatin alone or dl1520 plus lovastatin (in this group lovastatin was given 16 hours prior to 
dl1520). No statistical differences between control and lovastatin and between dl 1520 alone or plus 
lovastatin were observed. The difference between control and dl1520 alone or plus lovastatin is 
statistically significant (*p<0.05) up to T=30. 
B- per os administration of lovastatin enhances tumour growth delay induced by dl1520  
Lovastatin and dl1520+lovastatin groups received lovastatin in the drinking water starting from T=0 
until the end of the experiment. dl1520 and dl1520+lovastatin groups received dl1520 within the 
tumour twice a week, for 6 weeks, starting from T=6. Lovastatin treatment alone did not show 
statistically significant differences with the untreated control, whereas dl 1520 induced a statistically 
significant reduction (*p<0.05) in the initial phase of the treatment (up to T=30). The combination 
of dl1520+lovastatin significantly delayed tumour growth compared to dl1520 alone from T=36 
(**p<0.01). Data are presented as mean ± SD. 
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As shown in figure 6A and 6B, dl1520 treatment was able to significantly 
reduce (*p<0.05) the growth of tumour xenografts in the initial phase of the 
treatment (up to T=30). As shown in figure 6A, locally administrated lovastatin 
did not affect dl1520 activity; conversely, the combination lovastatin plus 
dl1520 was able to induce a highly significant reduction (**p<0.01) in tumour 
growth until the end of experiment (Fig.6B).  
Finally, we have evaluated by Real Time PCR the genome equivalent 
copies of dl1520 in animals bearing FRO xenografts and treated with dl1520 
alone or plus lovastatin. As expected, per os administration of lovastatin was 
able to induce a ten fold increase in viral replication (Fig.7B) while no 
differences were observed in samples obtained from intratumorally injected 
animals (Fig.7A). 
It is worth to note that the injection of lovastatin and the virus within the 
tumour did not increase the effects of dl1520, indicating that a constant 
lovastatin blood concentration should be obtained in order to enhance the 
effects of dl1520.  
It is also important to note that lovastatin alone -administrated both 
locally and per os- did not affect tumour growth, confirming previous 
observations that statins can enhance antitumour activity of other drugs but, at 
concentrations compatible with life in animal models,  do not show intrinsic 
antineoplastic effects. 
 
 
 
 
 
 
Figure 7 - Genome equivalent copies in tumour xenografts 
 
per os administration of lovastatin increases by ten fold genome equivalent copies in tumour 
xenografts  while intratumoural administration has no effect on viral replication. 
The data are the mean of three different experiments, the bar represents the standard deviation. 
 
 
The data presented here identify lovastatin as a promising agent for 
increasing the effects of oncolytic adenoviruses in ATC cells. It has been 
reported that HDAC inhibitors, such as FR901228 and valproic acid (Bieler et 
al. 2006), or MEK inhibitors, such as U0126 and PD184352 (Anders et al. 
2003), increase the antineoplastic effects of oncolytic adenoviruses. However, 
these agents have been used in a limited number of clinical trials, whereas 
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statins have been widely used to reduce cardiovascular diseases without major 
adverse effects.  
In the present study, in in vitro experiments, lovastatin was used at a final 
concentrations ranging from 5 to 10 μM and, in in vivo experiments, we have 
used a lovastatin concentration of 10 mg/kg/day. Although the therapeutic dose 
for the treatment of hypercholesterolemia is about 1 mg/kg/die, which yields 
serum levels of 0.1μM, it has been shown that serum concentrations of 2-4 μM 
of lovastatin are well tolerated in animal models and clinical trials of phase I 
and II have been performed using 25 mg/Kg/day with encouraging results 
(Hindler et al. 2006). All these data indicate that lovastatin at a dose of 10 
mg/kg/day could be probably used in ATC patients in combination with dl1520 
without major side effects.  
In conclusion, we have identified lovastatin as a drug that increases 
adenoviral replication and enhances the effects of an oncolytic adenovirus in 
vitro and in vivo against ATC cells. Therefore, lovastatin could be useful in the 
context of gene therapy for anaplastic thyroid carcinoma.  
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In the second part of my study, I focused my attention on Aurora B, that plays 
a pivotal role in chromosomal instability and aneuploidy, common features in 
anaplastic thyroid carcinoma.   
 
Aurora B is overexpressed in malignant thyroid carcinoma cells and in 
experimental model of thyroid carcinogenesis  
Thyroid carcinoma cell lines derived from papillary (NPA and TPC1), 
follicular (FB1 and WRO) and anaplastic thyroid carcinomas (ARO, CAL 62, 
KAT-4, 8550-C, BHT101, KAT-18, FRO) were analyzed for Aurora B 
expression by Western blot. An Aurora B specific band of 41KDa was detected 
in all the samples.  As shown in Figure 8, the highest expression levels were 
observed in the cell lines derived from anaplastic thyroid carcinoma, whereas 
only a faint band was observed in human thyroid primary culture cells (PrT). 
This data shows that Aurora B is more abundant in cell lines derived from 
more aggressive carcinoma. It’s worth to note that we did not use nocodazole 
or other mitotic drug to block cells in mitosis, since we did  not want to force 
Aurora B expression, but only to value normally expressed protein levels. 
 
 
 
Figure 8- Aurora B expression in thyroid cell lines  
 
Western blot analysis of Aurora B expression in human thyroid cells. 
NPA and TPC arise from papillary thyroid carcinoma whereas WRO and FB1 originate from 
follicular thyroid carcinoma. The remaining cells originate from ATC. Primary culture of human 
thyroid (PrT) was used as control. In all lanes, equal protein amounts were loaded (50μg) 
 
 
To confirm that Aurora B gene expression is increased in highly 
malignant thyroid carcinomas, Western Blot analysis was performed to 
evaluate its expression levels in thyroid glands from animal models of thyroid 
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carcinogenesis. We used transgenic mice lines, expressing RET/PTC3, HPV 16 
E7 and LT SV40 oncogenes under the transcriptional control of the 
thyroglobulin promoter. Overexpression of these oncogenes in the thyroid 
gland of transgenic mice causes, respectively, papillary, follicular and 
anaplastic thyroid carcinoma. As control of non neoplastic proliferation, 
thyroid glands of animals treated for 2 and 4 weeks with the goitrogenic agent 
propylthiouracil (PTU) were used. Furthermore, the thyroid gland of a 6 
months old wild type mouse was used as a control (Fig 9).  
It is important to note that in the glands of animals treated with the goitrogenic 
agent PTU, known to stimulate a reversible hyperplasia of the gland, a very 
low expression of Aurora B was observed despite the intense mitotic activity of 
the follicular cells. These data indicate that Aurora B increased expression is 
associated to the late stages of thyroid tumour progression and suggest that the 
Aurora B overexpression could contribute to thyroid tumour progression.  
 
 
 
 
 
Figure 9 - Aurora B expression in experimental models of carcinogenesis 
Western blot analysis of Aurora B expression in thyroid excised from different experimental models 
Normal thyroid: normal thyroid gland excised from a 6 months old wild type mouse;  PTU 2 and 4 
weeks: Thyroid gland excised from a mouse treated for 2 or 4 weeks with PTU; Tg E7 HPV16:  
Follicular carcinoma of a transgenic mouse expressing in the gland HPV 16 oncogene; Tg Ret/PTC3: 
Papillary carcinoma of a transgenic mouse expressing in the gland RET/PTC3 oncogene; Tg LTSV40: 
Anaplastic thyroid carcinomas obtained  from two transgenic mice (#84, #57); KAT-4: Positive control 
cells.    
 
Aurora B is overexpressed in human anaplastic thyroid carcinoma  
In order to evaluate the expression of Aurora B in human thyroid 
carcinoma tissues,  a panel of matched tumour/normal tissues was analysed by 
RT-PCR. No significant differences in Aurora B gene expression were 
observed in papillary carcinomas matched with normal thyroid tissue 
(Fig.10A), whereas an increased Aurora B expression was observed in 
anaplastic thyroid carcinomas with respect to the normal thyroid tissue 
(Fig.10B). Quantitative PCR was performed to confirm overexpression of 
Aurora B in anaplastic thyroid carcinomas. About 15 fold mRNA 
overexpression was observed in ATC samples with respect to the β-actin 
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reference gene, whereas in papillary thyroid carcinoma samples only a two fold 
increase was observed (Fig.10C)  
 
 
 
 
Figure 10 – Real Time analysis of Aurora B expression in matched tumour/normal tissues 
 
A Papillary thyroid carcinomas matched with normal thyroid tissues.   
B Anaplastic thyroid carcinomas matched with normal thyroid tissues. Levels of Aurora B were 
increased in the anaplastic thyroid carcinomas.  
C Real Time PCR analysis of Aurora B expression in papillary thyroid carcinomas and in anaplastic 
thyroid carcinomas. A 15 fold increase of Aurora B expression was observed in anaplastic thyroid 
carcinomas.  
 
 
Immunohistochemical analysis of Aurora B expression was performed on 
samples from normal thyroid, adenoma (5 cases), follicular (5 cases), papillary 
(10 cases) and anaplastic thyroid carcinomas (15 cases). Three cases of nodular 
goitre and three of Hashimoto’s thyroiditis were used as non neoplastic 
proliferation control. In normal thyroid tissue, few positive cells for Aurora B 
staining were observed. Conversely, all of thyroid anaplastic carcinoma 
examined showed a very high expression of Aurora B (Fig.11C and 11D). 
Positive cells were irregularly distributed throughout the tumour. Occasionally, 
a heterogeneous pattern of expression was seen, with areas showing strong 
labelling adjacent to areas with less intense Aurora B expression. In follicular 
or papillary differentiated carcinomas a less intense signal was observed 
(Fig.11B). The expression of Aurora B in anaplastic thyroid carcinomas or in 
differentiated carcinomas was compared to the expression of a well known 
proliferative marker such as Ki-67, by using MIB-1 antibody (Table 1). 
Staining for KI-67 was most intense in thyroid anaplastic carcinomas, showing 
a correlation with Aurora B expression.  
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Figure 11 - Aurora B expression and localisation in human  thyroid carcinomas 
 
A Paraffin embedded  section of a thyroid goitre. Expression of Aurora B protein was not observed. 
B Section of thyroid  papillary carcinoma, showing rare  immunoreactivity for Aurora B protein.   
C Section of anaplastic thyroid carcinoma, showing extensive immunoreactivity for Aurora B protein. 
D Higher magnification of  C,  presence of a clear signal in neoplastic cells. 
 
 
Table 1. Analysis of Aurora B and Ki-67 expression in thyroid specimen 
 
Hystological type of Number Average  immunostaining 
thyroid specimen of cases Aurora B Ki-67 
Normal thyroid 1 0.5 ± 0.2 0.9 ± 0.3 
Nodular goitre 3 1.2 ± 0.4 1.8 ± 0.6 
Hashimoto’s disease 3 0.8 ± 0.3 1.1 ± 0.6 
Papillary carcinoma 10 2.3 ± 0.4 3.1 ± 0.5 
Follicular carcinoma 10 2.8 ± 0.4 3.6 ± 0.6 
Anaplastic carcinoma 15 29.6 ± 3.4 43.2 ± 6.6 
                    Values are reported as percentage of immunopositive cells ± SD 
 
These data paralleled the results obtained using cell lines and 
experimental tumours, showing that Aurora B expression is abundant in 
anaplastic carcinomas. Conversely, no or low expression was observed in 
benign adenomas or in non neoplastic thyroid lesions, such as Hashimoto’s 
disease and in normal thyroid tissue. Our data extend to thyroid tumours the 
observation that the expression of Aurora B tends to group in higher grade of 
malignancy, as observed in seminona (Chieffi et al. 2006), colon carcinomas 
(Katayama et al. 1999), non small cell lung carcinoma (Smith et al 2005, 
Vischioni et al. 2006), mesothelioma (Lopez-Rios et al. 2006), glioblastoma 
(Araki et al. 2004, Zeng et al. 2007), oral cancer (Qi et al. 2007) and 
hepatocellular carcinoma (Kurai et al.  2005). It is possible that during tumour 
progression, in particular during the transition from differentiated to anaplastic 
thyroid carcinomas, Aurora B overexpression takes place and its over-
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expression might confer a growth advantage to the neoplastic cells. 
Furthermore, our data indicate that Aurora B expression may serve as a 
prognostic marker in thyroid tumours. Recently, our observations have been 
confirmed by Ulisse et colleagues (2006), further validating Aurora B role in 
thyroid neoplastic progression. 
Suppression of the Aurora B synthesis or function blocks cell proliferation 
To establish whether Aurora-B expression is crucial for thyroid 
neoplastic cell growth and to assess whether Aurora B could represent a target 
for antineoplastic therapy, we performed selective gene silencing analysis 
using small interference RNA (RNAi). ARO cells were transfected with RNAi 
for Aurora B (RNAi) or scramble sequence (RNAc) or untreated (Ctr) and 
harvested after 24 and 48 hours, for both Western Blot and cell survival 
analysis. Aurora B-RNAi significantly decreased the synthesis of Aurora B 
protein in ARO cells at 48 hours (Fig.12A) and, consistently with its 
physiological role, histone H3 phosphorylation. The block of Aurora B protein 
synthesis is specific, since Aurora A levels were not affected (Fig.12A). The 
same lysates were probed with anti PARP antibody, to check if the treatment 
could induce apoptosis. As control for PARP pathway activation, ARO cells 
were treated for 24 (lane 7) or 48 h (lane 8) with paclitaxel 20nM (Yeung et al. 
2000). As shown in figure 12A, lower panel, Aurora B RNAi does not induce 
PARP clivage. In figure 12B, cell survival of treated or untreated cells shows 
significant reduction in cell number after 48 hours of treatment.   
 
 
 
Figure 12- RNAi directed against Aurora B specifically inhibits its expression and blocks  the 
proliferation of anaplastic thyroid carcinoma cells 
A Inhibition of Aurora B expression by RNAi. 
ARO cells were transfected with 200 nM annealed sense (RNA i) and aspecific control RNA (RNA c) 
21-mer RNA oligonucleotides directed against Aurora B, or mock-transfected (Ctr). Cells were 
harvested at 24 and 48 h after transfection, and Western blot analysis was performed. A significant 
reduction of Aurora B expression and H3 phospshorylation was observed at 48 hours. Aurora A and H3 
levels were not affected by the treatment.  
B Time-dependent inhibition of ARO cell proliferation by Aurora B RNAi.  
ARO cells were transfected with 200 nM annealed sense (RNA i) and control (RNAc) 21-mer RNA 
oligonucleotides directed against Aurora B, or mock-transfected (Ctr). The data are expressed as 
percentages of the control cell proliferation and the standard deviation was calculated (bar).The data are 
the mean of three different experiments. 
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To block Aurora B activity we also used the quinazolin derivative: N-[4-
(6,7-dimethoxy-quinazolin-4-ylamino)-phenyl]-benzamide (Mortlock A et al., 
2001), here called AUR-inh. This compound is similar to AstraZeneca 
compound ZM1 (Girdler et al. 2006) and presents an Ic50 for Aurora A 20 fold 
higher than for Aurora B.  
ARO and FRO cells were treated with 0 or 15 μM  of  the Aurora kinase 
inhibitor and, after 24 or 48 hours, cells were collected and lysed. Lysates were 
immunoblotted with anti-phospho-Ser-10 H3 histone antibody and anti 
α−tubulin antibody. As shown in figure 13A, a dramatic reduction in 
phosphorylation of the H3 histone was observed. To evaluate the effects of 
Aurora kinase inhibitor on cell proliferation, ARO and FRO cells were treated 
with 0, 5, 10 and 15 μM of Aurora inhibitor, and cell proliferation was 
evaluated after 24 and 48 hours. 10 and 15 μM of inhibitor significantly 
reduced cell proliferation  (Fig.13B).  
 
 
 
 
Figure 13 - Reduction in phosphorylation of the H3 histone and reduction in ARO and FRO  
cells proliferation by Aurora B kinase inhibitor  
A ARO and  FRO cells (5x105) were treated with 15 μM of Aurora kinase inhibitor, after 24 and 48 
hours cells were lysed.  Western blot analysis with anti-Ser-10 phosphorylated H3 histone antibody 
showed a dramatic reduction in the phosphorylation of the H3 histone, as a control untreated ARO 
and  FRO cells were used.  50 μg of ARO lysate and 100 μg of FRO lysate were loaded in 12 % gel. 
B ARO and FRO cells were treated with 0, 5, 10, 15 μM of the Aurora kinase inhibitor (AUR-inh) 
as a control untreated ARO and FRO cells were used. After 24 and 48 hours cell proliferation was 
evaluated. A significant reduction in cell proliferation was observed. The data are expressed as 
percentages of the control cell proliferation and the standard deviation was calculated (bar). The data 
are the mean of three different experiments.   
 
 41
Due to lack of a specific substrate for Aurora A, it was not possible  to 
analyse Aurora A activity after AUR-inhibitor treatment. It is important to note 
that several studies (Girdler et al. 2006) indicate that the cellular events that 
occur following exposure to ZM1 are due to inhibition of Aurora-B, rather than 
Aurora-A. Furthermore in the present study we have observed that Aurora B 
inhibitor and RNAi showed quite similar effects.  Therefore, although it is not 
possible to exclude that part of this effect is depending on Aurora A inhibition, 
we can suppose that the most part is due to Aurora B inhibition.  
Aurora B antisense prolongs tumour latency but does not affect tumour 
incidence  
Transfection of ARO cells with a construct containing AuroraB cDNA in 
sense or antisense orientation was also performed. Several clones were then 
selected for further experiments. The reduced expression of Aurora B protein 
in antisense expressing clones was confirmed by Western blot analysis (data 
not shown). The colony growth rate in semisolid medium was reduced in 
Aurora B-antisense expressing clones with respect of sense or empty vector 
transfected cells. Although no differences in tumour incidence were observed 
upon injection into athymic mice, tumour latency period of Aurora B-antisense 
expressing clones was increased (Table 2). It is worth to note that Aurora B 
overexpression does not affect colony-forming efficiency, tumour incidence 
and latency period. Likely, endogenous Aurora B expression levels in ARO 
cells are so high that further overexpression can not affect anymore their 
tumorigenicity. Transfection of an Aurora B antisense construct was not able to 
reduce tumour incidence and only the latency period was increased. This 
indicate that the block of Aurora B expression is not able to revert the 
neoplastic phenotype and acts only on the tumour growth rate. This observation 
probably reflects the role of Aurora B in thyroid carcinoma progression, being 
overexpressed only in late stages.  
 
Table 2. Analysis of transformation markers of the ARO cells transfected with Aurora B 
cDNA in the sense or antisense orientation  
 
Transfected DNA Colony-forming efficiency (%)a 
Tumour 
incidenceb 
Latency 
period (d)c 
pCMV vector 56 ± 2 3/3 12 ± 1 
pCMV Aurora B 
antisense clone 4 27 ± 1.4 4/4 31 ± 0.8 
pCMV Aurora B 
antisense clone 6 30.6 ± 1.9 5/5 35.8 ± 0.8 
pCMV Aurora B 
antisense clone 9 23 ± 2 3/3 28.7 ± 0.6 
pCMV Aurora B 
sense clone 1 59 ± 1.8 4/4 12 ± 0.8 
pCMV Aurora B 
sense clone 5 61.6 ± 2.1 5/5 11.4 ± 1.1  
a Colonies larger than 64 cells were scored after 3 wk. Colony-forming efficiency was calculated with 
the formula: number of colonies formed/number of plated cells x 100. 
b Tumorigenicity was assayed by injecting 1*106 cells into athymic mice (6 weeks old). 
c The animals were monitored for the appearance of tumors. The mean tumour latency is the time 
needed for tumours to reach 10 mm in diameter.  
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5. CONCLUSION 
 
Anaplastic thyroid carcinoma is one of the most aggressive human 
neoplasia, that leads to death in few months. Surgery, radiotherapy and 
chemotherapy have no effects on its prognosis. Therefore, novel therapeutic 
approaches are required.  
Oncolytic viruses are viral mutants able to selectively replicate in tumour 
cells. I have studied the oncolytic adenovirus dl1520 in combination with the 
HMG-Co reductase inhibitor lovastatin, demonstrating that lovastatin enhances 
the oncolytic activity of dl1520 in vitro. Furthermore, I have shown that 
lovastatin acts on viral gene expression, enhancing viral replication, but does 
not affect membrane CAR levels. per os administration of therapeutical dose of 
lovastatin statistically enhances dl1520 oncolytic effect in vivo. Lovastatin is a 
commonly used agent, with few major adverse effects, therefore we suggest 
that it could be used as adjuvant in dl1520 therapy.  
I have also shown that Aurora B expression correlates with malignancy in 
human thyroid carcinoma and its inhibition blocks cell proliferation. Since 
Aurora B inhibitors act on proliferating cells and kill cells with non functional 
p53-mediated post-mitotic checkpoint, this class of drug should have a broad 
therapeutic index and we suggest that Aurora B could be a potential therapeutic 
target for anaplastic thyroid carcinoma. 
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Anaplastic thyroid carcinoma (ATC) is one of the most ag-
gressive solid tumors and shows morphological features of a
highly malignant, undifferentiated neoplasm. Patients with
ATC have a poor prognosis with a mean survival time of 2–6
months; surgery, radiotherapy, and chemotherapy do not im-
prove survival. Gene therapy approaches and oncolytic vi-
ruses have been tested for the treatment of ATC. To enhance
the antineoplastic effects of the oncolytic adenovirus dl1520
(Onyx-015), we treated ATC cells with lovastatin (3-hydroxy-
methylglutaryl-CoA reductase inhibitor), a drug used for the
treatment of hypercholesterolemia, which has previously
been reported to exert growth-inhibitory and apoptotic ac-
tivity on ATC cells. Lovastatin treatment significantly in-
creased the effects ofdl1520 againstATCcells. The replication
of dl1520 in ATC cells was enhanced by lovastatin treatment,
and a significant increase of the expression of the early gene
E1A 13 S and the late gene Pentonwas observed in lovastatin-
treated cells. Furthermore, lovastatin treatment significantly
enhanced the effects of dl1520 against ATC tumor xenografts.
Lovastatin treatment could be exploited to increase the effi-
cacy of oncolytic adenoviruses, and further studies are war-
ranted to confirm the feasibility of the approach in ATC
patients. (Endocrinology 148: 5186–5194, 2007)
THYROID NEOPLASIAS INCLUDE well-differentiatedfollicular and papillary carcinomas, poorly differenti-
ated papillary and follicular carcinomas, and undifferenti-
ated anaplastic carcinomas (1).
Anaplastic carcinoma (ATC) constitutes 1–7% of all thy-
roid cancer cases. It arises from thyroid follicular cells show-
ing morphological features of a highly malignant, undiffer-
entiated neoplasm with multiple atypical mitotic figures; it
reveals no follicular structures, colloid formation, or other
features of thyroid differentiation (2). p53 and -catenin mu-
tations are the genetic alterations most frequently found in
poorly differentiated and anaplastic carcinomas (3).
ATC represents one of the most aggressive human ma-
lignancies because it invariably has a fatal prognosis. In fact,
the absence of active therapies is themajor impediment to the
successful control of the disease (2–4). Therefore, novel ther-
apeutic approaches are required.
Selective replication oncolytic viruses represent a novel
therapeutic approach; adenovirus and other viruses have
been engineered for selective replication within neoplastic
cells. Themost common approach is the deletion of viral gene
whose product is necessary for replication in normal cells but
expendable in cancer cells. Unfortunately, due to the mul-
tifunctional nature of many viral proteins, the gene deletion
approach for viral selective replication frequently results in
a reduced replication and therapeutic potency (5).
The first replication-competent adenoviral mutant de-
scribed, dl1520 (Onyx-015), contains a deletion of E1B-55K,
which inhibits p53 and prevents apoptosis, allowing dl1520
replication in cancer cells lacking functional p53 pathway but
not in normal cells. dl1520 was expected to replicate selec-
tively in a high percentage of human cancers being the p53
pathway nonfunctional in about 50% of human neoplasia.
However, the role of p53 in determining dl1520 selectivity
has remained controversial for years because it was shown
that dl1520 can replicate in tumor cell lines retaining wild-
type p53 sequences, and its replication in primary cells is not
restricted by p53.
Recently it has been shown that E1B-55K mediates late-
viral RNA transport, and dl1520 tumor-selective replication
is determined by a unique property of tumor cells to effi-
ciently export late viral RNA in the absence of E1B-55K. Thus,
loss of E1B-55K-mediated late viral RNA export, rather than
p53 degradation, is the major determinant of dl1520 selective
replication in neoplastic cells (5).
The use of dl1520 oncolytic virus as monotherapy has
demonstrated limitations in efficacy, making more research
necessary for the design of strategies that will increase its
tumor-eradicating potential (6).
dl1520 has been used in conjunction with chemotherapeu-
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tic agents in clinical trials with evidence for potential syn-
ergistic antitumor activity. The use of dl1520 in conjunction
with cisplatin and 5-fluorouracil has been examined in a
phase II clinical trial involving head and neck carcinoma
patients. dl1520 has been used in combination with leucov-
orin and 5-fluorouracil in a phase II trial in patients with
gastrointestinal carcinoma metastatic to the liver and with
gemcitabine in a phase I/II trial in patients with unresectable
pancreatic carcinoma (6, 7). All these studies have shown that
combined treatment with dl1520 and chemotherapy in-
creases the therapeutic effects.
We previously demonstrated an antineoplastic activity of
dl1520 against ATC cell lines; however, high multiplicity of
infections (MOIs) were used (8). Synergistic cell killing ef-
fects of dl1520 with doxorubicin or paclitaxel were observed
in ATC cell lines, with the IC50 drug values reduced 1.75- to
11-fold in the presence of dl1520 (8). We have also shown
increased efficacy of dl1520 followed by ionizing radiations,
compared with either treatment alone (9). These data, pre-
viously obtained by us, suggest that dl1520 may be a valid
tool in the treatment of anaplastic thyroid carcinoma in com-
bination with other agents.
To develop novel therapeutic strategies based on replica-
tion selective adenoviruses, it is important to identify drugs
able to enhance the oncolytic activity. In the present study,
we evaluated the effects of lovastatin in combination with
dl1520 against ATC cells.
Lovastatin (3-hydroxy-methylglutaryl-CoA reductase in-
hibitor), a drug used for the treatment of hypercholesterol-
emia, has been reported to exert growth-inhibitory activity in
vitro and in vivo. Farnesyl- and geranylgeranylpyrophos-
phate, intermediates in the cholesterol synthetic pathway,
are needed for isoprenylation, a crucial step for membrane
attachment of cellular proteins like Ras, Rho, Cdc42, Rac, etc.
(10, 11). By inhibiting protein isoprenylation, lovastatin in-
duces a reduction of cell proliferation and apoptosis (10–11).
Moreover, it has been demonstrated that low doses of lova-
statin induce apoptosis of ATC cells (12, 13).
We have observed that lovastatin significantly enhanced
the antineoplastic activity of dl1520 against ATC cells and its
replication. Furthermore, a significant increase in viral gene
expression was induced by lovastatin in ATC cells. Finally,
the combined treatment induced a significant reduction of
the growth of ATC tumor xenografts.
Materials and Methods
Cell lines and preparation of adenoviruses
The human anaplastic thyroid carcinoma cell lines used in the study
are ARO, FRO, KAT-4, and Cal 62.
ARO and FRO human thyroid anaplastic carcinoma cell lines were
established by Dr. G. J. Juillard (Department of Radiation Oncology,
University of California, Los Angeles, Los Angeles, CA), and ARO and
FRO cell lines were kindly provided by Professor J. A. Fagin (University
of Cincinnati College of Medicine, Cincinnati, OH). KAT-4 cells were
obtained from Dr. Ain (University of Kentucky, Lexington, KY). Cal 62
cell line was obtained from Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH (Braunschweig, Germany), German Collection
of Microorganisms and Cell Cultures.
The NPA line derives from poorly differentiated papillary carcinoma
and was obtained by Dr. G. J. Juillard. The FB1 cell line derives from a
follicular carcinoma (14). Human embryonic kidney (HEK)-293 cells
were obtained from American Type Culture Collection (Manassas, VA).
KAT-4 cells harbor amutated p53 gene, (273Arg-His), whereas FRO
cells express very low levels of p53, but no p53 gene mutation was
observed (8).
Cells were grown in DMEM supplementedwith 10% fetal calf serum,
glutamine, and ampicillin/streptomycin.
dl1520 (ONYX-015), a gift from Dr. A. Balmain (Cancer Research
Institute, University of California, San Francisco, CA) and Dr. I. Ganly
(Memorial Sloan-Kettering Cancer Center, New York, NY), is a chimeric
human group C adenovirus (Ad2 and Ad5) that has a deletion between
nucleotides 2496 and 3323 in the E1B region that encodes the 55-kDa
protein. In addition, there is a C to T transition at position 2022 in region
E1B that generates a stop codon at the third codon of the protein. Viral
stocks were expanded in the HEK-293 cell line and purified, as previ-
ously reported (8).
Stocks were stored at 70 C after the addition of glycerol to a con-
centration of 50% (vol/vol). Virus titer was determined by plaque-
forming units (pfu) on the HEK-293 cells.
Adenovirus infection
Cells were detached, counted, and plated in 6-well plate at 70% cell
density. After 24 h, cells were infected with a green fluorescent protein
(GFP)-transducing adenovirus (AdGFP), a nonreplicating E1 and E2-
deleted adenovirus encoding GFP, diluted in growth medium at dif-
ferent MOIs; medium was replaced after 2 h. Cells were washed 24 h
after infection and then trypsinized, washed, and resuspended in 300 l
PBS and analyzed for GFP expression on a fluorescence-activated cell
sorter (FACS) cytometer (Dako Cytomation, Carpinteria, CA) and Sum-
mit version 4.3 software (Dako, Carpinteria, CA).
Different treatment conditions were used for the evaluation of lova-
statin effects: antineoplastic effects were evaluated in the presence of
lovastatin, whereas experiments designed to evaluate the effects of the
drug on the early phases of viral infection were performed with a short
treatment time.
For the evaluation of lovastatin effects on adenoviral entry and GFP
expression, the cells were treated for 16 hwith 10m lovastatin and then
infected for 24 h with AdGFP. Cells were harvested and prepared for
FACS analysis as previously described.
For the evaluation of the cytoxic effects of the dl1520 virus, 1  103
cells were seeded in 96-well plates, and 24 h later lovastatin was added
to the incubation medium. After an additional 16 h, medium was re-
placed with a medium containing or not lovastatin plus dl1520 at dif-
ferent MOIs. After 14 d the cells were fixed with 10% trichloroacetic acid
and stained with 0.4% sulforhodamine B in 1% acetic acid (15). The
bound dye was solubilized in 200 l of 10 mm unbuffered Tris solution,
and the optical density was determined at 490 nm in amicroplate reader
(Bio-Rad Laboratories, Mu¨nchen, Germany). The percent of survival
rates of treated cells were calculated by assuming the survival rate of
untreated cells to be 100%.
Quantitative PCR of dl1520
To quantify the amount of dl1520 virus genome on lovastatin treat-
ment, ATC cells were treated with 10 m lovastatin for 16 h and then
media replaced with a medium containing different MOIs of dl1520
alone orwith lovastatin. After 24 h of infection, cell mediawere collected
and viral DNA extracted using a QIAamp DNA minikit (QIAGEN,
Valencia, CA). Viral DNA was then quantified by real-time PCR using
assay-specific primer and probe. A real-time-based assaywas developed
using the following primers: 5-GCCACCGAGACGTACTTCAGC-
CTG-3 (upstream primer) and 5-TTG TAC GAG TAC GC G GTA
TCCT-3 (downstream primer) for the amplification of 143 bp sequence
of the viral hexon gene (from bp 99 to 242 bp). For quantification, a
standard curve was constructed by assaying serial dilutions of dl1520
virus ranging from 0.1 to 100 pfu.
To quantify the amount of dl1520 virus genome in tumor xenografts,
total DNA was extracted from 20 mg of each sample using a DNA
purification system (Promega Corp., Madison, WI). DNA was resus-
pended in 200 l of water and 2 l used for the real-time PCR-based
assay. For each experiment the DNA was extracted from three different
samples of each treatment group.
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Quantitative RT-PCR of dl1520 gene expression
Cells were infected with 10 or 100 pfu of dl1520, in the presence or in
the absence of 10 m of lovastatin, and harvested at 24 h after infection.
Cells were dissolved in 1 ml Trizol (Invitrogen, Carlsbad, CA). RNA
quality was evaluated by agarose gel electrophoresis; DNase treatment
was performed. One microgram of total RNA was reverse transcribed
and the expression of E1A 13 S and Penton genes monitored using
real-time PCR with the following specific primers: E1A 13 S forward,
5-AATGGCCGCCAGTCTTTT-3 and reverse, 5-ACACAGGACTG-
TAGACAA-3; Penton forward, 5-TAACCAGTCACAGTCGCAAG-3
and reverse, 5-CCCGCGCCTTAAACTTATT-3 (16). To calculate the
relative expression levels, we used the 2[][]cycle threshold (Ct)
method. Negative controls, samples without RT-PCR, or CDNA tem-
plate were included in every PCR run, always resulting negative (data
not shown).
Detection of cell surface coxsackievirus-adenovirus receptor
(CAR) receptor
Cells were grown in six-well plates. After 48 h cells were detached in
PBS-EDTA 10 mm, washed with PBS, and then incubated 1.5 h in FACS
buffer with a mouse anti-CAR monoclonal antibody RmcB (1:250) (17).
After washing, the cells were incubated in FACS buffer containing the
secondary antibody conjugated to fluorescein isothiocyanate (FITC) (1:
100; Sigma, St. Louis, MO) and analyzed for CAR expression on a Cyan
cytometer (Dako Cytomation) and Summit version 4.3 software (Dako).
Human thyroid tissue samples and real time RT-PCR
Normal and neoplastic human thyroid tissues were obtained from
surgical specimens and immediately frozen in liquid nitrogen. Thyroid
tumors were collected at the Laboratoire d’Histologie et de Cytologie,
Centre Hospitalier (Lyon Sud, France) and the Laboratoire d’Anatomie
Pathologique, Hospital de L’Antiquaille (Lyon, France).
Total RNAwas isolated and DNase digested using the RNeasy mini-
kit (QIAGEN) according to the manufacturer’s recommendations. One
microgramof total RNA fromeach samplewas reverse transcribedusing
random hexamers as primers andMoloney leukemia virus reverse tran-
scriptase (Applied Biosystems, Foster City, CA) to yield cDNA.
To design a quantitative PCR assay, a human ProbeLibray system
(Exiqon, Vedbaek, Denmark) was used. Probe and primers pair to am-
plify a fragment for real-time PCR of Cxadr mRNA were selected en-
tering its accession number (NM001338.3) on the assay design page of
the ProbeFinder software. ProbeFinder generated an intron-spanning
assay identifying the exon-exon boundarieswithin submitted transcript.
An amplicon of 93 nucleotides scattered among sixth and seventh exon
was selected. The primer sequences were: Cxadr forward, 5-AT-
GAAAAGGAAGTTCATCAACGTA-3, Cxadr reverse, 5-AATGAT-
TACTGCCGATGTAGCTT-3. The same procedure was used to select
probe and primes for housekeeping gene G6PDH, accession no. X03674.
The primer sequences were: G6PDH forward, 5-ACAGAGTGAGC-
CCTTCTTCAA-3, G6PDHreverse, 5-GGAGGCTGCATCATCGTACT-
3. All fluorigenic probes were dual labeled with FAM at 5end andwith
a black quencer at the 3end.
Relative quantitative TaqMan RT-PCR was performed in a Chromo4
detector (MJ Research, Waltham, MA) in 96-well plates using a final
volume of 25 l. The conditions used for PCR were 10 min at 95 C and
then 45 cycles of 20 sec at 95 C and 1 min at 60 C. Each reaction was
performed in duplicate. To calculate the relative expression levels, we
used the 2[][]Ct method, where [][]Ct []Ct,sample []Ct,reference.
Written informed consent was obtained from all participants. The
study protocol was approved by the ethics committees of the Centre
Hospitalier Lyon Sud and the University Federico II, Napoli, and con-
ducted in accordance with the principles of the Declaration of Helsinki
as revised in 2000.
Protein extraction and Western blot analysis
In all experiments 70% confluent cells were used. Cells were homog-
enized directly into lysis buffer (50 mm HEPES, 150 mm NaCl, 1 mm
EDTA, 1 mm EGTA, 10% glycerol, 1% Triton X-100, 1 mm phenylmeth-
ylsulfonyl fluoride, 1 g/ml aprotinin, 0.5 mm sodium orthovanadate,
20 mm sodium pyrophosphate). The lysates were clarified by 20 min
centrifugation at 14,000  g. Protein concentrations were estimated by
a Bio-Rad assay, and then proteins were boiled in Laemmli buffer [Tris-
HCl (pH 6.8) 0.125 m, sodium dodecyl sulfate 4%, glycerol 20%, 2-mer-
captoethanol 10%, bromophenol blue 0.002%] for 5 min before electro-
phoresis. Proteins were subjected to SDS-PAGE (10% polyacrylamide)
under reducing conditions. After electrophoresis, proteins were trans-
ferred to nitrocellulose membranes (Immobilon; Millipore Corp., Bil-
lerica, MA); complete transfer was assessed using prestained protein
standards (Bio-Rad, Hercules, CA). After blocking with Tris-buffered
saline-BSA [25 mm Tris (pH 7.4), 200 mmNaCl, 5% BSA], the membrane
was incubated with the primary polyclonal rabbit antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) against CAR receptor SC-15–405 (1:200)
for 1 h (at room temperature) or with the monoclonal antibody against
against-actin (Sigma).Membraneswere then incubatedwith the horse-
radish peroxidase-conjugated secondary antibody (1:10,000) for 45 min
(at room temperature), and the reaction was detected with an ECL
system (Amersham Life Science, Buckinghamshire, UK).
Tumorigenicity assay
Experiments were performed with 6-wk-old female athymic mice
(Charles River, Calco, Lecco, Italy). FRO cells (4 106) were injected into
the right flank of 80 athymic mice. After 20 d, when tumors were clearly
detectable, the animals were divided into four groups (20 animals/
group), and tumor volume was evaluated. Two groups received lova-
statin in the drinking water (40 mg/1000 ml) and after 6 d dl1520 (5 
107 pfu) was injected in the peritumoral area in a group treated with
lovastatin and in an untreated group.
Tumor diameters were measured with calipers every second day by
two blind and neutral observers until the animals were killed. Nomouse
showed signs of wasting or other indications of toxicity. Tumor volumes
were calculated by the formula of rotational ellipsoid: Tumor volume
A B2/2, where A is the axial diameter and B is the rotational diameter.
All mice were maintained at the Dipartimento di Biologia e Patologia
Cellulare e Molecolare Animal Facility. The animal experimentations
described hereinwere conducted in accordancewith accepted standards
of animal care and in accordance with the Italian regulations for the
welfare of animals used in studies of experimental neoplasia, and the
study was approved by our institutional committee on animal care.
The amount of lovastatin administered was chosen considering that
the average daily water intake for each mouse was 5–7.5 ml and 10
mg/kg/d was the best dose of lovastatin for obtaining biological effects
in mice.
To evaluate the genome equivalent copies of dl1520 in tumor xeno-
grafts, three animals bearing FRO xenografts received lovastatin in the
drinking water (40 mg per 1000 ml). After 6 d, dl1520 (5  107 pfu) was
injected in the peritumoral area of the mice treated with lovastatin and
in three untreated mice.
After 48 h animals were killed, tumors excised, DNA extracted, and
viral replication evaluated by real-time PCR. DNAquality was analyzed
by real-time PCR of the -actin gene.
Statistical analysis
Comparisons among different treatment groups in the experiments
in vivo were made by the ANOVA method and the Bonferroni post hoc
test using a commercial software (Prism 4; GraphPad, San Diego, CA).
Assessment of differences among rate of tumor growth in mice was
made for each time point of the observation period; treatment groups
were control, dl1520, lovastatin, and lovastatin plus dl1520.
The analysis of the cell-killing effect in vitro was also made by the
ANOVA method and the Bonferroni post hoc test. For all the other
experiments, comparisons among groups were made by the ANOVA
method and t test.
Results
Analysis of adenoviral infectivity of human thyroid
carcinoma cell lines
To evaluate the susceptibility of ATC cells to adenoviral
infection, we infected a panel of thyroid carcinoma cell lines
using an AdGFP; the results are shown in Fig. 1A.
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The anaplastic thyroid carcinoma cell linesARO, FRO, and
KAT-4 display the lowest percentage of fluorescent cells at
all the MOIs used; indeed 100 pfu/cell are required to obtain
greater than 50% ARO- and KAT-4-positive cells, whereas at
10 pfu/cell, about 50% of FRO cells are positive. Conversely,
follicular thyroid carcinoma cell line FB1 and papillary thy-
roid carcinoma cell line NPA showed about 90% of GFP-
positive cells at 10 MOI. As a positive control HEK-293 cells
were used.
Because adenoviral infection occurs via the attachment to
the CAR (18), we analyzed CAR expression by Western blot;
two CAR-specific bands of 44 and 46 kDa, respectively, were
detected in all the samples (Fig. 1B). However, certain dif-
ferences were observed in their levels; in ATC cell lines,
variable levels ranging from very low to intermediate were
observed; the papillary thyroid carcinoma-derived NPA cell
line, the follicular carcinoma-derived FB-1 cell lines, and the
ATC-derived KAT-4 cell line express the highest CAR levels.
A cytofluorimetric analysis was performed to evaluate the
presence of CAR on the cell membrane (Fig. 1C), showing the
absence of CAR on the cell surface in FRO, NPA, Cal 62, and
FB1 cells. This observation suggests a CAR-independent en-
try of AdGFP in these cell lines. The cell lines ARO and
KAT-4 showed the presence of CAR on the cell membrane
despite being the less susceptible to adenoviral infection.
To confirm that anaplastic thyroid carcinomas express low
levels of CAR, we evaluated the CAR mRNA levels in human
thyroid carcinoma tissuesbyRT-PCR. Significantly lower levels
(**, P  0.01) in CAR gene expression were observed in pap-
illary carcinomas, follicular carcinomas, and anaplastic thyroid
carcinomas with respect to normal thyroid samples (Fig. 2).
Lovastatin enhances the cell killing effects and the
replication of the oncolytic adenovirus dl1520
Because our data show that ATC are not readily infected
by therapeutic adenoviruses, we decided to evaluate the
effects of lovastatin in combination with dl1520. KAT-4 cells
were chosen as representative of ATC cells at low sensitivity
to the infection with dl1520; the FRO cell line was chosen as
representative of an intermediate infectivity (8, 9).
In both cell lines, the combined treatment enhanced the
cell-killing activity of dl1520. In FRO cells treated with 10
pfu/cell of dl1520, an additive and significant (2.5 m) and
FIG. 1. A, Percentage of positive cells upon AdGFP infection. Cells were infected at different MOIs with AdGFP, and after 24 h the percentage
of fluorescent cells was evaluated by FACS analysis. ATC cell lines ARO and KAT-4 were the less sensitive to AdGFP infection at all MOIs
used, whereas FRO and Cal 62 cells displayed a higher percentage of GFP-expressing cells. FRO cells showed about 50% of GFP-positive cells
at 10 MOI; conversely, Cal 62 at the same MOI showed about 80% of positive cells. Follicular thyroid carcinoma cell line FB1 and papillary
thyroid carcinoma cell line NPA showed about 90% of GFP-positive cells at 10 MOI. HEK-293 cells were used as a positive control. The data
are the mean of three different experiments; the bar represents the SD. B, Western blot analysis of CAR expression in thyroid carcinoma cell
lines. Cal 62, FRO, and ARO cells showed low expression of total CAR levels, whereas FB1, KAT-4, and NPA cells expressed the higher of total
CAR levels. Equal amounts of protein lysates (50 g) were loaded. C, Cytofluorimetric analysis of CAR expression on the membrane of thyroid
carcinoma cell lines. Flow cytometry analysis showed the absence of cell surface CAR expression in FRO, NPA, Cal 62, and FB1 thyroid cancer
cell lines. ARO and KAT-4 cell lines showed the presence of CAR on the membrane. HEK-293 cells were used as positive control. Cells were
incubated with a anti-CAR (RmcB) monoclonal antibody or FITC-labeled mouse alone. In all experiments, 70% confluent cells were used.
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highly significant (5m) increase in cell killingwas observed.
In KAT-4 cells a highly significant increase in cell killing was
induced by lovastatin treatment at all MOIs and lovastatin
concentrations used (Fig. 3A).
Next, we quantified the amount of dl1520 virus genome by
real-time PCR in FRO and KAT-4 cells untreated, treated
with lovastatin for 16 h (lovastatin 16 h) before infection, or
kept in the presence of lovastatin after the infection (lova-
statin) and infected with different MOIs. In FRO cells at 10
pfu/cell, both lovastatin treatments induced an highly sig-
nificant (**, P  0.01) increase in viral replication (Fig. 3B).
KAT-4 cells kept in the presence of lovastatin also showed a
highly significant increase in viral replication (**, P  0.01),
whereas 16 h treatment did not modify viral replication.
Lovastatin enhances the expression of viral genes
Because ATC cells infected in the presence of lovastatin
show an increase in viral replication, we decided to evaluate
the infectivity of ATC cells in the presence of lovastatin.
KAT-4 and FRO cells were pretreated with a noncytotoxic
concentration of lovastatin (10 m) for 16 h and then infected
with AdGFP at different MOIs. FACS analysis of treated or
untreated cells showed that lovastatin treatment induced a
highly statistically significant (**, P  0.01) increase in the
number positive cells ranging from 3 up to 10% (Fig. 4A).
Both cell lines showed a strong increase in fluorescence to
cell ratio on lovastatin treatment (Fig. 4A).
Pharmacological inhibitors of the Raf-MAPK kinase
(MEK)-ERK pathway up-regulates CAR expression on the
cell surface of cancer cells (19); lovastatin is a well-known
inhibitor of p21 Ras isoprenylation and activity. Therefore,
we evaluated the effects of lovastatin on CAR expression in
FIG. 2. CAR expression in thyroid carcinoma tissues. Three normal
thyroid samples (1–3), eight anaplastic (4–11), two follicular (12 and13),
and four papillary (14–17) thyroid carcinomas were used for real-time
RT-PCRanalysis ofCARexpression, showinga reduction inCARmRNA
levels in all neoplastic tissues with respect to normal thyroid samples.
FIG. 3. A,Lovastatin treatment enhances the cell-killing effects of the oncolytic adenovirusdl1520.FROandKAT-4 cellswere treatedwith lovastatin
and then infectedwith the oncolytic adenovirus dl1520 at differentMOIs. In FRO cells kept in the presence of lovastatin, a highly significant increase
(**,P 0.01) in the cell-killing activity of 10 pfu/cell of dl1520was observed in associationwith 5M of lovastatin. In KAT-4 cells kept in the presence
of 1 and 2.5 M of lovastatin, a highly significant increase (**, P  0.01) of the cell-killing activity in combination with 1 and 2.5 pfu/cell of dl1520
wasobtained.Viral concentrationable to induce thesamecell-killing in the twocell lineswereused.Thedataareexpressedaspercentagesofuntreated
control cells andare themeanof five different experiments; thebar represents the SD.B,Lovastatin treatment enhances the replication of the oncolytic
adenovirus dl1520. FROandKAT-4 cells were treatedwith lovastatin (10M) for 16 h and then infectedwith amedium containing dl1520 (lovastatin
16 h) or dl1520 plus lovastatin (lovastatin). FRO cells at 10 pfu/cell showed a highly significant increase (**, P  0.01) of dl1520 replication in both
groups. KAT-4 cells at 5 and 10 pfu/cell showed a highly significant increase (**, P 0.01) of dl1520 replication only in the group kept in the presence
of lovastatin. The data are the mean of three different experiments; the bar represents the SD.
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ATC cells. CAR levels on cell surface, evaluated by FACS
analysis (Fig. 4B), were not modified by lovastatin treatment.
Because lovastatin-treated cells showed an increased in flu-
orescence to cell ratio, we hypothesized that lovastatin treat-
ment could enhance viral gene expression. To monitor the ex-
pression of adenoviral genes in lovastatin-treatedATC cells we
selected two adenoviral genes, whose expression is correlated
with different stages of the adenoviral life-cycle: E1A 13 S rep-
resenting genes transcribed from the immediate early region
and Penton representing genes expressed from the late region.
FRO and KAT-4 cells were infected respectively with a
MOI of 100 and 10 pfu of dl1520 in the presence or in the
absence of lovastatin (10 m). The expression levels of E1A
13 S and Penton gene were measured by real-time RT-PCR at
24 h. Cotreatment with lovastatin significantly (*, P  0.05)
enhanced the expression levels of E1A 13 S and Penton gene
in both cell lines (Fig. 5).
Lovastatin in combination with dl1520 reduces the growth
of ATC tumor xenografts
To demonstrate that the combined treatment lovastatin
and dl1520 could potentially yield improved clinical efficacy,
we evaluated the effects of lovastatin treatment in vivo.
FRO cells were injected into the right flank of athymic mice,
and after 20 d, when tumors were clearly detectable (T  0),
animals were randomized into four groups and lovastatin was
added in the drinking water of two groups. The animals re-
ceived lovastatin until the end of the experiment. After 6 d
dl1520 was injected within the tumor (T  6), twice per week.
In Fig. 6A, tumorgrowth is expressed as apercentage of growth
relative to the volume observed at T  0.
dl1520 treatmentwas able to significantly reduce (*,P 0.05)
the growth of tumor xenografts in the initial phase of the treat-
ment (up to T  30). Conversely, the combination lovastatin
plus dl1520was able to induce a highly significant reduction (**,
P  0.01) in tumor growth until the end of experiment, con-
firming that lovastatin enhances the antineoplastic effects of
dl1520. No toxicities were observed in treated animals.
Finally, we evaluated by real-time PCR (Fig. 6B) the genome
equivalent copiesofdl1520 inanimalsbearingFROxenograftsand
treated with dl1520 and dl1520 plus lovastatin. Lovastatin treat-
ment was able to induce a 10-fold increase in viral replication.
Discussion
ATC represents one of the most lethal human neoplasia
being refractory to conventional therapies, including sur-
FIG. 4. A, Percentage of GFP-positive cells and fluorescence to cell ratio in lovastatin-treated cells. FRO and KAT-4 cells were treated with 10 M
of lovastatin for 16 h and then infected with AdGFP at different MOIs. FACS analysis was performed 24 h after the infection. Lovastatin increased
the percentage of AdGFP-positive KAT-4 and FRO cells (upper panel). Highly significant difference between treated and untreated cells is observed
in both cell lines starting from 10 pfu/cell point. Lovastatin-treated cells showed an increase in fluorescence to cell ratio (lower panel). The difference
is statistically high (P  0.01), starting from 25 pfu/cell (FRO cells) or 50 pfu/cell (KAT-4 cells).The data are the mean of five different experiments;
the bar represents the SD.B, Lovastatin does notmodifyCARexpression on the cell surface ofKAT-4 andFROcells.KAT-4 andFROcellswere treated
with 10M lovastatin for 16 h and then incubatedwith anti-CAR (RmcB)monoclonal antibody (lovastatin) and comparedwith untreated control cells
(control). Background emission was assessed by incubating KAT-4 and FRO cells with FITC-labeled mouse alone (FITC). CAR expression was not
modified by lovastatin treatment. The data are representative of three different experiments.
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gery, radioactive iodine, and chemotherapy (2–4). Develop-
ment and evaluation of novel treatment strategies are
needed.
Replication-selective oncolytic viruses (virotherapy) are
being developed as a novel, targeted form of anticancer treat-
ment. dl1520 (Onyx-015) was the first virus that had been
genetically engineered for replication-selectivity for treat-
ment in cancer patients. Recent results from a phase III clin-
ical trial have confirmed the ability of an oncolytic adeno-
virus (H101) bearing an E1B-55kD gene deletion similar to
that present in dl1520 to increase the response rate of naso-
pharyngeal carcinoma in combination with cisplatin (20).
Selective oncolytic replicating adenoviruses have been
tested inATC cell lines and tumor xenografts showing prom-
ising results (8, 9); however, high MOIs of dl1520 were re-
quired to efficiently kill ATC cells.
The efficacy of oncolytic adenoviruses as therapeutic
agents relies on the capability of target neoplastic cells to
bind, internalize, and sustain the replication of adenoviruses.
We analyzed the infectivity of a panel of human thyroid
carcinoma cell lines, showing a low infectivity in most ATC
cell lines. Conversely, papillary or follicular thyroid carci-
noma cells display a higher infectivity. In a previous study,
we evaluated the infectivity of ATC cell lines ARO, KAT-4,
and FRO infecting the cells for 48 h with a lacZ-transducing
adenovirus and evaluating the percentage of infected cells
counting stained cells in randomly selected fields. The dif-
ferent results obtained in the two studies can be explained
with the use of different reporter genes, infection times, and
detection techniques.
Adenovirus internalization relies on the presence of cell
surface of the CAR; a Western blot analysis has been per-
formed on total cell lysates showing discrete or high expres-
sion levels of CAR.However, cytofluorimetric assay for CAR
expression on cell surface showed a low or absent expression
of CAR, suggesting a CAR-independent adenoviral entry in
thyroid carcinoma cells lines. Furthermore, a significant re-
duction in CAR gene expression was observed in anaplastic
FIG. 6. Tumor growth delay induced by lovastatin and dl1520. A, Relative tumor growth of animals treated with dl1520 and lovastatin and
control groups. Lovastatin treatment alone did not show statistically significant differences with the untreated control, whereas dl1520 induced
a statistically significant reduction (P  0.05) in the initial phase of the treatment (up to T  30). The combination of dl1520 plus lovastatin
significantly delayed tumor growth, compared with dl1520 single treatment group from T  36 (P  0.01). Data are presented as mean  SD.
B, Genome equivalent copies in tumor xenografts. A 10-fold increase in genome equivalent copies in tumor xenografts excised from lovastatin
plus dl1520 group was observed. The data are the mean of three different experiments; the bar represents the SD.
FIG. 5. Lovastatin increases viral gene
expression in ATC cells. FRO and KAT-4
cells were treated with 10 M of lovastat-
in; after 16 h cells were infected with
dl1520. For FRO cells a MOI of 100 pfu
was used; KAT-4 cells were infected with
10 pfu. After 24 h the levels of expression
of the adenoviral immediate early region
gene E1A 13 S and the adenoviral of late
region gene Penton were measured by
real-time RT-PCR. Lovastatin treatment
significantly enhanced the expression
levels of theE1A 13 S and Penton gene. In
FRO cells a 4-fold increase of E1A 13 S
expression levels and 16-fold increase of
Penton gene were obtained. In KAT-4
cells, a 5-fold increase of E1A 13 S ex-
pression levels and 12-fold increase in
Penton expression levels were observed.
The data are the mean of three different
experiments; the bar represents the SD.
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thyroid carcinomas samples, compared with normal thyroid
tissues.
Our observations are in agreement with previous studies
and confirm a low susceptibility of ATC cells to therapeutic
approaches based on adenoviral vectors (21).
It is worth noting that CAR expression is negatively reg-
ulated by TGF- during the switch from epithelial to mes-
enchymal phenotype, and human pancreatic carcinoma cells
show loss of epithelial differentiation and CAR surface lo-
calization on TGF- treatment (22). In ATC cell lines, we
observed discrete or high total expression levels of CAR and
loss of surface localization of CAR. Our results indicate that
the loss of thyroid differentiation, a typical feature of ATC,
causes an intracellular localization of CAR receptor, proba-
bly by increasing the recycling of CAR receptors or shifting
them to the cytosol.
BecauseATC cells display a low infectivity and a highMOI
of dl1520 is required to efficiently kill these cells, we decided
to enhance the oncolytic activity by using lovastatin in com-
bination with dl1520.
Lovastatin, a drug used for the treatment of hypercholes-
terolemia, has previously been reported to exert growth-
inhibitory activity in vitro and in vivo. Farnesyl- and gera-
nylgeranylpyrophosphate, intermediates in the cholesterol
synthetic pathway, are needed for isoprenylation a crucial
step for membrane attachment of cellular proteins like of p21
Ras, Rho, Cdc42, Rac, etc. (10). By inhibiting protein isopre-
nylation, lovastatin exerts its cellular effects, including a
reduction of cell proliferation and induction of apoptosis
(10). It is worth noting that low doses of lovastatin induce
apoptosis or differentiation of ATC cells (11, 12).
Our study demonstrates that the treatment of ATC cell
lines KAT-4 and FRO with lovastatin significantly increased
the effects of dl1520.
A significant increase in viral replication was observed in
lovastatin-treated cells. In FRO cells a significant increase
was observed infecting lovastatin-treated cells with 10 pfu/
cell, whereas at 1 pfu/cell, no significant differences were
observed. In KAT-4 cells kept in the presence of lovastatin
and infected with 5 or 10 pfu/cell, significant increase was
observed; however, the pretreatment with lovastatin for 16 h
was not able to increase viral replication.
These results suggest that the increase in viral replication
observed treating ATC cells with lovastatin is viral dose or
lovastatin treatment time dependent. Therefore, it is possible
that higher MOIs of dl1520 in combination with a 16-h lo-
vastatin pretreatment could result in enhanced viral repli-
cation in KAT-4 cells.
Increased infection efficacy could account for the increased
oncolytic activity after lovastatin treatment; moreover, lova-
statin inhibits the isoprenylation and the activity of p21 ras,
blocking MEK activity, and it has been reported that MEK
inhibitors, U0126 and PD184352, increase the expression of
CAR protein and adenoviral entry in cancer cells (19). There-
fore, we evaluated the adenoviral entry and CAR expression
levels in ATC cell lines treated with lovastatin. We observed
a modest, albeit significant, increase in adenoviral entry (3–
10%), which that it is not sufficient to explain the effects of
lovastatin on viral replication and cell survival.
CAR expression levels either total (data not shown) or on
the cell surface were not modified by lovastatin treatment.
Cholesterol deprivation of FRO and KAT-4 cells did not
modify adenoviral entry (data not shown), suggesting that
the effects of lovastatin were not mediated by the inhibition
of cholesterol synthesis.
It has been shown that lovastatin inhibits the invasiveness
of an ATC cell line (ARO) and focal adhesion kinase phos-
phorylation, a nonreceptor tyrosine kinase playing a crucial
role in integrin-mediated cell adhesion (23); therefore, it is
not possible to exclude that lovastatin induces changes in
integrin pattern on cell surface. Because it has been suggested
that integrins can act as a coreceptor for adenovirus types 2
and 5 (24), the modest increase in adenoviral entry observed
by us could be due to changes in integrins pattern induced
by lovastatin. Further studies are required to verify this
hypothesis.
A high increase in the fluorescence to cell ratio of lovas-
tatin-treated cells was observed. This observation suggested
to us that the drug could enhance the expression of viral
genes, thereby increasing viral replication. To confirm this
hypothesis, the expression of two viral genes, representing
the early and the late phases, was analyzed in ATC cells
infected with dl1520. Lovastatin increased significantly the
expression of early gene E1A 13 S and a late gene Penton.
It has been proposed that drugs able to affect the cell cycle
could enhance viral oncolysis by modulating viral gene ex-
pression (25). Lovastatin together with other clinically used
statins (fluvastatin and simvastatin) induces a G1 arrest of
prostate cancer cells (26). A block of the cell cycle inATC cells
could enhance viral gene expression and increase the repli-
cation of dl1520. Further studies are required to clarify the
mechanisms responsible for the effects of lovastatin on dl1520
gene expression and replication.
The administration of lovastatin per os to nude mice bear-
ing ATC tumor xenografts enhances the antitumoral effects
of dl1520 and increases the viral replication in vivo, confirm-
ing that this treatment could improve the clinical efficacy of
replicating oncolytic adenoviruses. Interestingly, the injec-
tion of lovastatin and the virus within the tumor did not
increase the effects of dl1520 (data not shown), indicating that
a constant lovastatin blood concentration should be obtained
to enhance the effects of dl1520.
The data presented here identify lovastatin as a promising
agent for increasing the effects of oncolytic adenoviruses in
ATC cells. It has been reported that FR901228 and trichos-
tatin A, members of a new group of anticancer agents, the
histone deacetylase inhibitors (27–29), or the MEK inhibitors
U0126 and PD184352 (18) increase the antineoplastic effects
of oncolytic adenoviruses. However, these agents have been
used in a limited number of clinical trials, whereas 3-hy-
droxy-3-methylglutaryl coenzyme A reductase inhibitors
have been widely used to reduce cardiovascular diseases
withoutmajor adverse effects (10, 11). Lovastatin is generally
well tolerated; the most important adverse effect is myotox-
icity within the first 3 months of therapy (11). The risk of
muscle dysfunction is increased by coadministration of other
drugs able to interfere with lovastatin metabolism (11).
In the present study, in in vitro experiments, lovastatinwas
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used at final concentrations ranging from 2.5 to 10 m, and
in in vivo,we used a lovastatin concentration of 10mg/kg/d.
Although the therapeutic dose for the treatment of hyper-
cholesterolemia is about 1 mg/kg/d, which yields serum
levels of 0.1 m, it has been shown that serum concentrations
of 2–4 m of lovastatin are well tolerated in animal models,
and clinical trials of phase I and II have been performedusing
25 mg/kg/d with encouraging results (11). All these data
indicate that lovastatin at a dose of 10 mg/kg/d could prob-
ably be used in ATC patients in combination with dl1520
without major side effects.
In conclusion, we have identified lovastatin as a drug that
increases adenoviral replication and enhances the effects of
an oncolytic adenovirus in vitro and in vivo against ATC cells.
Therefore, lovastatin could be useful in the context of gene
therapy for anaplastic thyroid carcinoma. Further studies are
required to confirm the feasibility of this approach in ATC
patients.
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AuroraBExpressionDirectlyCorrelatesWith
ProstateCancerMalignancyand Influence
ProstateCell Proliferation
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BACKGROUND. Chromosomal instability is one of the most common features of prostate
cancer (PC), especially in advanced stages. Recent studies suggest that defects in mitotic
checkpoints play a role in carcinogenesis. Lack of mitotic regulation induces aneuploidy in
cancer cells acting thereafter as a driving force for malignant progression. Serine/threonine
protein kinases of theAurora genes family play an important throughout the entire cell cycle. In
that Aurora B regulates chromosome segregation by ensuring the orientation of sister
chromatids. As a consequence, the overexpression of Aurora B in diploid human cells NHDF
induces the appearance of multinucleate cells.
METHODS. Archive samples of normal and neoplastic prostate tissue, and prostate derived
cell lines were screened for the expression of Aurora B.
RESULTS. Immunohistochemical analysis showed increased nuclear expression of Aurora-B
in high Gleason grade PCs respect to low and intermediate grade cases and in all cancers in
respect to hyperplastic and normal glands. Furthermore, in the high Gleason grade anaplastic
cancer tissuesAurora B expressionwas accompanied by the phosphorylation of the histoneH3.
In analogy to the in vivo situation, Aurora B was vigorously expressed in the androgen
independent PC cell lines PC3 and DU145, while a very modest expression of the kinase was
observed in the androgen sensitive LnCap cells and in the EPN cells, a line of epithelial cells
derived from normal prostate tissue. In addition, in PC3 cells Aurora B expression is ac-
companied the by the phosphorylation of the histone H3. The block of Aurora B expression
induced by an inhibitor of Aurora kinase activity significantly reduced the growth of prostate
carcinoma cells, but not that of non-transformed EPN cells.
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CONCLUSIONS. Our data are the first demonstration of a role of Aurora B in PC progression.
In addition, the observation that Aurora B specific inhibitors interfere with PC cell proliferation
but notwith that of non-transformedprostate epithelial cells suggest thatAurora B is a potential
therapeutic target for PC. Prostate 66: 326–333, 2006. # 2005 Wiley-Liss, Inc.
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INTRODUCTION
Prostate cancer (PC) is the most common neoplasia
in men and the second leading cause of death after
cardiovascular diseases [1]. Because the complex struc-
ture of the prostate gland and the lack of appropriate
model systems the mechanisms underlying initial
development and progression of PC are still largely
unknown. In addition, a part from PSA, reliable bio-
chemical or genetic markers for early cancer detection
or for prognostic use are not available at the moment
and the diagnosis, and the disease management are
complicated by the multifocal presentation and the
phenotypic and genotypic heterogeneity of PC [2–4].
The molecular model of PC progression from initial
normal dysplasia to terminal late-stage metastatic
disease suggests the involvement of multiple genetic
alterations. High-grade prostate intraepithelial neopla-
sia (HPIN) is the most likely precursor of PC [5].
Currently there is no available clinical, immunohis-
tochemical, or morphologic criteria that are predictive
of this progression. As a consequence it is very impor-
tant to recognize early markers enabling us to dis-
criminate between the pre-neoplastic lesion,whichwill
progress into invasive cancer and those that will not
progress. Chromosomal instability leading to the gen-
eration of numerical and structural changes has been
implicated in the pre-neoplastic and neoplastic stages
of PC. Unstable chromosome number in cancer cells is
currently believed to act as a driving force during the
malignant progression and aneuploidy is the most
prevalent genomic alteration identified in solid tumors
[6,7]. A critical step for the maintenance of genetic
stability is the chromosome segregation, which re-
quires a high coordination of cellular process [8,9]. Loss
of the mitotic regulation is a possible cause of aneu-
ploidy in human epithelial malignancy and it is
thought to create an abnormal nuclear morphology in
cancer cells. Serine/threonine protein kinases of the
Aurora genes family play a regulatory role from G2 to
cytokinesis, encompassing key cell cycle events such as
centrosome duplication, chromosome bi-orientation,
and segregation [10,11]. The family of theAurora genes
includes Aurora A/STK-15, Aurora B/AIM-1, and
Aurara C/AIK3. Aurora A is overexpressed in several
solid tumors, and NIH 3T3 fibroblasts overexpressing
AuroraAgene showan increase in centrosomenumber
and aneuplody leading to neoplastic transformation
[12–14].
Aurora B is a chromosome passenger protein, loca-
lized on the centromeres from prophase through the
metaphase-anaphase transition [10,14–19]. Another
chromosome passenger protein is INCENP, which
tightly associates with Aurora B, probably regulating
its activity. Survivin, a conserved inhibitor of apoptosis
(IAP) like protein is a third member of the Aurora B
complex [8,9]. Aurora B has been described to phos-
phorylate histone H3 at ser-10 and phosphorylation
of histone H3 is required for proper chromosome
dynamics during mitosis [14–19]. It has been also
demonstrated that Aurora B overexpression in diploid
human cells NHDF induces multinuclearity. Further-
more, Aurora B transfected cells have an unstable
chromosome number and show an aggressive pheno-
type in vivo [18,19].
Since Aurora B plays a crucial role for chromosome
dynamics, and aneuploidy is a common feature of
prostate carcinomas, we analyzed Aurora B expression
in archive prostate carcinoma tissue and in human
prostate cell lines, originating from normal and neo-
plastic prostate tissue. All of prostate carcinoma cell
lines showed increased Aurora B levels compared to
the non-transformed cell line. Immunohistochemical
studies performed on archive samples showed that
Aurora B was detectable in normal prostate tissue and
that its expression progressively increased with
increasing of the Gleason Score, with a strong signal
in anaplastic prostate carcinomas. The block of Aurora
B kinase B activity by means of specific kinase in-
hibitors induced growth inhibition in human prostate
anaplastic carcinoma cells but not in non-transformed
prostate epithelial cells.
MATERIALSANDMETHODS
Cell Culture
The two androgen-independent human PC cell lines
PC3 [20] and DU145 [21] and the androgen-sensitive
cell line, LnCap [22] used in these studies were grown
in DMEM supplemented with 10% fetal bovine serum.
EPN cells, a line of non-transformed epithelial cells
derived by human normal prostate tissue sponta-
neously adapted to grow in culture, were routinely
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cultured in Keratynocyte serum free medium (KSFM)
supplemented with 3% fetal bovine serum (FBS) [23].
Growth curves were performed as previously
described [23]. As for evaluation of the effect of the
kinase inhibitor on cell proliferation the following
method was applied. DU145, LnCap, PC3 cells were
plated at a concentration of 1 103 cell/well in a
96-well plate and after 24 hr the cells were treated with
5, 10, 15 mMof the inhibitor. The quinazolin derivative:
N-[4-(6,7-dimethoxy-quinazolin-4-ylamino)-phenyl]-
benzamide [24] was dissolved in DMSO at a concentra-
tion of 10 mM. Cell proliferation was evaluated after
24 and 48 hr by using the Cell Titer 961 Aqueous cell
proliferation assay (Promega, Milan, Italy). The values
reported represent themean SDof three independent
samples per each experimental point.
FACS
Cytofluorimetric estimation of cell proliferation was
performed as follows: the plates were washed in cold
PBS and trypsin was added. Cells were collected,
washed again in PBS andfixed in cold PBS, 70%ethanol
for 30 min. Ethanol was removed by two PBS washes,
and cells were incubated in PBS, 50 mg/ml propidium
iodide, 10 mg/ml ribonuclease A, and deoxyribonu-
clease-free overnight at 48C. Cells were then analyzed
by flow cytometry using a FACScan (BectonDickinson,
Mountain View, CA). G0–G1, S, and G2–M cell cycle
phases were gated and the corresponding cells were
counted.
Histology
Archival formalin-fixed, paraffin-embedded prosta-
tectomy tissuewas acquired from the files of the Patho-
logy Section of the Biomorphological and Functional
Sciences Department, University of Naples Federico II,
Naples, Italy.
A total of 35 cases of PCwere retrieved and, for each
case, a paraffin block from themost representative area
of the tumor was selected, as well as a block selected
from different regions of the same prostate containing
normal and/or hyperplastic prostatic glands. Four
micrometer-thick serial sections were then cut from
each block, and a hematoxylin and eosin section of each
tumor was re-examined to confirm the original diag-
nosis and staging of PC. TheGleason sum scores for the
cases ranged from 4 to 9.
Immunohistochemistry
Serial sections of each case were de-waxed, re-
hydrated through decreasing alcohols and treatedwith
3% hydrogen peroxide for 5 min to inactivate endo-
genous peroxidases, and then washed in distilled
water. The slides were then pre-incubated in a micro-
wave oven three times for 5 min in 10 mM, 6 pH buffer
citrate. After quenching of endogenous peroxidase,
antigen retrieval was achieved by boiling sections at
1208C at 3.4 atm for 10 min in 1% citrate buffer; the
sections were then blocked for 2 hr at room tempera-
ture with 1.5% blocking serum (DAKO). Incubation
with the primary antibody was carried out overnight,
in a moist chamber, with the anti AIM-1 (Aurora B,
1:1,000, #611082,BD Transduction Laboratories, San
Diego, CA). Finally, binding of the primary antibody
was detected by the conventional streptavidin-biotin
linkedhorseradishperoxidase (LSAB-HRP)procedure,
using 3,30-diaminobenzidine (DAB) as chromogen [25].
Negative controls were performed on serial sections of
the same tissues, substituting the primary antibody
with non-immune serum.
Slight nuclear counterstaining was performed with
Harris’ hematoxylin; slides were then coverslipped
using a synthetic mounting medium.
The results of the immunohistochemical staining
were evaluated separately by two observers. Only cells
with a definite brown staining were judged as positive.
The immunohistochemical expression was quanti-
fied semi-quantitatively, using a 40 objective and ex-
pressed as percentage of positive nuclei. Then, tumors
and respective normal and/or hyperplastic glandular
tissue were assigned to one of the following arbitrary
categories: (1) from 0% to<5%of positive cells; (2) from
5% <10%; (3) from 10% to 25%; (4) >25% of cells.
The data were analyzed utilizing the one-way Anal-
ysis of Variance (ANOVA) and Student-Newman–
Keuls Multiple Comparisons Test (SPSS statistical
software, version 6.1 for Windows. For the categorical
parameters the Chi-square test was used; the non-
parametric Mann–Whitney U-test was utilized for
continuous variables). Only values of P< 0.05 were
considered as significant.
Protein Extraction andWestern BlotAnalysis
Prostate samples or cellswere homogenized directly
into lysis buffer (50 mM HEPES, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 10% glycerol, 1%Triton-X-100,
1 mM phenylmethylsulfonyl fluoride, 1 mg aprotinin,
0.5 mM sodium orthovanadate, 20 mM sodium
pyrophosphate). The lysates were clarified by centri-
fugation at 14,000 10 min. Protein concentrations
were estimated by a Bio-Rad assay (Bio-Rad,Mu¨nchen,
Germany), and boiled in Laemmli buffer (Tris-HCl
pH 6.8 0,125M, SDS 4%, glycerol 20%, 2-mercaptoetha-
nol 10%, bromophenol blue 0.002%) for 5 min before
electrophoresis. Proteins were subjected to SDS–PAGE
(10% polyacrylamide) under reducing condition. After
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electrophoresis, proteins were transferred to nitrocel-
lulosemembranes (ImmobilonMillipore Corporation);
complete transfer was assessed using prestained pro-
tein standards (Bio-Rad, Hercules, CA). After blocking
with TBS-BSA (25mM Tris, pH 7.4, 200 mM NaCl, 5%
bovine serum albumin), the membrane was incubat-
ed with the primary antibody against: (1) Aurora B
(1:400; # 611082, BD Transduction Laboratories); (2)
Phospho H3 (ser 10) (1:250, # 06-570, Upstate, Lake
Placid, NY); (3) b-Tubulin (1:500, # T-4026, SIGMA
Chemical Corporation, St. Louis, MO) for 1 hr (at room
temperature). Membranes were then incubated with
the horseradish peroxidase-conjugated secondary anti-
body (1:2,000) for 45 min (at room temperature) and
the reaction was detected with an ECL system
(Amersham, Life Science, Chiltern Hills, UK).
RESULTS
Aurora BExpression in ProstateTissue
A total of 35 cases of archive prostate tissue com-
prising normal prostate and neoplastic tissues scoring
Gleason 4 to 7/8 were retrieved and the original histo-
logical diagnosis and grading of PC was confirmed for
all the cases examined. Tissues were stained with anti
Aurora B antibodies. Results showed increased nuclear
expression of Aurora-B in high-score PCs respect to
low and intermediate score cases (P< 0.05) and in all
cancers respect to hyperplastic (P< 0.05) and normal
(P< 0.01) glands (Table I, Fig. 1a–c).
Four cases of PC showed a diffuse, strong cytoplas-
mic staining, in addition or instead of the nuclear stain-
ing. In two cases of benign hyperplasia a cytoplasmic
localization ofAurora B immunostainingwas observed
in isolate epithelial cells. Dynamic exchange from
cytoplasm and centrosome has been already reported
for other members of the Aurora gene family [26,27]. In
normal prostate tissue, few cells positive for Aurora B
staining were observed (Fig. 1a). The expression of
Aurora B was confined to the epithelial cells and no
positive cells could be observedwithin the stromal part
of the gland. Similarly to that of Aurora B the ex-
pression of Ki-67 increased in tumors tissues in respect
to normal or hyperplastic areas (data not shown).
Western Blot analysis of total protein extracted from
the frozen prostate tissue comprising normal prostate
and neoplastic tissues scoring Gleason 4 to 7/8 con-
firmed themorphological results.Aband of 41 kDawas
observed in all the samples tested. Aurora B expression
dramatically increased with the Gleason score, being
extremely high in undifferentiated tumors (Fig. 2a).
Aurora B has been described to phosphorylate histone
H3 at Ser-10, therefore to investigate the biological
activity of the kinase in the prostate tissue, the same
samples were immunoblotted with anti-phospho-Ser-
10 H3 histone antibodies. As shown in Figure 2b, an
increased phosphorylation of the H3 histone was ob-
served in the higher Gleason grade tissues. b-Tubulin
was used to assess the equal amounts of protein
(Fig. 2c).
Aurora BExpression inHuman
ProstateCell Lines
The expression of Aurora B was investigated in
prostate cell lines derived from normal and neoplastic
tissues by Western blot. As shown in Figure 3a Aurora
B was expressed in the androgen independent PC3 cell
line and at a lesser extent in theDU145 cell lineswhile a
much weaker expression of the kinase was observed
the androgen sensitive LnCap cells. In the EPN cells, a
line of non-transformed androgen sensitive epithelial
cells the expression of Aurora B was consistently
weaker then that of the tumor cell lines. In addition,
in PC3 and in DU145 cell lines Aurora B expression is
associated to an increase in the phosphorylation of
histone H3 (Fig. 3b). b-Tubulin was used to assess the
equal amounts of protein (Fig. 3c).
TABLE I. Immunohistoclinical expression andtopographical localization of AURORABin 35 cases ofprostate cancer.
Cases Gleason’s score Aurora B score Normal prostaic glands Benign hyperplastic glands
N¼ 14 4 2 (n¼ 6, N*) 1 (N¼ 7) 1 (N¼ 3)
3 (n¼ 6, N) 2 (N¼ 7) 2 (N¼ 11)
4 (n¼ 2, N)
N¼ 12 >4 to 7 3 (n¼ 5, N) 1 (N¼ 2) 2 (N¼ 12)
4 (n¼ 7, N) 2 (N¼ 10)
N¼ 9 >7 4 (n¼ 7, 5N, 2NþC**) 2 (N¼ 9) 2 (N¼ 7) 3 (N¼ 2)
4 (n¼ 2, C)
*Nuclear.
**Cytoplasmic localization of Aurora B.
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Aurora BKinase Inhibitor and
ProstateCell Proliferation
A small molecule similar to the quinazolin de-
rivative: N-[4-(6,7-dimethoxy-quinazolin-4-ylamino)-
phenyl]-benzamide has been shown to inhibit the
Aurora B kinase activity [24,28]. To evaluate the effects
ofAurora kinase inhibitor onprostate cell proliferation,
PC3, DU145, LnCap, and EPN cellswere treatedwith 5,
10, and 15 mM, and cell proliferation was evaluated
after 24 and 48 hr. The Aurora kinase inhibitor signi-
ficantly reduced the proliferation of PC cells, while
had no effects on the non-transformed EPN cells,
which expressed only small concentrations ofAurora B
Fig. 1. Aurora B expression in human prostate tissues. Localiza-
tionof theAuroraBproteininhumanprostate tissuebyimmunocy-
tochemistry; (a) paraffin embedded section of normal prostate
tissue.ExpressionofAuroraBproteinwasnotobserved;(b) section
of intermediate Gleason grade prostate carcinoma, showing some
nuclear immunoreactivity for Aurora B protein; (c) section of ana-
plasticprostatecarcinoma,showingextensivenuclearimmunoreac-
tivity forAuroraBprotein(400).[Color figurecanbeviewedinthe
onlineissue,whichis availableatwww.interscience.wiley.com.]
Fig. 2. Western blot analysis of Aurora B expression in prostate
humantissues;(a)theexpressionofAuroraBproteinincreaseswith
increasing Gleason score being maximal in anaplastic carcinomas;
(b) inadditioninthesamplescorresponding tohighgradecarcinoms
itpresentabandcorresponding to thephosphorylatedhystoneH3;
(c)b-Tubulinwasusedtoassess theequalamountsofprotein.
Fig. 3. Western blot analysis of Aurora B expression in human
prostate cell lines;(a) thelevelofexpressionincreased fromnormal
differentiated androgen dependent to non-differentiated androgen
independentcelllines.AuroraBwashighlyexpressedinthePC3;ata
lesserextentin theDU145cells, anditwasbasicallyabsentinLnCap
andintheEPNcells;(b) inthePC3AuroraBmediatedthephosphor-
ylation of H3 hystone; (c) b-Tubulin was used to assess the equal
amountsofprotein.
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kinase (Fig. 4). As expected FACS analysis showed that
the kinase inhibitor blocked the cell cycle of PC3,
DU145, and LnCap cells at the G2/M phase.
DISCUSSION
In the present study we have evaluated the expres-
sion of Aurora B in prostate cell lines and human
prostate tumors. The immunohistochemical analysis of
neoplastic or non-neoplastic prostate tissues showed
that the expression of Aurora B directly correlates with
increase in the Gleason grade of the PC being abundant
in undifferentiated carcinomas. Conversely, lower ex-
pression was observed in normal tissues and in low-
grade prostate carcinomas. This observation suggests
that during tumor progression, in particular during the
transition from differentiated prostate carcinomas to
undifferentiated prostate carcinomas, Aurora B over-
expression takes place and Aurora B overexpression
might confer a growth advantage to the neoplastic cells
[29–33].
By using a selective Aurora B kinase inhibitor
we demonstrated that the block of Aurora B activity
dramatically reduces the proliferation of prostate
carcinoma cells [24,28]. It is important to note that the
growth of EPN cells, a line originated from normal
epithelial prostate tissue, which express low levels of
Aurora B, was not affected by the Aurora B inhibitor.
In LnCap cells the expression of Aurora B is weaker
than that in PC3 and Du145. It is important to note that
LnCap cells, although derived from a lymphnode of an
aggressive PC, are among the PC derived cell lines, the
less aggressive and tumorigenic. Moreover, LnCap
cells retain prostate differentiated markers including
the sensitivity to androgen stimulation, also suggesting
a less aggressive phenotype. In addition, the prolifera-
tion rate ismuch lower than that of PC3 andDu145 [22],
therefore the expression of Aurora B correlates with the
proliferative rate and the aggressiveness of the differ-
ent cell lines.
Alterations of the mechanisms responsible for
maintaining the chromosome balance are common in
neoplastic cells [15,16]. Disruption of mitotic check-
points induces unstable chromosome number or aneu-
ploidy, which is thought to create abnormal nuclear
morphology in cancer cells and contribute to genetic
instability. Alterations in chromosome number have
been described as a common feature of almost all solid
tumors. Aneuploidy has been observed also in PC.
Interestingly, studies using loss of heterozygosity
analyses, CGH2 and fluorescent in situ hybridization
revealed few recurrent chromosomal aberrations in
early PCs [34–36]. Low-stage primary tumors tend to
be near diploid with few clonal numerical and/or
structural aberrations. In contrast, high-stage, advanc-
ed primary, or metastatic prostate tumors tend to be
aneuploid with a high degree of chromosomal aberra-
tions [2,8]. Moreover several chromosomal abnormal-
ities have been reported and summarized in the expert
reviews published on http://www.expert reviews.org
in 2003 [37].
Although chromosomal instability is a key mechan-
ism in the process of malignant transformation in
human epithelial tissues, yet the molecular mechan-
isms responsible for chromosome destabilization dur-
ing carcinogenesis are largely unknown [38–41].
Fig. 4. Aurorakinaseinhibitorreducedthegrowthofprostate tumorcellsPC3,DU145,andLnCapbutnotthatofnormalprostateepithelial
cells,EPN.
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Centrosome defects have been invoked to contribute
to genomic instability during PC progression. Centro-
somes are structurally andnumerically abnormal in the
vast majority of metastatic and invasive prostate carci-
nomas. The extent of centrosome abnormalities in in-
vasive prostate carcinoma correlates with the Gleason
grade [42].
Two recent set of data reported the potential role of
STK15 (Aurora-A) a serine/threonine kinase found in
centrosomes and involved in mitotic chromosomal
segregation in PC. Overexpression of Aurora-A is pre-
sent in some normal and in the majority of high-grade
PIN lesions and is an early event leading to the genetic
instability in prostate carcinogenesis [43,44].
Thus, dysfunction inmitotic checkpoints represent a
primary cause of genomic instability and as a con-
sequence of accumulation of structural and numeral
chromosomal abnormalities present in tumor cells.
Aurora B assuring the correct orientation of sister
chromatidesplays a crucial role inmitosis.A significant
overexpression of Aurora B has been observed in
human cancer cell lines, and in colorectal tumors a
correlation between Aurora B expression levels and
Duke’s grade in colorectal tumors has been describ-
ed [33]. Furthermore, it has been observed that the
forced expression of Aurora B produced aneuploid
cells with a malignant and aggressive phenotype,
indicating that Aurora B is relevant in aneuploidy
development during carcinogenesis [18,19]. Recently,
we have demonstrated that high expression levels of
Aurora B are a consistent feature of human seminomas
and in thyroid anaplastic carcinomas a high expression
of Aurora B was observed [45–47]. In these previous
studies, the expression of Ki-67 was analyzed showing
an increase in tumors tissues in respect to normal or
hyperplastic areas similar to Aurora B. In agreement
with our previous results a highly statistical correlation
between expression Aurora B and that of Ki-67 with a
percentage of Aurora-B positive cells lower than that of
the Ki-67-positive cells (data not shown)was observed.
CONCLUSIONS
Although large efforts have been put in the research
of appropriate therapy of PC the appearance in the
population of the tumor of androgen insensitive cells
vanishes the good result obtained by the hormonal
therapy. The observation that in PC tissue Aurora B
gene expression levels directly correlates to the stage of
malignant progression, that the block of Aurora B
expression or activity via an Aurora B inhibitor,
reduces the proliferation of anaplastic prostatic carci-
noma cells but not that of epithelial normal cells could
contribute to the development of novel therapeutic
strategies. The implications of these findings include
Aurora B assessment as an useful biomarker in the gray
zone for monitoring disease in prevention strategies
and for improving early diagnosis.
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Alterations in chromosome number (aneuploidy) are common
in human neoplasias. Loss of mitotic regulation is believed to
induce aneuploidy in cancer cells and act as a driving force
during the malignant progression. The serine/theronine pro-
tein kinases of aurora family genes play a critical role in the
regulationof key cell cycleprocesses. AuroraBmediates chro-
mosome segregation by ensuring orientation of sister chro-
matids and overexpression of Aurora B in diploid human cells
NHDF (normal human diploid fibroblast) inducesmultinucle-
arity.
We analyzed Aurora B expression in human thyroid car-
cinomas. Cell lines originating from different histotypes
showed an increase in Aurora B expression. Immunohisto-
chemical analysis of archive samples showed a high expres-
sionofAuroraB inanaplastic thyroid carcinomas; conversely,
Aurora B expression was not detectable in normal thyroid
tissue. Real-time PCR analysis confirmed a strong expression
of Aurora B in anaplastic thyroid carcinomas.
The block of Aurora B expression induced by RNA inter-
ference or by using an inhibitor of Aurora kinase activity
significantly reduced the growth of thyroid anaplastic carci-
noma cells. (J Clin Endocrinol Metab 90: 928–935, 2005)
THYROID CARCINOMA IS the most frequent malignantendocrine tumor in humans. Thyroid neoplasia in-
cludes tumors with different molecular and clinical features
including differentiated follicular and papillary carcinomas,
poorly differentiated papillary and follicular carcinomas and
undifferentiated anaplastic carcinomas (1, 2). Papillary car-
cinomas represent more than 70% of thyroid malignant tu-
mors and rearrangements of RET gene have represented for
years themost frequent genetic alterations found in papillary
carcinomas (3, 4). More recently several studies (5–9) indi-
cated a high percentage of B-RAF mutations in thyroid pap-
illary carcinomas. Follicular carcinomas are differentiated
thyroid tumors,which frequently showRASgenes activating
mutations (10) and paired domain-containing transcription
factor (PAX-8) and peroxisome proliferator-activated recep-
tor (PPAR) gamma 1 rearrangements (11). Poorly differen-
tiated and anaplastic carcinomas derive from differentiated
carcinomas through a process of neoplastic progression. Al-
terations of the p53 tumor suppressor gene are a peculiar
feature of anaplastic carcinomas (12–14). Although critical
molecular mechanisms of thyroid tumorigenesis have been
identified, other molecular steps of thyroid neoplastic pro-
gression need to be clarified. Unstable chromosome number
in cancer cells is currently believed to act as a driving force
during the malignant progression, and aneuploidy is the
most prevalent genomic alteration identified in solid tumors
(15, 16). Alterations in chromosome number are common in
follicular thyroid carcinomas (17, 18); however, the cause of
aneuploidy in many sporadic thyroid cancers is currently
unknown.
A critical step for themaintenance of genetic stability is the
chromosome segregation, which requires a high coordina-
tion of cellular process (19, 20). Loss of the mitotic regulation
is a possible cause of aneuploidy in human epithelial ma-
lignancy, and it is thought to create an abnormal nuclear
morphology in cancer cells. The serine/theronine protein
kinases of the Aurora family genes play a regulatory role
from G2 to cytokinesis, encompassing key cell cycle events
such as centrosome duplication, chromosome biorientation,
and segregation (21, 22). The family of the Aurora genes
includesAuroraA/STK-15,Aurora B/AIM-1, andAURORA
C/AIK3. Aurora A is overexpressed in several solid tumors,
andNIH3T3 fibroblasts overexpressingAuroraAgene show
an increase in centrosome number and aneuploidy, leading
to neoplastic transformation (23, 24). A polymorphism in
Aurora A gene has been also associatedwith a certain degree
of aneuploidy in human tumors (25).
Aurora B (AIM1) is a chromosome passenger protein, lo-
calizing on centromeres from prophase through the met-
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aphase-anaphase transition (21, 26–30). Another chromo-
some passenger protein is INCENP, which tightly associates
with Aurora B, probably regulating its activity. Survivin, a
conserved inhibitor of apoptosis-like protein, is a thirdmem-
ber of the Aurora B complex (19, 20). Aurora B has been
described to phosphorylate histone H3 at ser-10, and phos-
phorylation of histoneH3 is required for proper chromosome
dynamics during mitosis (26–30). It has also been demon-
strated that Aurora B overexpression in diploid human cells
normal human diploid fibroblast induces multinuclearity.
Furthermore, Aurora B-transfected cells have an unstable
chromosome number and show an aggressive phenotype in
vivo (29, 30).
Because Aurora B plays a crucial role for chromosome
dynamics and aneuploidy is a common feature of thyroid
carcinomas, we analyzed Aurora B expression in human
thyroid carcinoma cell lines, originating from different his-
totypes and archive thyroid carcinoma tissue. All of the thy-
roid carcinoma cell lines showed increased Aurora B levels.
Immunohistochemical studies performed on archive sam-
ples showed a clear expression of Aurora B in thyroid car-
cinomas, with a strong signal in anaplastic thyroid carcino-
mas, whereas Aurora B was not detectable in normal thyroid
tissue. The block of Aurora B synthesis by RNA interference
(RNAi) induced growth inhibition in human thyroid ana-
plastic carcinoma cells. The same effectwas achieved treating
anaplastic thyroid carcinoma cells with an inhibitor of the
Aurora kinases.
Materials and Methods
Cell lines, plasmids, and transfections
The human anaplastic thyroid carcinoma cell lines used in the study
are ARO, FRO, 8550-C, BHT 101, KAT-18, Cal 62, and KAT-4.
ARO and FRO human thyroid anaplastic carcinoma cell lines were
obtained by Dr. G. F. Juillard (University of California, Los Angeles).
ARO and FRO cell lines were kindly provided by Prof. J. A. Fagin
(University of Cincinnati College of Medicine, Cincinnati, OH).
KAT-4 and KAT-18 cell lines were established and obtained from Dr.
K. B. Ain (University of Kentucky, Lexington, KY). 8505-C anaplastic
thyroid cell line was established by Dr. M. Akiyama (Radiation Effects
Research Foundation, Hiroshima, Japan), BHT 101 anaplastic thyroid
carcinoma cell line was established by Dr. I. Palyi (National Institute of
Oncology, Budapest, Hungary), andCal 62 anaplastic thyroid carcinoma
cell line was established by Dr. J. Gioanni (Centre A. Lacassagne, Nice,
France). 8505-C, BHT 101, and Cal 62 cell lines were obtained from
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH,
German Collection of Microorganisms and Cell Cultures (Braun-
schweig, Germany).
TheNPA line derived from poorly differentiated papillary carcinoma
and was obtained by Dr. Juillard, the TPC 1 cell line derived from a
papillary thyroid carcinoma (31), and the WRO and FB1 cell lines de-
rived from a follicular carcinoma (32, 33).
Cells were grown in DMEM medium supplemented with 10% fetal
calf serum and ampicillin/streptomycin.
Cell proliferation was evaluated by using a colorimetric assay for
determining the number of viable cells, Cell Titer 96 Aqueous cell pro-
liferation assay (Promega,Madison,WI) according to themanufacturer’s
suggestions.
The pCMV-AIM1 construct, containing the human Aurora B gene
cDNA (accession no. NM 004217), was obtained as follows: mRNA from
human testis (Clontech, Palo Alto, CA) was reverse transcribed using
random hexamers as primers and Muloney leukemia virus reverse
transcriptase (Applied Biosystems, Foster City, CA) to yield cDNA.
The forward (5-CTCTGGATCCATGGCCCAGAAGGAGAAC-3) and
reverse (5-ACAGGGATCCTCAGGCGACAGATTGAAG-3) primers
were used to amplify the cDNA. The PCR product was cloned into the
BamH1 site of the pcDNA His-tagged (Invitrogen Life Technologies,
Carlsbad, CA).
The pCMV AIM-1 sense and antisense constructs were obtained by
inserting the Aurora B cDNA in both sense and antisense orientation in
the pCMV vector under the transcriptional control of the cytomegalo-
virus promoter. The vector also carries the gene for G418 resistance. The
transfection was performed according to the calcium phosphate trans-
fection protocol (32). After 36 h the cells were trypsinized and expanded,
and stable transfectants were generated after selection with 400 g/ml
geneticin (G418) (Life Technologies, Italy). Six independent clones were
isolated from pCMV AIM-1 sense, pCMV AIM-1 antisense, and control
transfections. The clones carrying sense or antisense plasmid were then
selected for further experiments.
The quinazoline derivative: N-[4-(6,7-dimethoxy-quinazolin-4-
ylamino)-phenyl]-benzamide (34) was dissolved in dimethylsulfox-
ide at a concentration of 10 mm. Then 1  103 ARO cells were plated
in a 96-well plate, and after 24 h the cells were treated with 5, 10, or
15 m of the inhibitor. Cell proliferation was evaluated after 24 and
48 h by using the Cell Titer 96 aqueous cell proliferation assay (Pro-
mega). Soft agar colony assays were performed according to a pre-
viously described technique (35).
Synthesis of Aurora kinase inhibitor
For the synthesis of Aurora kinase inhibitor, the methodology de-
scribed elsewhere (34) was followed.
RNAi and transfection of RNA oligonucleotides
For design of small interfering RNA (siRNA) oligos targeting Aurora
B, the sequence AAG GAGAACUCCUACCCCUGG (RNAi) was se-
lected, corresponding to the nucleotides located 67–87 bp of the human
Aurora B gene. As a control of siRNA oligo, the following aspecific
sequence was used AAG GUC CCC AUC CUCAAGAGG (RNAc). The
siRNAs were purchased from Dharmacon Research (Lafayette, CO).
Approximately 6  105 cells were plated per 6-well plate in media
containing 10% fetal bovine serum to give 30–50% confluence. Trans-
fection of the RNA oligonucleotides was performed after 24 h to result
in a final RNA concentration of 200 nm. Transfections were performed
using Oligofectamine (Invitrogen, Carlsbad, CA).
Human thyroid tissue samples, semiquantitative RT-PCR,
real-time PCR, and immunohistochemistry
Normal and neoplastic human thyroid tissue was obtained from
surgical specimens and immediately frozen in liquid nitrogen. Thyroid
tumors were collected at the Laboratoire d’Histologie et de Cytologie,
Centre Hospitalier Lyon Sud, France, and the Laboratoire d’Anatomie
Pathologique, Hospital de L’Antiquaille Lyon, France. Total RNA was
isolated and DNase digested using the RNeasy minikit (Qiagen, Valen-
cia, CA) according to the manufacturer’s recommendations. Three mi-
crograms of total RNA from each sample were reverse transcribed using
random hexamers as primers andMoloney leukemia virus reverse tran-
scriptase (Applied Biosystems) to yield cDNA. Semiquantitative RT-
PCR was carried out on cDNA using the GeneAmp PCR System 9600
(Applied Biosystems). A RNA PCR core kit (Applied Biosystems) was
used to perform PCR. The human -actin gene primers, amplifying a
109-bp cDNA fragment, were used as a control with the following
program: 95 C for 10 min; 25 cycles at 95 C for 30 sec, 60 C for 30 sec,
and 72 C for 30 sec; and 72 C for 5 min for a final extension.
To amplify the Aurora B mRNA, RT-PCR was performed using two
primers that amplified a 128-bp nucleotide cDNA fragment encompass-
ing exons 5 and 6 with the following program: 95 C for 10 min; 29 cycles
of 95 C for 30 sec, 59.5 C for 30 sec, and 72 C for 30 sec; and a final
extension of 72 C for 5 min.
Quantitative PCR was performed in triplicate using iCycler (Bio-Rad
Laboratories, Mu¨nchen, Germany) with SYBR Green PCR master mix
(Applied Biosystems) as follows: 95 C 10 min and 40 cycles (95 C 15 sec
and 60 C 1 min). Fold mRNA overexpression was calculated according
to the formula 2(RtEt)/2(RnEn) as described previously (36), where Rt
is the threshold cycle number for the reference gene (-actin) in the
tumor, Et for the experimental gene in the tumor, Rn for the reference
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gene in the normal sample, and En for the experimental gene in the
normal sample. Specific primers used are as follows. Aurora B forward,
5-CTGGAATATGCACCACTTGGA, reverse, 5CGAATGACAGTAAG-
ACAGGG; and -actin-forward, 5-TCGTGCGTGACATTAAGGAG;
-actin-reverse, 5-GTCAGGCAGCTCGTAGCTCT.
The cellular distribution of Aurora B protein was assessed by im-
munohistochemical analysis. Aurora B expressionwas evaluated in both
nonneoplastic and neoplastic thyroid tissues. Hematoxylin and eosin-
stained slides were retrieved from the files of the Department of Bio-
Morphological Sciences at the University Federico II of Naples; in all
cases the histological diagnosis was confirmed on review. Paraffin-
embedded sections were obtained from these samples, and Aurora B
expressionwas evaluated. Xylene-dewaxed and alcohol-rehydratedpar-
affin sections were placed in Coplin jars filled with a 0.01 m trisodium
citrate solution and heated for 3 min in a conventional pressure cooker.
After heating, slides were thoroughly rinsed in cool running water for
5 min and then washed in Tris-buffered saline (pH 7.4).
Aurora B protein was detected by using the polyclonal antibody
raised in rabbit (no. 611082; BD Transduction Laboratories, San Diego,
CA). The incubation with the primary antibody was followed by incu-
bation with biotinylated antimouse immunoglobulins and by peroxi-
dase-labeled streptavidin (LSAB-Dako, Carpinteria, CA). The signalwas
developed by using diaminobenzidine chromogen as substrate. Nega-
tive controls were run with normal rabbit serum instead of the primary
antibody, or the antibody was preadsorbed with the cognate peptide
(106m). Cases were scored by assessing the percentage of labeled cells,
and percentage of positive cells was evaluated by analyzing 1000 neo-
plastic cells in five different high power fields. The study was approved
by the Ethics Committee of the Centre Hospitalier Lyon Sud and the
University Federico II Napoli. In all cases written informed consent was
obtained.
Protein extraction and Western blot analysis
Cells were homogenized directly into lysis buffer (50 mmHEPES, 150
mm NaCl, 1 mm EDTA, 1 mm EGTA, 10% glycerol, 1%Triton X-100, 1
mm phenylmethylsulfonyl fluoride, 1 g/ml aprotinin, 0.5 mm sodium
orthovanadate, and 20 mm sodium pyrophosphate). The lysates were
clarified by centrifugation at 14,000  10 min. Protein concentrations
were estimated by an assay (Bio-Rad) and boiled in Laemmli buffer
[0.125 m Tris-HCl (pH 6.8), 4% SDS, 20% glycerol, 10% 2-mercaptoetha-
nol, and 0.002% bromophenol blue] for 5 min before electrophoresis.
Proteins were subjected to SDS-PAGE (10% polyacrylamide) under re-
ducing conditions. After electrophoresis, proteins were transferred to
nitrocellulose membranes (Immobilon, Millipore Corp., Bedford, MA);
complete transfer was assessed using prestained protein standards (Bio-
Rad, Hercules, CA). After blocking with Tris-buffered saline-BSA [25
mm Tris (pH7.4), 200 mm NaCl, and 5% BSA], the membrane was
incubated with the primary antibody against Aurora B for 1 h (at room
temperature). Membranes were then incubated with the horseradish
peroxidase-conjugated secondary antibody (1:10,000) for 45 min (at
room temperature), and the reaction was detected with an enhanced
chemiluminescence system (Amersham Life Science, Buckinghamshire,
UK).
Tumorigenicity assay
Experimentswere performed in 6-wk-oldmale athymicmice (Charles
River, Italy). Untransfected ARO cells (1  106) or respectively trans-
fected with a plasmid-containing Aurora B in the sense or antisense
orientation were injected into the right flank of the mice. The animals
were monitored for the appearance of tumors and tumor latency eval-
uated. The mean tumor latency is the time needed for tumors to reach
10 mm in diameter. All mice were maintained at the Dipartimento di
Biologia e Patologia Animal Facility. Animal experimentations de-
scribed in the present paper have been conducted in accordance with
accepted standards of animal care, in accordance with the Italian reg-
ulations for the welfare of animals used in studies of experimental
neoplasia, and the study was approved by Ethics Committee on Animal
Care of the University Federico II Napoli.
Results
Aurora B expression in thyroid carcinoma cell lines
Thyroid carcinoma cell lines derived from papillary car-
cinomas, follicular carcinomas, and anaplastic thyroid car-
cinomas were analyzed for Aurora B expression by Western
blot. An Aurora B-specific band of 41 kDawas detected in all
the samples. As shown in Fig. 1, A and B, the highest ex-
pression levels were observed in the cell lines derived from
anaplastic thyroid carcinoma (ARO, FRO, 8505-C, BHT101,
KAT-18, Cal 62, and KAT-4), whereas only a faint band of 41
kDa was observed in human thyroid primary culture cells.
Therefore, these data would indicate that the expression of
FIG. 1. Aurora B expression in thyroid carcinoma cell lines and ex-
perimental thyroid carcinomas. A, Western blot analysis of Aurora B
expression in human thyroid cells: ARO, Cal 62, FB1, KAT-4, NPA,
and TPC1. Expression levels were increased in the anaplastic thy-
roid carcinoma cell lines ARO, Cal 62, and KAT-4. In the papillary
thyroid carcinoma-derived cell lines NPA and TPC 1 and the fol-
licular thyroid carcinoma-derived cell line FB1, a clear band was
observed. In the primary culture of human thyroid (PrT), a faint
bandwas observed. B,Western blot analysis of Aurora B expression
in human thyroid cells: 8505-C BHT101, KAT-18, WRO, and FRO.
Expression levels were increased in the anaplastic thyroid carci-
noma cell lines 8505-C, BHT101, KAT-18, and FRO. In follicular
thyroid carcinoma-derived cell line WRO, Aurora B expression was
clearly detectable. The primary culture of human thyroid (PrT) was
used as a control. C, Western blot analysis of Aurora B expression
in thyroid carcinoma excised from different experimental model of
thyroid carcinogenesis. Normal thyroid: Normal thyroid gland ex-
cised from a 6-month-old wild-type mouse; PTU 2 weeks: thyroid
gland excised from a mouse treated for 2 wk with the goitrogenic
agent PTU; PTU 4 weeks: thyroid gland excised from a mouse
treated for 4 wk with the goitrogenic agent PTU; Tg E7 HPV16:
follicular carcinoma of the thyroid obtained from a transgenic
mouse expressing in the gland HPV16 oncogene; Tg Ret/PTC3:
papillary carcinoma of the thyroid obtained from a transgenic
mouse expressing in the gland RET/PTC3 oncogene; Tg LTSV40:
anaplastic thyroid carcinoma obtained from a transgenic mouse
expressing in the gland SV 40 LT oncogene (animal 84); Tg
LTSV40: anaplastic thyroid carcinoma obtained from a transgenic
mouse expressing in the gland SV 40 LT oncogene (animal 57);
KAT-4: positive control cells.
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Aurora B is more abundant in cell lines characterized by a
malignant and aggressive phenotype.
Aurora B expression in experimental models of thyroid
carcinogenesis
To confirm that Aurora B gene expression is increased in
highly malignant thyroid carcinomas, Aurora B expression
in thyroid glands obtained from animal models of thyroid
carcinogenesis was evaluated by Western blot. We used
transgenic animals lines expressing RET/PTC3, HPV 16 E7,
and LT SV40 oncogenes under the transcriptional control of
the thyroglobulin promoter.
RET/PTC3 is an oncogene frequently activated in human
thyroid papillary carcinomas, and it has been shown to in-
duce thyroid papillary carcinomas when expressed in the
thyroid cells of transgenic animals (37). Transgenic mice
carrying HPV 16 E7 oncogene under the transcriptional con-
trol of the thyroglobulin gene promoter develop follicular
carcinomas of the thyroid (38), whereas thyroid anaplastic
carcinomas are obtained in animals with thyroid-targeted
expression of LT SV40 oncogene (39). Thyroid glands of
animals treated with the goitrogenic agent propylthiouracil
(PTU) for 2 wk and 1 month (40) were used as a control for
nonneoplastic proliferation. Furthermore, the thyroid gland
of a 6-month-oldwild-typemousewas used as a control (Fig.
1C). The results shown are representative of three different
experiments.
Elevated levels of Aurora B protein expression were ob-
served in the experimental thyroid anaplastic carcinomas. A
weaker signal was observed in the papillary and follicular
carcinomas. Conversely, very low levels of Aurora B were
observed in normal thyroid tissue as in thyroid glands stim-
ulated by PTU.
Aurora B expression in the normal human thyroid and
thyroid neoplastic lesions
To evaluate the expression of Aurora B in human thyroid
carcinoma tissues, a panel of matched tumor/normal tissues
was analyzed by RT-PCR. No significant differences in Au-
rora B gene expression were observed in papillary carcino-
mas matched with normal thyroid tissue (Fig. 2A), whereas
an increasedAurora B expressionwas observed in anaplastic
thyroid carcinomas with respect to the normal thyroid tissue
(Fig. 2B).
Quantitative PCR was performed to confirm overexpres-
sion of Aurora B in anaplastic thyroid carcinomas. About
15-fold mRNA overexpression was observed in ATC sam-
ples with respect to the -actin reference gene. A 2-fold
increase was observed in papillary thyroid carcinoma sam-
ples (Fig. 2C).
Archive thyroid tumors comprising adenoma (five cases),
follicular (five cases), papillary (10 cases), and anaplastic
thyroid carcinomas (15 cases) were stained for Aurora B. As
a control three cases of nodular goitre and three cases of
Hashimoto’s thyroiditis were analyzed. In normal thyroid
tissue, few positive cells for Aurora B staining were ob-
served. Conversely, all of thyroid anaplastic carcinoma ex-
amined showed a very high expression of Aurora B (Fig. 3,
C andD). Positive cells were irregularly distributed through-
out the tumor. Occasionally, a heterogeneous pattern of ex-
pression was seen, with areas showing strong labeling ad-
jacent to areas with less intense Aurora B expression. The
signal wasmost intense in dividing cells, withmitotic figures
depicted by the antibody.
In follicular or papillary differentiated carcinomas, a less
intense signal was observed. Also in differentiated carcino-
mas, signal was most intense in dividing cells, and the cy-
toplasm of positive cells was devoid of signal (Fig. 3B). The
expression of Aurora B in anaplastic thyroid carcinomas or
differentiated carcinomaswas comparedwith the expression
of a well-known proliferative marker such as Ki-67, by using
MIB-1 antibody (Table 1). Staining for Ki-67wasmost intense
in thyroid anaplastic carcinomas, showing a correlation with
Aurora B expression.
Effects of the suppression of the Aurora B protein synthesis
in anaplastic thyroid carcinoma cells
To establish whether Aurora B expression is crucial for
thyroid neoplastic cell growth and assess whether Aurora B
FIG. 2. Aurora B expression in matched tumor (T)/normal (N) tis-
sues. A, RT-PCR analysis of Aurora B expression in papillary thyroid
carcinomas samples 1–4. Papillary thyroid carcinomas matched with
normal thyroid tissues. B, RT-PCR analysis of Aurora B expression
in anaplastic thyroid carcinomas samples 1–4. Anaplastic thyroid
carcinomas matched with normal thyroid tissues. Levels of Aurora B
were increased in the anaplastic thyroid carcinomas. C, Real-time
PCR analysis of Aurora B (AUR-B) expression in papillary thyroid
and anaplastic thyroid carcinomas. A 15-fold increase of Aurora B
expression was observed in anaplastic thyroid carcinomas.
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could represent a target for antineoplastic therapy, we
performed an RNAi selective gene silencing analysis using
siRNAs (41–43). We observed that Aurora B RNAi signifi-
cantly decreased the synthesis of Aurora B protein in ARO
cells at 48 h (Fig. 4A). The block of Aurora B protein synthesis
is specific because Aurora A levels were not affected (Fig.
4A). Aurora B has been described to phosphorylate histone
H3 at Ser-10 during mitosis in vivo. To confirm the effects of
RNAi, cell lysates, respectively, obtained fromRNAi treated,
untreated control ARO cells, and aspecific RNA treatedARO
cells were immunoblotted with anti-phospho-Ser-10 H3 hi-
stone antibody and anti-H3 histone antibody. As shown in
Fig. 4A, a reduced phosphorylation of the H3 histone was
observed in the RNAi-transfected cells at 48 h. RNAi treat-
ment significantly reduced cell proliferation (Fig. 4B).
Transfection of ARO cells with an antisense construct
(pCMV AIM-1 antisense) of the Aurora B DNA was also
performed. Control transfections were performed using an
Aurora B sense construct (pCMV AIM-1 sense) or an empty
vector (pCMV). Clones were isolated from each transfection
and the integration of the constructs was confirmed by
Southern blot (data not shown). The reduced expression of
Aurora B protein was confirmed in pCMV AIM-1 antisense
clones byWestern blot analysis (data not shown). The colony
growth rate in semisolid medium was reduced in Aurora B
antisense-expressing clones with respect to sense transfected
or control cells. Although no differences in tumor incidence
were observed on injection into athymic mice, tumor latency
period of Aurora B antisense-expressing clones was in-
creased (Table 2 and Fig. 5).
A small molecule similar to the quinazoline derivative:
N-[4-(6,7-dimethoxy-quinazolin-4-ylamino)-phenyl]-benz-
amide has been shown to inhibit the Aurora B kinase activ-
ity (33, 44). To further evaluate the role of the Aurora B
kinase activity on thyroid carcinoma cell proliferation, 5 
105 ARO and 5  105 FRO cells were treated with 15 m of
the Aurora kinase inhibitor; after 24 and 48 h, cells were
collected and lysed. Lysates were immunoblotted with anti-
phospho-Ser-10 H3 histone antibody and antitubulin anti-
body. As shown in Fig. 6A, a dramatic reduction in phos-
phorylation of the H3 histone was observed in the treated
cells. To evaluate the effects of Aurora kinase inhibitor on
cell proliferation, ARO and FRO cells were treated with 5,
10, and 15 m, and cell proliferation was evaluated after 24
and 48 h. Ten and 15 m of Aurora kinase inhibitor signif-
icantly reduced cell proliferation (Fig. 6B).
Discussion
Alterations of themechanisms responsible formaintaining
the chromosome balance are common in neoplastic cells (15,
16). Disruption ofmitotic checkpoints induces unstable chro-
mosome number or aneuploidy, which is thought to create
abnormal nuclear morphology in cancer cells and contribute
to genetic instability. It has been described that alterations in
chromosome number are common in neoplasias from thy-
roid follicular cells; however, the mutational analysis of two
TABLE 1. Analysis of Aurora B and Ki-67 expression in thyroid
specimens
Histological type of
thyroid specimen
No. of
cases
Average immunostaining
Aurora B Ki-67
Normal thyroid 1 0.5  0.2 0.9  0.3
Nodular goitre 3 1.2  0.4 1.8  0.6
Hashimoto’s disease 3 0.8  0.3 1.1  0.6
Papillary carcinoma 10 2.3  0.4 3.1  0.5
Follicular carcinoma 10 2.8  0.4 3.6  0.6
Anaplastic carcinoma 15 29.6  3.4 43.2  6.6
Values are reported as percentage of immunopositive cells  SD.
FIG. 3. Aurora B expression in human
thyroid carcinomas. Localization of the
Aurora B protein in human thyroid car-
cinomas by immunocytochemistry. A,
Localization of the Aurora B protein in
a paraffin-embedded section of a thy-
roid goitre. Expression of Aurora B pro-
tein was not observed. B, Section of
thyroid papillary carcinoma (case 8),
showing rare immunoreactivity for Au-
rora B protein. C, Section of anaplastic
thyroid carcinoma (case 12), showing
extensive immunoreactivity for Aurora
B protein. D, Highermagnification of C,
showing presence of a clear signal in
neoplastic cells.
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components of the spindle assembly checkpoint pathway,
BUB1 andBURBR1, has shown that these two proteins do not
account for the development of aneuploidy in thyroid cancer
(17).
The Aurora protein kinases play a crucial role in the reg-
ulation of the cell cycle processes. Three Aurora-related ki-
nases have been described in mammals, Aurora A (STK15),
Aurora B (AIM 1), and Aurora C (STK13) (19–21). All three
mammalian members of this family are overexpressed in
human cancer cells. Overexpression of Aurora A is thought
to relate to multiple centrosome production, and its role has
been evaluated in humanmammary (45), pancreatic (46), and
other neoplastic lesions (47, 48).
A significant overexpression of Aurora B has been ob-
served in human cancer cell lines and colorectal tumors, and
a correlation between Aurora B expression levels and Duke’s
grade in colorectal tumors has been described (30, 49). Fur-
thermore, it has been observed that the forced expression of
Aurora B produced aneuploid cells with a malignant and
aggressive phenotype, indicating that Aurora B is relevant in
aneuploidy development during carcinogenesis (29). Re-
cently it has been shown that high expression levels of Au-
rora B are a consistent feature of human seminomas (50).
In the present study, we evaluated the expression of Au-
rora B in thyroid carcinoma cell lines and experimental and
human thyroid tumors, and we observed that the expression
of Aurora B is increased in cell lines derived from thyroid
anaplastic carcinomas. An increase of Aurora B expression
was observed in experimental anaplastic thyroid tumors,
whereas in differentiated experimental thyroid tumors, a
lower expression of the Aurora B gene was observed. It is
important to note that a very low expression of Aurora Bwas
observed in the glands of animals treated with PTU, despite
the intense mitotic activity of the follicular cells (40). These
data indicate that Aurora B-increased expression is associ-
ated with the late stages of thyroid tumor progression and
suggest that the Aurora B overexpression could contribute to
thyroid tumor progression.
The immunohistochemical analysis of neoplastic or non-
neoplastic thyroid lesions paralleled the results obtained us-
ing cell lines and experimental tumors, showing that the
expression is abundant in anaplastic carcinomas. Con-
versely, no or low expression was observed in benign ade-
nomas, nonneoplastic thyroid lesions such as Hashimoto
disease, and normal thyroid tissue. Our data on thyroid
carcinomas extend to this type of tumor the observation that
the expression of Aurora B displays a tendency to group in
higher grade of malignancy as previously observed in colon
carcinomas (49). This observation suggests that during tumor
progression, in particular during the transition from differ-
entiated thyroid carcinomas to anaplastic thyroid carcino-
mas, Aurora B overexpression takes place, and Aurora B
overexpression might confer a growth advantage to the neo-
plastic cells. Furthermore, our data indicate that Aurora B
expression may serve as a prognostic marker in thyroid
tumors.
FIG. 4. RNAi directed against Aurora B specifically inhibits its ex-
pression and blocks the proliferation of anaplastic thyroid carcinoma
cells. A, Inhibition of Aurora B expression by RNAi. ARO cells were
transfected with 200 nM annealed sense (RNAi) and aspecific control
RNA (RNAc) 21-mer RNA oligonucleotides directed against Aurora B
or mock transfected (C). Cells were harvested at 24 and 48 h after
transfection, and Western blot analysis was performed. A significant
reduction of Aurora B expression andH3 phosphorylation (PH3) was
observed at 48 h. Aurora A and H3 levels were not affected by the
treatment. B, Time-dependent inhibition of ARO cell proliferation by
Aurora B RNAi. ARO cells were transfected with 200 nM annealed
sense (RNAi) and control (RNAc) 21-mer RNA oligonucleotides di-
rected against Aurora B or mock-transfected (control). The data are
expressed as percentages of the control cell proliferation, and the SD
was calculated (bar). The data are the mean of three different
experiments.
TABLE 2. Analysis of transformation markers of the ARO cells
transfected with the Aurora B cDNA in the sense or antisense
orientation
Transfected DNA Colony-formingefficiency (%)a
Tumor
incidenceb
Latency
period (d)c
pCMV vector 56 3/3 12
pCMV Aurora B
antisense clone 4
27 4/4 31
pCMV Aurora
B antisense clone 6
31 5/5 36
pCMV Aurora
B antisense clone 9
23 3/3 29
pCMV Aurora
B sense clone 1
59 4/4 12
pCMV Aurora
B sense clone 5
62 5/5 11
a Colonies larger than 64 cells were scored after 3 wk. Colony-
forming efficiency was calculated with the formula: number of colo-
nies formed/number of plated cells  100.
b Tumorigenicity was assayed by injecting 1  106 cells into athy-
mic mice (6 wk old).
c The animals were monitored for the appearance of tumors. The
mean tumor latency is the time needed for tumors to reach 10 mm in
diameter. In pCMV Aurora B antisense transfected cells, the median
tumor latency differed significantly from that of control.
Sorrentino et al. • Aurora B Gene and Thyroid J Clin Endocrinol Metab, February 2005, 90(2):928–935 933
 at Childrens Hospital Medical Library on November 29, 2007 jcem.endojournals.orgDownloaded from 
In our study, the functional consequences of RNAi-medi-
ated decrease of Aurora B expression in anaplastic thyroid
cancer cellswere determined using assays of gene expression
and cellular proliferation. Our results demonstrate that the
Aurora B siRNA treatment induces a significant reduction in
cell proliferation. No cells with apoptotic figures were ob-
served, and the analysis of the apoptotic cascade indicated
that the pathway was not activated by the Aurora B RNAi
treatment (data not shown). It is possible to conclude that the
block of Aurora B protein synthesis does not induce apo-
ptosis in ARO cell line; moreover, an accumulation of Aurora
B RNAi-treated cells in G2/M phase was observed by flow
cytometry (data not shown). The inhibition ARO cells pro-
liferation was about 40% on RNAi treatment; these data
indicate that cell proliferation is not completely dependent
on Aurora B activity.
Aurora B cDNA antisense transfection decreased colony
formation in soft agar and resulted in increased tumor la-
tency. By using a selective Aurora B kinase inhibitor, we
confirmed that the block of Aurora B activity dramatically
reduces the proliferation of anaplastic thyroid carcinoma
cells.
Anaplastic thyroid carcinoma is resistant to currently
available therapeutic agents. The observation that the block
of Aurora B expression or activity reduces the proliferation
of anaplastic thyroid carcinoma cells could contribute to the
development of novel therapeutic strategies.
In conclusion, our data indicate that in thyroid carcinomas
Aurora B gene expression levels are correlated to the stage
of malignant progression, and the block of Aurora B expres-
sion or its kinase activity significantly reduces the growth of
thyroid anaplastic carcinoma cells, suggesting that Aurora B
is a potential therapeutic target.
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Raised expression of the antiapoptotic protein ped/pea-15 increases
susceptibility to chemically induced skin tumor development
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ped/pea-15 is a cytosolic protein performing a broad
antiapoptotic function. We show that, upon DMBA/TPA-
induced skin carcinogenesis, transgenic mice overexpres-
sing ped/pea-15 (Tgped/pea-15) display early development of
papillomas and a four-fold increase in papilloma number
compared to the nontransgenic littermates (Po0.001).
The malignant conversion frequency was 24% for the
Tgped/pea-15 mice and only 5% in controls (Po0.01). The
isolated application of TPA, but not that of DMBA,
was sufﬁcient to reversibly upregulate ped/pea-15 in both
untransformed skin and cultured keratinocytes. ped/pea-
15 protein levels were also increased in DMBA/TPA-
induced papillomas of both Tgped/pea-15 and control mice.
Isolated TPA applications induced Caspase-3 activation
and apoptosis in nontransformed mouse epidermal tissues.
The induction of both Caspase-3 and apoptosis by TPA
were four-fold inhibited in the skin of the Tgped/pea-15
compared to the nontransgenic mice, accompanied by a
similarly sized reduction in TPA-induced JNK and p38
stimulation and by constitutive induction of cytoplasmic
ERK activity in the transgenics. ped/pea-15 expression
was stably increased in cell lines from DMBA/TPA-
induced skin papillomas and carcinomas, paralleled by
protection from TPA apoptosis. In the A5 spindle
carcinoma cell line, antisense inhibition of ped/pea-15
expression simultaneously rescued sensitivity to TPA-
induced Caspase-3 function and apoptosis. The antisense
also reduced A5 cell ability to grow in semisolid media by
65% (Po0.001) and increased by three-fold tumor
latency time (Po0.01). Thus, the expression levels of
ped/pea-15 control Caspase-3 function and epidermal cell
apoptosis in vivo and determine susceptibility to skin
tumor development.
Oncogene (2005) 24, 7012–7021. doi:10.1038/sj.onc.1208871;
published online 25 July 2005
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Introduction
There is evidence that deregulation of apoptosis plays an
important role in tumorigenesis. Indeed, alterations of
apoptosis-related genes have been identiﬁed in a number
of human cancers (Debatin and Krammer, 2004). ped/
pea-15 is a 15 kDa, death effector domain (DED)-
containing protein featuring ubiquitous expression, and
originally identiﬁed as a major astrocytic phosphopro-
tein (Araujo et al., 1993; Condorelli et al., 1998). ped/
pea-15 exerts a broad antiapoptotic action through at
least three distinct mechanisms. Firstly, it inhibits the
formation of the death-inducing signaling complex
(DISC) and Caspase-3 activation triggered by FASL,
tumor necrosis factor alpha, and the tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL) (Con-
dorelli et al., 1999; Kitsberg et al., 1999; Hao et al.,
2001). Secondly, ped/pea-15 inhibits stress-induced
apoptosis by simultaneously blocking stress-activated
protein kinases (SAPK) and increasing the function
of cytosolic extracellular signal-regulated kinases
(ERK1/2) (Condorelli et al., 2002). Thirdly, ped/
pea-15 prevents degradation of the antiapoptotic
protein XIAP caused by release of proapoptotic
mitochondrial proteins (Trencia et al., 2004).
Studies in our own and other laboratories have shown
that elevated expression of ped/pea-15 occurs in several
tumor-derived cell lines. Indeed, ped/pea-15 is highly
expressed in human glioma and metastatic breast cancer
cell lines and induces resistance to chemotherapic agents
in these cells (Ramos et al., 2000; Hao et al., 2001;
Condorelli et al., 2002; Trencia et al., 2004). ped/pea-15
is also expressed at high levels in tumor cell lines derived
from human larynx, cervix, and skin tumors (Condorelli
et al., 1998), and in human mammary carcinomas as
well (Tsukamoto et al., 2000). Finally, the ped/pea-15
gene was demonstrated to be increasingly expressed
during tumor progression in murine squamous carci-
nomas (Dong et al., 2001). However, despite these
mounting evidence supporting the role of ped/pea-15 in
neoplastic transformation and tumor progression,
whether ped/pea-15 has a direct role in tumorigenesis
and progression in vivo has not been investigated yet.
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published online 25 July 2005
*Correspondence: F Beguinot; E-mail: beguino@unina.it
Oncogene (2005) 24, 7012–7021
& 2005 Nature Publishing Group All rights reserved 0950-9232/05 $30.00
www.nature.com/onc
Transgenic mice overexpressing ped/pea-15 ubiqui-
tously have recently been generated (Vigliotta et al.,
2004). These mice feature reduced glucose tolerance due
to both impaired insulin action and secretion. We have
now used these transgenics and a well-characterized
mouse model of chemically induced multistep skin
carcinogenesis (Balmain and Harris, 2000) to explore
the role of ped/pea-15 in the initiation, promotion and
progression of skin tumors. Our study shows, for the
ﬁrst time, that ped/pea-15 expression level has a
signiﬁcant impact on skin tumor development in a
mouse model of chemically induced skin carcinogenesis.
Results
Skin carcinogenesis in ped/pea-15 transgenic mice
We have investigated whether the variation in ped/pea-
15 expression levels affects skin tumorigenesis. To this
end, we have used transgenic mice overexpressing the
human cDNA of ped/pea-15 (Tgped/pea-15; Vigliotta et al.,
2004). Based on Western blot analysis, ped/pea-15
protein was overexpressed by about four-fold
(Po0.001) in the epidermis of these transgenics, as
compared to their nontransgenic littermates (WT)
(Figure 1a).
Tgped/pea-15 and control mice (n¼ 40/group; M/F¼ 1)
were subjected to a single DMBA topical application
followed by repeated applications of the tumor promo-
ter TPA. This treatment resulted in the development of
papillomatous lesions. Visible papillomas began to
appear on the dorsal skin of both the Tgped/pea-15 and
WT mice at 7 weeks of promotion, indicating no
difference in the benign tumor latency between the two
groups of mice (Figure 1b). The incidence of papilloma
development reached 100% at 10 weeks of promotion
in the Tgped/pea-15, and at week 12 in the WT mice
(Po0.001; Figure 1b). Interestingly, there was a
signiﬁcant increase in the average number of papillomas
per mouse in the Tgped/pea-15 compared to WT mice
throughout the entire promoter treatment period. The
difference in papilloma number was already signiﬁcant
at week 8. By the end of promotion (week 15), Tgped/pea-15
mice showed 18.4710.7 papillomas per mouse com-
pared to 4.974.8 in the WT mice (Po0.001)
(Figure 1c). No gender-related difference was evidenced
in either the incidence or the number of papillomas in
transgenic and control mice (data not shown).
At 35 weeks after promoter treatment suspension, the
lesions from Tgped/pea-15 and WT mice were subjected to
histological examination. The malignant conversion
frequency was 24% in the Tgped/pea-15 mice (12 out of
50 analysed lesions, Figure 2A). As in previous studies
(Burns et al., 1978), the frequency was only 5% (two out
of 40 analysed lesions) in the control mice (Po0.001),
however. Sections of the lesions from Tgped/pea-15 mice
more frequently showed the presence of a poorly
differentiated epithelial neoplasm composed of nests of
small undifferentiated cells with minimal keratinization,
occasional squamous pearl formation and extremely
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Figure 1 Chemically induced skin carcinogenesis in Tgped/pea-15
mice. (a) Duplicate samples from the dorsal skin of ped/pea-15
transgenic mice (Tgped/pea-15) and the nontransgenic littermates
(n¼ 40 animals/group; male/female¼ 1) were solubilized and
proteins (50mg) analysed by Western blotting with ped/pea-15
antibodies as in Vigliotta et al. (2004). To ensure normalization,
aliquots from the samples were also blotted with tubulin
antibodies. Bars represent the average values (7s.d.) obtained
from ped/pea-15 band densitometry, normalized for tubulin
band densitometry. A representative blot is also shown on the
top. (b and c) Tgped/pea-15 and control mice (three independent
experiments; n¼ 40 animals/group in each; male/female¼ 1) were
subjected to skin carcinogenesis as described under Materials and
methods. The number of papillomas was recorded weekly and is
expressed either as percentage of mice containing at least one
papilloma (b) or the average number (7s.d.) of papillomas per
mouse (c). Statistical signiﬁcance was assessed by t-test analysis
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intense mitotic activity (Figure 2B(c)). As shown in
Figure 2B(d), the majority of the neoplastic cells
displayed intense PCNA nuclear labeling, and stained
cells were scattered throughout the tissue, reﬂecting the
neoplastic modiﬁcations. At variance, lesions from WT
mice more commonly showed benign hyperplastic
proliferation of the epidermis, with epithelial cells
featuring normal morphological characteristics, without
signiﬁcant nuclear atypia (Figure 2B(a)). Based on
PCNA immunostaining, cycling cells were present only
at the basal epidermal level (Figure 2B(b)). Differentiat-
ing squamous cells exhibited no staining, consistent with
lack of dysplatic/neoplastic changes in the WT mouse
skin.
ped/pea-15 levels during skin tumor initiation and
promotion
To investigate the signiﬁcance of ped/pea-15 expression
to skin tumor development and malignant progression,
we have ﬁrst analysed ped/pea-15 levels in papilloma-
tous lesions and in the corresponding skin upon
regression of the lesions. Despite the four-fold increase
in the normal skin of Tgped/pea-15 versus control mice,
ped/pea-15 was raised to comparable absolute levels in
papillomas from WT and Tgped/pea-15 mice (Figure 3a).
Immunohistochemical analysis with ped/pea-15 anti-
bodies revealed comparable distribution of ped/pea-15
between the stromal and epithelial components of the
epidermal tissues from transgenic and control mice (data
not shown). After papilloma regression, there were no
longer differences in ped/pea-15 levels between the skin
a b
c d
Mouse line
No. of mice
At 35 weeks 
by the end of 
promotion
No. of 
carcinomas per 
no. of 
papillomas
Frequency of 
malignant 
conversion
Tgped/pea-15 12 12/50 24%
Wt 20 2/40 5%
A
B
Figure 2 Malignant conversion frequency in Tgped/pea-15 mice. (A)
ped/pea-15 transgenic and control mice were subjected to chemical
carcinogenesis as described under Materials and methods. Total
papilloma and carcinoma numbers were recorded. Carcinoma
numbers were scored by morphological appearance on collection
followed by histological conﬁrmation after H&E staining of
parafﬁn sections. (B) Representative H&E stained parafﬁn sections
( 100 magniﬁcation) of tumors at 35 weeks after the end of
promotion treatment from control (a) and Tgped/pea-15 mice (c). In
the transgenics, PCNA immunostaining ( 100 magniﬁcation) was
scattered throughout the the tumour tissue (d), while limited to
the basal cells in the control mice (b), as evidenced at higher
magniﬁcation ( 400). Representative microphotographs are
shown
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Figure 3 ped/pea-15 expression in cell lines from chemically
induced skin tumors and papillomas from Tgped/pea-15 mice.
(a) Papillomatous lesions (P; n¼ 32), samples from unaffected skin
of the surrounding areas (NS; n¼ 34), or from the skin corresponding
to the papillomatous base upon regression of the lesion (R; n¼ 28)
from control (WT) and ped/pea-15 transgenic mice (Tgped/pea-15)
animals (n¼ 27/group) were excised and lysed as described in the
legend to Figure 1. ped/pea-15 and tubulin expression were detected
in the lysates (50mg of proteins/sample) by Western blotting and
autoradiography. Blots were revealed by ECL and autoradiography
and analysed by laser densitometry. Bars represent the average
(values7s.d.) of the tubulin-normalized expression of ped/pea-15 in
duplicate determinations from four independent experiments. The
difference between P and NS was signiﬁcant at the P¼ 0.001 (Wt)
and Po0.001 (Tg). (b) The C5N, P1 and A5 cell lines derived,
respectively, from normal keratinocytes, DMBA/TPA-induced
papillomas and spindle cell carcinomas, were cultured as described
under Materials and methods. Cell proteins (50mg) were Western
blotted with ped/pea-15 or tubulin antibodies as indicated. Blots
were revealed and further analysed as in (a). Bars represent the
average (values7s.d.) of the tubulin-normalized expression of ped/
pea-15 in duplicate determinations from four independent experi-
ments. The difference between the P1 and C5N cells and between the
A5 and C5N cells were signiﬁcant at the Po0.001 level. A
representative autoradiograph is also shown
ped/pea-15 transgenic mice and skin cancer
P Formisano et al
7014
Oncogene
where the lesion had originated and the surrounding
normal skin, in both the Tgped/pea-15 and the WT mice.
We next analysed mouse cell lines derived from
DMBA/TPA-induced skin tumors at different stages
of carcinogenesis (Portella et al., 1998). By Western
blotting, ped/pea-15 protein was similarly overexpressed
(almost three-fold; Po0.001) in both the P1 benign
papilloma cells and the A5 highly anaplastic, invasive
spindle carcinoma cells compared to the C5N immorta-
lized nontumorigenic keratinocytes (Figure 3b). Thus, in
the cell lines as well as in vivo, the increase in ped/pea-15
protein level appeared to occur at an early stage during
skin carcinogenesis.
Repeated applications of the DMBA initiator on the
mouse skin did not change ped/pea-15 levels either
in the Tgped/pea-15 or in WT mice (Figure 4a). Also,
transfection of the constitutively active H-Ras61 mutant
in keratinocytes showed no effect on ped/pea-15 levels
(Figure 4b), indicating that Ras activation is not
sufﬁcient to upregulate ped/pea-15. At variance with
DMBA, TPA treatment raised ped/pea-15 expression in
skin cells, both in the absence and in the presence of the
H-Ras61 mutant (Figure 4b). Indeed, exposure of the
nontumorigenic C5N keratinocytes to 100 mg/ml TPA
increased ped/pea-15 protein level in a time-dependent
manner (Figure 5a). The effect achieved a plateau (ﬁve-
fold increase) within 24 h and was maintained for 24
more hours, returning to baseline upon TPA with-
drawal. Also, a single TPA application to the skin of
both WT and Tgped/pea-15 mice caused a ﬁve-fold
elevation of ped/pea-15 protein for up to 48 h, declining
thereafter and returning to the pretreatment level by
144 h (still four-fold higher in transgenic compared to
WT mice; Figure 5b). Previous studies showed that
phosphorylation by both Akt/PKB and PKC increases
intracellular stability of ped/pea-15 (Trencia et al.,
2003). Based on immunoblotting with speciﬁc pSer116
and pSer104 ped/pea-15 antibodies, these increased ped/
pea-15 levels in TPA-treated skin were accompanied by
2.5- and four-fold increased phosphorylation of ped/
pea-15 on the Akt/PKB and PKC sites (Ser116 and
Ser104, respectively). There were no differences in these
phosphorylations in Wt and transgenic mice suggesting
that increased ped/pea-15 stability may, at least in part,
account for the effect of TPA in these animals
(Figure 5c).
Effect of ped/pea-15 on skin tissue apoptosis
To examine the consequences of ped/pea-15 overexpres-
sion and its role in skin tumorigenesis, we compared
in vivo apoptosis in the skin of Tgped/pea-15 and WT mice
upon the application of TPA. Based on skin lysate
determination, Tgped/pea-15 mice showed a signiﬁcant
decrease in the number of apoptotic cells compared to
WT animals (Figure 6a). Importantly, TPA application
to the skin of WT mice induced the appearance of the
20K fragment of the terminal caspase Caspase-3 in the
lysates, evidencing Caspase-3 activation (Figure 6b).
Activation of Caspase-3 by TPA was barely detectable
in the skin of Tgped/pea-15 mice, however. Consistently,
cleavage of the Caspase-3 substrate PARP was well
evident upon treating WT mouse skin with TPA, but
>10-fold less measurable in Tgped/pea-15 mice
(Figure 6c).
At variance with Caspase-3, TPA treatment exhibited
very little effect on the activation of the upstream
caspase, Caspase-8, in both WT and Tgped/pea-15 mouse
skin (data not shown).
In different cell types, ped/pea-15 protects the
inhibitor of apoptosis XIAP from the intracellular
degradation following certain apoptotic stimuli, thereby
preventing Caspase-3 activation (Trencia et al., 2004).
However, skin lysates from WT and Tgped/pea-15 mouse
showed no difference in XIAP levels (Figure 7a),
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Figure 4 Effect of DMBA application and of constitutively active
Ras mutant on ped/pea-15 expression. (a) Mouse dorsal skin
was treated by repeated DMBA applications at times 0, 6 and 12 h.
ped/pea-15 and tubulin expression was determined at the indicated
times upon the ﬁrst application of DMBA, as described above.
Bars represent the mean7s.d. of duplicate determinations of the
tubulin-normalized expression of ped/pea-15 in 2 (a: n¼ 20 mice/
time point) independent experiments. Representative blots are also
shown in the insets. (b) The C5N cells were transfected with 2.5 or
5.0mg of H-Ras61 or with 5.0 mg of the empty vector (pc) as
described under Materials and methods. After TPA treatment,
cells were lysed and cell proteins (50mg) were Western blotted with
ped/pea-15 or tubulin antibodies as indicated. Blots were revealed
by ECL and autoradiography and analysed by laser densitometry.
Bars represent the average (values7s.d.) of the tubulin-normalized
expression of ped/pea-15 in duplicate determinations from three
independent experiments. Representative blots are also shown in
the insets
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suggesting that alternative mechanisms are responsible
for the reduced apoptosis occurring in the Tgped/pea-15
mouse skin after TPA exposure. Indeed, previous
studies in 293 cells indicated that ped/pea-15 antiapop-
totic function requires ped/pea-15 simultaneous inhibi-
tion of the SAPK signaling system of JNK/p38 and
activation of ERK1/2 (Condorelli et al., 2002). In WT
mouse skin, TPA elicited a 10-fold increase in phos-
phorylation of the key activation sites of JNK (Thr183
and Tyr185) and those of p38 (Thr180, Thr182),
indicating activation of these kinases (Figure 7b).
Interestingly, the effect of TPA was ﬁve-fold reduced
in Tgped/pea-15 mouse skin, despite normal expression of
both JNK and p38. ERK1/2 phosphorylation was also
constitutively increased in Tgped/pea-15 compared to Wt
mouse skin (Figure 7c). Despite the eight-fold induction
in the WT mouse, ERK phosphorylation in response to
TPA showed little further increase in the transgenics,
with no signiﬁcant difference in ERK1/2 expression.
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Figure 5 Effect of isolated applications of TPA on ped/pea-15
expression and phosphorylation. C5N keratinocytes (a) and shaved
dorsal skin of WT and Tg mice (b) were exposed to TPA,
respectively, by addition to the culture medium (a) and topical
application (b) as described under Materials and methods. Upon
48h, TPA was removed from the cell cultures by medium
replacement (a). At the indicated times, cells (a) and tissue samples
(b) were lysed and analysed by Western blotting with ped/pea-15
and tubulin antibodies. Skin lysate ﬁlters were also reblotted with
speciﬁc phosphoserine104 and phosphoserine116 antibodies (c).
Blots were revealed by ECL and autoradiography and subjected
to densitometric quantitation. Bars represent the mean7s.d. of
duplicate determinations of the tubulin-normalized expression of
ped/pea-15 in three (a, b: n¼ 20 mice/time point) and two (c)
independent experiments. Representative blots are also shown in
the insets
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Figure 6 TPA-induced apoptosis and activation of Caspase 3 in
Tgped/pea-15 mice. (a) Transgenic and control mice (n¼ 30/group;
M/F ratio¼ 1 in each group) were subjected to TPA applications
(6.25 mg of TPA in 200ml acetone for 24 h) as described under
Materials and methods. Samples of squamous stratiﬁed epithelium
from the treated areas were solubilized and analysed with the
ELISAPLUS kit for detection of apoptosis. Bars represent the mean
values (7s.d.) of triplicate determinations in three independent
experiments. (b) The dorsal skin of Tgped/pea-15 and control mice
was treated with TPA as above. Samples from the treated skin were
excised and analysed by Western blotting with Caspase-3 (b) or
PARP antibodies (c). Blots were revealed by ECL and autoradio-
graphy. A representative autoradiography is shown; same results
were obtained in three further experiments
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Consistent with the reported ability of ped/pea-15 to
prevent nuclear migration of ERK1/2, phosphorylation
of the ELK substrate in response to TPA was drastically
reduced in tissues from Tgped/pea-15 compared to control
mice. At variance with ELK, TPA phosphorylation of
the H3 histone target of the ERK1/2-downstream and
ped/pea-15 binding kinase RSK2 (Vaidayanathan
and Ramos, 2003) showed no difference in Tgped/pea-15 and
control mice (data not shown). Thus, at least in part,
overexpression of ped/pea-15 may inhibit TPA-induced
apoptosis by dysregulating selective pathways of the
MAPK signaling and by inhibiting Caspase-3.
The role of caspase-3 inhibition in chemically induced
skin tumorigenesis
To further address the involvement of impaired Cas-
pase-3 activation in the increased susceptibility to skin
carcinogenesis of the Tgped/pea-15 mice, we ﬁrst compared
TPA effect in the C5N nontumorigenic mouse kerati-
nocytes and the A5 highly malignant invasive spindle
carcinoma cells. Based on its own cleavage and that of
the PARP substrate, TPA induction of Caspase-3 was
barely detectable in the ped/pea-15 overexpressing A5
cells, despite the evident effect occurring in the C5N
keratinocytes (Figure 8a). The reduced activation of
Caspase-3 in the A5 carcinoma cells was paralleled by a
six-fold decrease in TPA-induced apoptosis, compared
to the C5N keratinocytes (Figure 8b). We then silenced
the expression of ped/pea-15 using a speciﬁc antisense
cDNA (Hao et al., 2001). In the A5 cells, the antisense
inhibited ped/pea-15 expression to levels comparable to
those of the untreated C5N keratinocytes (Figure 8c). In
parallel, the antisense rescued TPA apoptosis in the A5
cells, rendering the A5 as responsive to TPA as the C5N
cells (Figure 8b). Caspase-3 and PARP cleavage in
response to TPA was similarly rescued in antisense-
transfected A5 cells (Figure 8a).
The colony growth rate in semisolid medium was also
reduced in the antisense expressing A5 clones compared
to cells tansfected with the empty vector (65% reduc-
tion; Po0.001) (Table 1). Importantly, injection of A5
cells transfected with either the ped/pea-15 antisense
cDNA or the empty vector into athymic mice showed no
signiﬁcant difference in tumor incidence. However, the
tumor latency period of the antisense expressing clones
was almost three-fold increased compared to that of
control cells (Po0.01).
Discussion
There is evidence that increased expression of the
antiapoptotic protein ped/pea-15 is associated to devel-
opment of malignancy (Condorelli et al., 1998; Ramos
et al., 2000; Tsukamoto et al., 2000; Dong et al., 2001;
Hao et al., 2001). However, no information is available,
to date, to assess whether modulation of ped/pea-15
expression may directly affect tumorigenesis and/or
progression in vivo. Chemically induced skin carcino-
genesis studies have provided valuable information
concerning the impact of genetic alterations on multi-
step tumorigenesis and progression in genetically
modiﬁed mice (Balmain and Harris, 2000). In the
present paper, we have addressed the role of ped/pea-
15 in skin tumor initiation, promotion and progression
and used transgenic mice overexpressing the ped/pea-15
gene. These mice express three- to four-fold higher skin
levels of ped/pea-15 compared to their nontransgenic
littermates. We now report that, in parallel with the
increased ped/pea-15 expression, the transgenics show
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Figure 7 Effects of TPA on XIAP expression and JNK, p38,
ERK1/2 and ELK1 phosphorylations. Transgenic and control mice
(n¼ 12/group; M/F ratio¼ 1 in each group) were subjected to TPA
applications (6.25mg of TPA in 200ml acetone for 24 h) as described
under Materials and methods. Samples from the treated skin were
excised and analysed by Western blotting with XIAP, tubulin (a),
phospho-JNK, JNK, phospho-p38, p38 (b), phospho-ERK1/2,
ERK1/2, phospho-Elk1, and Elk-1 antibodies (c). Blots were
revealed by ECL and autoradiography. The autoradiographs
shown are representative of four (a and b) and three (c)
independent experiments
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anticipated as well as increased occurrence of benign
papillomatous lesions upon being topically treated with
the tumor initiator DMBA followed by repeated
applications of the tumor promoter TPA. Interestingly,
ped/pea-15 expression is also increased in papillomas
from WT mice, compared to the adjacent normal skin.
The signiﬁcance of the increased ped/pea-15 levels to
skin tumorigenesis is further strengthened by the ﬁnding
that, upon papilloma regression, ped/pea-15 returns to
basal levels in the skin where the lesions have been
produced. In addition, the malignant conversion fre-
quency of the papillomatous lesion was signiﬁcantly
higher in ped/pea-15 transgenic compared to the control
animals. These results indicate, for the ﬁrst time, that
increased levels of ped/pea-15 confer greater suscept-
ibility to skin carcinogenesis in vivo and may enhance
cutaneous tumor progression toward malignancy.
Indeed, after suspension of TPA treatment, the trans-
genic mice maintain stably elevated ped/pea-15 levels
compared to the WT animals where the effect of
TPA vanishes.
We show that the constitutively active H-Ras61
mutant does not affect ped/pea-15 expression levels in
keratinocytes. Consistently, DMBA application did not
upregulate ped/pea-15 in mouse skin, indicating that Ras
mutation is not sufﬁcient to cause ped/pea-15 over-
expression. At variance, treatment with TPA alone
rapidly increased ped/pea-15 expression levels in the skin
of both transgenic and control mice, suggesting that
ped/pea-15 overexpression represents an early event
during cutaneous tumor promotion, though not initia-
tion. At least in part, the effect of TPA may be mediated
by induction of PKB/Akt and PKC. Indeed, (i)
phosphorylation of ped/pea-15 on PKB/Akt and PKC
sites is increased in TPA-treated skin; and (ii) previous
studies (Trencia et al., 2003) demonstrated that phos-
phorylation of these sites increases cellular stability of
ped/pea-15. In addition, transformed cell lines derived
from DMBA/TPA-induced skin tumors consistently
show higher ped/pea-15 levels compared to immorta-
lized nontumorigenic keratinocytes. It is conceivable,
therefore, that higher ped/pea-15 levels may confer
a distinctive advantage to the cells upon DMBA
initiation, leading to selection of those overexpressing
ped/pea-15.
Transgenic mice overexpressing ped/pea-15 feature
insulin-resistance and decreased glucose tolerance
(Vigliotta et al., 2004). Considerable epidemiological
evidence exists indicating that these metabolic abnorm-
alities have a role in determining the occurrence of a
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Figure 8 Effect of ped/pea-15 silencing on TPA apoptosis in C5N
and A5 cells. (a) C5N and A5 cells stably transfected with ped/pea-
15 antisense cDNA were obtained as described under Materials
and methods. Antisense-expressing and control cells were exposed
to TPA for 24 h and then solubilized. Cell lysates (50 mg per point)
were then analysed by Western blotting with Caspase-3 or PARP
antibodies, as indicated. The effect of the antisense on ped/pea-15
expression was controlled in the same cell lysates by Western
blotting with ped/pea-15 antibodies as described in the legend to
Figure 3(c). Filters were revealed by ECL and autoradiography.
The autoradiographs shown are representative of three indepen-
dent experiments. Alternatively (b), TPA-stimulated cells were
solubilized and analysed with the ELISAPLUS kit for detection of
apoptosis as described under Materials and methods. Bars
represent the mean values (7s.d.) of triplicate determinations in
three independent experiments
Table 1 Analysis of transformation markers of A5 carcinoma cells
Transfected
DNA/caspase
inhibitor
Colony-forming
efﬁciency (%)a
Tumor
incidenceb
Latency period
(days)c
— 58 5/5 14
pcDNA vector 56 6/6 14
pcDNA AS 20 6/6 39
Z-DEVD-FMK 14 — —
aColonies larger than 64 cells were scored after 3 weeks. Colony-
forming efﬁciency was calculated by dividing the number of colonies
formed by the number of plated cells  100. bTumorigenicity was
assayed by injecting 1 106 cells into 6-week-old athymic mice. CThe
animals were monitored for the appearance of tumors. The mean
tumor latency is the time needed for tumors to reach 10mm in
diameter. The tumor latency of the antisense (AS)-transfected cells
differed signiﬁcantly from controls (Po0.001)
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number of tumors in humans (Calle and Kaaks, 2004).
Transgenic mice overexpressing ped/pea-15 show no
greater prevalence of spontaneous tumors, but whether
insulin-resistance and/or impaired glucose tolerance
contribute to the increased susceptibility to skin
carcinogenesis cannot be concluded from the present
study. Different mechanisms likely play a greater role,
however, as TPA-induced upregulation of ped/pea-15
also accompanies skin tumor development in nontrans-
genic mice featuring normal insulin sensitivity and
glucose tolerance.
ped/pea-15 performs a broad antiapoptotic action in
cultured cells (Condorelli et al., 1999, 2002; Kitsberg
et al., 1999; Hao et al., 2001; Trencia et al., 2004). At
least in part, ped/pea-15 antiapoptotic action is due to
inhibition of the induction of the terminal caspase,
Caspase-3 (Hao et al., 2001; Condorelli et al., 2002). In
this paper, we show that TPA-induced apoptosis in
squamous stratiﬁed epithelium in vivo is also signiﬁ-
cantly inhibited in ped/pea-15 transgenic mice. This
decrease is accompanied by reduced activation of
Caspase-3 and cleavage of the Caspase-3 substrate
PARP in response to TPA. Reduced apoptosis and
Caspase-3 activation in response to TPA also occur in
the A5 cells, which are derived from DMBA/TPA-
induced spindle cell carcinomas and overexpress ped/
pea-15. Consistently, in the normal C5N keratinocytes
that express lower levels of endogenous ped/pea-15,
transfection of ped/pea-15 cDNA and treatment with the
speciﬁc Caspase-3 inhibitor Z-DEVD-FMK prevented
TPA apoptosis in a nonadditive manner (data not
shown). Expression of a speciﬁc ped/pea-15 antisense
cDNA in the A5 cells simultaneously reduced ped/pea-
15 levels and rescued TPA-induced apoptosis and
Caspase-3 activation. Importantly, the antisense signiﬁ-
cantly increased the latency preceding tumor formation
upon A5 cell injection in nude mice. The A5 cell growth
in semisolid medium was also signiﬁcantly reduced by
decreasing ped/pea-15 expression. Thus, the impaired
apotosis determined by inhibition of Caspase-3 activity
in ped/pea-15 overexpressing skin cells might affect the
malignant progression as well as tumorigenesis.
Previous studies by other investigators and by us have
shown that ped/pea-15 may inhibit Caspase-3 function
by preventing the activation of Caspase-8 (Condorelli
et al., 1999; Kitsberg et al., 1999) as well as by increasing
stability of the inhibitor of apoptosis protein XIAP
(Trencia et al., 2004). These events do not account for
ped/pea-15 inhibition of Caspase-3 in TPA-treated skin,
as ped/pea-15 overexpression does not affect TPA action
on either Caspase-8 function or XIAP levels. In certain
cell types, block of the JNK and p38 members of the
MAPK family also plays an important role in mediating
the ped/pea-15 protection from apoptosis (Condorelli
et al., 2002), which may lead to Caspase-3 inhibition
(Kamata et al., 2005). Full antiapoptotic function in
these cells requires concomitant ped/pea-15 induction of
the ERK1/2 MAPKs and/or ERK1/2 anchoring into the
cytoplasm (Formstecher et al., 2001; Condorelli et al.,
2002). Impaired JNK and p38 activation and increased
ERK1/2 cytoplasmic activity have also been detected in
the skin of Tgped/pea-15 mice upon exposure to TPA,
indicating they may mediate the decreased susceptibility
to apoptosis caused by overexpression of ped/pea-15 in
these cells. Indeed, same as in other cell types
(Condorelli et al., 2002), in the A5, the rescue of JNK
function by overexpression of the upstream kinase
MKK6 signiﬁcantly enhanced the apoptotic response
to TPA (data not shown).
Intriguingly, Gaumont-Leclerc et al. (2004) have very
recently reported evidence that ped/pea-15 may exert a
tumor suppressor function in the IMR90 ﬁbroblasts. It
is possible that this function is also exerted in the mouse
keratinocyte model. Upon DMBA/TPA exposure of
these cells, the antiapoptotic function of ped/pea-15
seems to prevail, however. Consistently, ped/pea-15
overexpression confers raised susceptibility to chemical
carcinogenesis in the skin. Thus, different settings may
lead ped/pea-15 to have its pro- or antioncogenic
functions overriding.
Deregulated apoptosis has been suggested to play an
important role in tumorigenesis and malignant progres-
sion of transformed cells by contributing the cells with
the capability to skip cell death programs, accumulating
DNA damage (Debatin and Krammer, 2004). In certain
tumors, these abnormalities may occur because of loss
of proapoptotic molecules such as Bax, Apaf-1 or
Caspase-8 (Harada and Grant, 2003; Baldi et al., 2004).
In other situations, impaired apoptosis has been
associated to increased expression of antiapoptotic
molecules of the Bcl-2 family (Harada and Grant,
2003). In this paper, we have shown that increased
expression levels of the antiapoptotic protein ped/pea-15
may also determine susceptibility to skin tumorigenesis
and tumor progression by inhibiting Caspase-3-depen-
dent apoptosis in DMBA/TPA-treated mice. Several
alterations occurring in these chemically induced mouse
skin tumors have also been observed in the homologous
cutaneous tumors in humans (Balmain and Harris,
2000). ped/pea-15 might represent a novel target for
cutaneous cancer treatment and prevention.
Materials and methods
Transgenic ped/pea-15 mice
The C57BL/6JxDBA/2J ped/pea-15 transgenic mice were
described in Vigliotta et al. (2004). The animals were
maintained in the animal facility at the Dipartimento di
Biologia e Patologia Cellulare e Molecolare, Federico II
University of Naples. Experiments involving animals were
conducted in accordance with accepted standards of animal
care and the Italian regulations for the welfare of animals. The
study protocol was approved by the Institutional Committee
on Animal Care of the University of Naples.
Two-stage skin carcinogenesis
The dorsal skin of 8-week-old mice were shaved, and, 2 days
later, a single dose of 50mg of 7,12-dimethylbenz[a]anthracene
(DMBA) in 200ml of acetone was applied. At 1 week after
initiation, the mice were treated with 6.25mg of 12-O-
tetradecanoylphorbol-13-acetate (TPA) in 200ml of acetone
ped/pea-15 transgenic mice and skin cancer
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twice a week for 15 weeks. The number of papillomas detected
by palpation was recorded once a week.
At 1 week after termination of TPA treatment, mice were
killed, and skin tissues snap frozen in liquid nitrogen and/or
ﬁxed in freshly prepared 4% paraformaldehyde followed by
parafﬁn embedding. Mice were maintained for 35 additional
weeks after TPA discontinuation, and tumor progression was
investigated. Tumors were scored as papillomas or carcinomas
by histological analysis after H&E staining of parafﬁn
sections.
Histology
Tissues were ﬁxed in formalin, dehydrated, blocked in parafﬁn
and sectioned at 6mm. The tissue sections were stained with
hematoxylin and eosin. A total of 76 nonmalignant papillomas
and all malignant tumors were examined. Malignant skin
tumors were densely cellular spindle cell tumors in the dermis
underlying the papilloma, often exhibiting invasion through
skeletal muscle and sometimes associated with lymph node
metastasis. Premalignant lesions were squamous cells showing
atypia (enlarged nuclei, mitotic activity) but not associated
with spindle cell proliferation, invasion and metastasis.
Cell culture and growth, transfection and Western blot analysis
The C5N, P1 and A5 cells have been previously described
(Portella et al., 1998) and were kindly provided by Dr A
Balmain (University of California, San Francisco, Compre-
hensive Cancer Center, USA). Cells were cultured in DMEM
supplemented with 10% foetal calf serum, 10 000U/ml
penicillin, 10 000mg/ml streptomycin and 2% L-glutamine in
a humidiﬁed CO2 incubator as described in Portella et al.
(1998). Transfection of the constitutively active H-Ras61 in
C5N cells, tissue collection and Western blots were performed
as described in Vigliotta et al. (2004). The pcDNA-ped/pea-15
antisense construct has been previously described (Hao et al.,
2001). Clones expressing the antisense were selected as in Hao
et al. (2001). Soft agar colony assays were performed accord-
ing to a previously described technique (Macpherson and
Montagnier, 1964). The antibodies used include ped/pea-15
antibodies (Vigliotta et al., 2004), phosphoserine104ped/pea-15
and phosphoserine116ped/pea-15 antibodies (Trencia et al.,
2004), tubulin, caspase-3, XIAP and PARP antibodies (Santa
Cruz Biotechnology, CA, USA).
Detection of apoptosis
Animals were subjected to topical applications of acetone-
dissolved TPA (6.25 mg) or DMBA (50 mg) or acetone alone, as
indicated. The animals were killed, skin tissues were removed
and then solubilized as in Vigliotta et al. (2004) and processed
for the apoptosis assay using the Cell Death Detection
ELISAPLUS Kit (Roche Diagnostics GmbH, Mannheim,
Germany), according to the manufacturer instructions. For
studies in isolated cells, apoptosis was investigated as
previously described (Trencia et al., 2004).
Tumorigenicity assay
Experiments were performed in 6-week old male athymic mice
(Charles River, Italy). A5 cells (1 106), either transfected with
the ped/pea-15 antisense cDNA or not, were injected into
the right ﬂank of the mice. The animals were monitored for
the appearance of tumors and tumor latency was evaluated.
The mean tumor latency is the time needed for tumors to reach
10mm in diameter. All mice were maintained at the animal
facility of the Dipartimento di Biologia e Patologia Cellulare e
Molecolare of the Federico II University of Naples.
Densitometry and statistical analysis
Densitometric analysis was performed using a Scion Image
Analyser. All the data were expressed as mean7s.d.
Signiﬁcance was assessed by Student’s t-test for comparison
between two means.
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Abstract
Aurora/Ipl1-related kinases are a conserved family of
proteins that have multiple functions during mitotic pro-
gression. High levels of Aurora kinases are characteristic of
rapidly dividing cells and tumours. Aurora B encodes a
protein that associates with condensing chromatin, con-
centrates at centromeres, and then relocates onto the
central spindle at anaphase. In this study the expression
and the localisation of Aurora B throughout germinal
epithelial progression in normal testis and its neoplastic
counterpart were analysed.
Immunocytochemistry and RT-PCR analysis of mouse
germinal epithelium cells showed the presence of Aurora
B in spermatogonia and occasionally in spermatocytes.
Western blot analysis revealed the typical Aurora B
isoform (41 kDa) in the same cellular types. A similar
distribution was observed in human testis by immuno-
histochemistry. Moreover, the distribution and the
expression of Aurora B were investigated in neoplasms
derived from germ cells. Surgical samples of seminomas
were analysed, and a high percentage of Aurora B positive
cells (51%) was detected; the expression of Aurora B was
significantly related to the MIB-1 proliferation marker
(R=0·816).
The data presented here demonstrate that Aurora B
expression occurs in spermatogonial division. Further-
more, our results indicate that the expression of Aurora B
is a consistent feature of human seminomas.
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Introduction
Mitosis is a highly coordinated process that ensures the
fidelity of chromosome segregation and is characterised by
dramatic morphological changes which occur in a strictly
sequential order (Cao & Wang 1990). The mechanisms
that coordinate the cycle of chromosome condensation and
decondensation with the assembly, function, and subse-
quent disassembly of the mitotic spindle are poorly under-
stood. Highly conserved genes essential for chromosome
condensation have been found through genetic screens in
yeasts and Drosophila (Bhat et al. 1996, Sutani et al. 1999).
Protein phosphorylation has been suggested as an import-
ant regulatory mechanism for cytokinesis. Among the
protein kinases, serine/threonine protein kinase of the
Aurora family (Aurora A/STK-15, Aurora B/AIM-1,
Aurora C/AIK-3) are known to be required for the
progression through the M phase. It has been shown that
the products of the Aurora family genes are expressed in
proliferating cells and are overexpressed in neoplastic cells
(Tanaka et al. 1999). In particular, Aurora B has been
found overexpressed in human cancer cells of diﬀerent
origin such as HeLa, Lovo, HT29, and in cell lines derived
from colorectal tumours (Tatsuka et al. 1998). Moreover,
high expression levels of Aurora B were detected in
primary human colorectal cancers at various pathologic
stages with a tendency to group in higher grades of
malignancy defined by pathological observation (Katayama
et al. 1999). Finally, overexpression of Aurora B in diploid
human cells NHDF induced multinuclearity, which is one
of the most common features of tumour cells (Tatsuka et al.
1998, Terada et al. 1998).
During the cell cycle Aurora B (AIM-1) peaks after
Aurora A and is prominent at the midzone during
anaphase and in postmitotic bridges during telophase.
The two kinases display distinct subcellular localisations.
Aurora B and its corresponding proteins, Caenorhabditis
elegans AIR-2, Xenopus laevis AIRK2, and Drosophila IAL,
have roles in cytokinesis (Terada et al. 1998). Moreover,
double-stranded RNA interference analysis has revealed
that Aurora B plays a critical role in chromosome
segregation as well as in cytokinesis (Adams et al. 2001).
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Spermatogenesis is a hormonally regulated and unique
developmental process whereby diploid stem cells diﬀer-
entiate through an ordered sequence of steps into haploid
spermatozoa, highly specialised in structure and function.
This process can be divided into mitotic, meiotic, and
postmeiotic phases that are synchronised and are an ideal
model for studying the control of cellular growth and
diﬀerentiation. The molecular mechanisms that regulate
and coordinate the expression of genes throughout sper-
matogenesis in vertebrates are not completely understood
(Sharpe 1994, Sassone-Corsi 1997).
The aim of this study is to clarify the spatio-temporal
localisation of Aurora B kinase in the mouse germinal
epithelium progression, and its expression in normal hu-
man testis and in testicular neoplastic lesions. Our results
document that Aurora B is detected in the germinal
epithelium in the spermatogonia and occasionally in sper-
matocytes. In addition, these data support the notion that
Aurora B is involved in germ cell proliferation of normal
and neoplastic testis. A high percentage of Aurora
B-positive cells in seminomas was detected and the
expression of Aurora B was significantly related to the
MIB-1 proliferation marker.
Materials and Methods
Preparation of testicular cells
Germ cells were prepared from testes of adult CD1 mice
(Charles River Italia, Calco, Italy). Testes were removed
from the albuginea membrane and digested for 15 min in
0·25% (w/v) collagenase (type IX, Sigma) at room tem-
perature under constant shaking. They were then washed
twice in Minimum Essential Medium (Life Technologies,
Inc.), seminiferous tubules were cut into pieces with a
sterile blade and further digested in Minimum Essential
Medium containing 1 mg/ml trypsin for 30 min at 30 C.
Digestion was stopped by adding 10% fetal calf serum and
the germ cells released were collected after sedimentation
(10 min at room temperature) of tissue debris. Germ cells
were centrifuged for 13 min at 1500 r.p.m. at 4 C and
the pellet resuspended in 20 ml elutriation medium
(120·1 mM NaCl, 4·8 mM KCl, 25·2 mM NaHCO3,
1·2 mM MgSO4 (7H2O), 1·3 mM CaCl2, 11 mM glu-
cose, 1essential amino acid (Life Technologies, Inc.),
penicillin, streptomycin, 0·5% bovine serum albumin).
Pachytene spermatocyte and spermatid germ cells were
obtained by elutriation of the unfractionated single cell
suspension as described elsewhere (Meistrich 1977).
Homogeneity of cell populations ranged between 80 and
85% for pachytene spermatocytes, 95% for spermatids, and
was routinely monitored morphologically. Mature sperma-
tozoa were obtained from the cauda of the epididymus of
mature mice as described previously (Sette et al. 1997).
Spermatogonia were obtained from prepubertal mice as
previously described (Grimaldi et al. 1993, Rossi et al.
1993).
The NIH-3T3 mouse fibroblasts used in these studies
were cultured as recommended by the American Type
Culture Collection (Rockville, MD, USA).
Tissue samples
As a source of normal tissue, ten CD1 adult mice were
killed and the testes were removed and fixed in Bouin’s
fluid. Samples were serially dehydrated in ethanol and
cleared in xylene before processing on a commercial
automated tissue processor. The animals used in the
present study were maintained at the Department of
Biology and Pathology Animal Facility. The animal ex-
perimentations described herein were conducted in ac-
cordance with accepted standards of animal care and in
accordance with the Italian regulations for the welfare of
animals used in experimental studies. The study was
approved by our institutional committee on animal care.
As a source of neoplastic tissues, paraﬃn-embedded blocks
from ten cases of classic seminoma were retrieved from the
files of the Department of Bio-Morphological Sciences at
the University ‘Federico II’ of Naples on the basis of the
Faculty of Medicine and Surgery Ethical Committee
approval; in all instances, the diagnosis was confirmed on
review.
Immunohistochemistry and quantitative analysis
In normal and neoplastic testis the cellular distribution of
Aurora B protein was assessed by the polyclonal antibody
raised in rabbits (no. 611082; BD Transduction Labora-
tories, San Diego, CA, USA). The conditions of pre-
treatment of the histological samples most suitable for
Aurora B staining have been determined by preliminary
experiments on colon cancer paraﬃn-embedded sections
that express high levels of this protein (Bischoﬀ et al.
1998). We observed that regardless of the length of
fixation, a proceeding step of the heat-induced antigen
retrieval technique yielded a larger number of cells with
specific Aurora B nuclear staining (data not shown). Based
on these observations, xylene-dewaxed and alcohol-
rehydrated paraﬃn sections were placed in Coplin jars
filled with a 0·01 M tri-sodium citrate solution, and heated
for 3 min in a conventional pressure cooker. After heating,
slides were thoroughly rinsed in cool running water for
5 min. They were then washed in Tris–buﬀered saline
(TBS) pH 7·4 before incubating overnight with the
Aurora B (1:1000) antibody. The incubation with the
primary antibody was followed by incubation with bio-
tinylated anti-mouse immunoglobulins and by peroxidase-
labelled streptavidine (LSAB-DAKO, Copenhagen,
Denmark); the signal was developed by using diaminoben-
cidine chromogen as substrate. Negative controls were run
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with normal mouse serum instead of the primary antibody
or the antibody was preabsorbed with the cognate peptide
(106 M).
In order to assess the relationship between Aurora
B expression and cell proliferation, seminomas were
also stained with the MIB-1 antibody. The antibody
(Immunotech, Marseille, France; diluted 1:50) recognised
Ki-67, a nuclear protein expressed in the G1, S and G2/M
phases; this antibody, known to stain spermatogonia, was
also used as a control of antigenic preservation and of
successful antigenic retrieval. Labelling indices for
Aurora-B and MIB-1 antibodies were determined in the
same manner. Adjacent sections were used and counting
was performed in similar areas. Quantitative analysis
performed with a computerised analyser system (CAS 200,
Becton Dickinson, Chicago, USA) was used to score the
nuclei of individual cells for expression of Aurora B and
MIB-1 proteins. As already described, nuclear boundary
optical density and antibody threshold were adjusted for
each case examined (Bischoﬀ et al. 1998). A minimal
threshold was established by counting at least 1000 neo-
plastic cells per seminoma sample. In each case the
distributions of Aurora B and MIB-1 proteins were
evaluated and expressed as percentages of the total cell
population. Data are reported as median and ranges.
Statistical analysis was performed by means of the SPSS
Inc. package (SPSS, Chicago, IL, USA). The relationship
between Aurora B and MIB-1 immunostaining was
analysed by calculating the nonparametric Spearman R
coeﬃcient. A P value less than 0·05 was considered
significant.
Protein extraction and Western blot analysis
Mouse testes were homogenised directly into lysis buﬀer
(50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 10% glycerol, 1% Triton-X-100, 1 mM phenyl-
methylsulphonyl fluoride, 1 µg aprotinin, 0·5 mM sodium
orthovanadate, 20 mM sodium pyrophosphate). The
lysates were clarified by centrifugation at 14 000g for
10 min. Protein concentrations were estimated by a
Bio-Rad assay (Bio-Rad, München, Germany), and
boiled in Laemmli buﬀer (Tris–HCl (pH 6·8) 0·125 M,
SDS 4%, glycerol 20%, 2-mercaptoethanol 10%,
Bromophenol Blue 0·002%) for 5 min before electro-
phoresis. Proteins were subjected to SDS-PAGE (10%
polyacrylamide) under reducing conditions. After electro-
phoresis, proteins were transferred to nitrocellulose
membranes (Immobilon Millipore Corporation, Bedford,
MA, USA); complete transfer was assessed using
prestained protein standards (Bio-Rad, Hercules, CA,
USA). After blocking with TBS-BSA (25 mM Tris, pH
7·4, 200 mM NaCl, 5% bovine serum albumin), the
membrane was incubated with the primary antibody
against Aurora B (1:400; #611082, BD Transduction
Laboratories) and -tubulin (1:500; clone DM1A, Sigma-
Aldrich, Milan, Italy) for 1 h (at room temperature).
Membranes were then incubated with the horseradish
peroxidase-conjugated secondary antibody (1:10 000) for
45 min (at room temperature) and the reaction was
detected with an ECL system (Amersham Life Science,
UK).
RNA extraction and RT-PCR
Total RNA was extracted from cells and tissue using the
RNAzol kit (Tel-Test, Inc., Friendswood, TX, USA)
according to standard procedures. Total RNA (1 mg) was
extracted from specimens (Tel-Test, Inc.) and reverse
transcribed (Life Technologies Italia srl). cDNA was
amplified using Aurora B specific primers. The primers
used were as follows: Aurora B forward: 5-TTG ACA
ACT TTG AGA TTG GG-3; Aurora B reverse: 5-GCT
GGT CGT AGA AGT AGT TGT-3. Expression of the
Figure 1 Expression of Aurora B mRNA in mouse testis. RT-PCR analysis of aurora B mRNA in adult
mouse testis (lane 1), interstitium (lane 2), normal mouse testis germ cells (lane 3–6), NIH-3T3 cells as
a positive control (lane 7), and without reverse transcriptase (RT, lane 8). Total mRNA was then
extracted, reversed transcribed and subjected to PCR analysis using primers (see Materials and
Methods). The integrity of mRNA samples was determined by using -actin as control (lower frame).
The RT-PCR analysis is representative of three separate experiments.
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-actin gene was utilised as an internal control for the
amount of cDNA in the PCRs by using the following
primers: -actin forward: 5-GTC AGG CAG CTC ATA
GCT CT-3; -actin reverse: 5-TCG TGCGTG
ACATTA AAG AG-3. PCR amplification was performed
at 94 C (1 min), 52 C (1 min), and 72 C (1 min) for
30 cycles. Reaction products were subjected to agarose
gel electrophoresis. Samples amplified without previous
reverse transcription were used to confirm that the signal
was not due to amplification of contaminating DNA (data
not shown).
Results
Aurora B expression in the mouse testicular cells
Aurora B expression in various mouse testis cells was
evaluated by the RT-PCRmethod. Aurora B mRNA was
expressed in germ cells almost exclusively in spermato-
gonia (spg) with a faint band present in spermatocytes
(spc) (Fig. 1); a band was also detected in the interstitial
cells (Fig. 1).
Western blot analysis of whole mouse testis and cell
extracts from fractionated adult testis cells showed a single
product migrating as a 41 kDa protein (Fig. 2). Among
germ cells, it was abundant in spg, present in a few spc,
and absent in spermatids (spt) and spermatozoa (spz), in
agreement with the RT-PCR results. Aurora B protein
was also present in the interstitial extract cells indicating a
proliferative activity of these cells (Fig. 2).
Immunohistochemical analysis of Aurora B protein in
mouse testis
Immunocytochemistry was performed on serial mouse
testis sections using an antibody against Aurora B protein.
Figure 2 Distribution of Aurora B protein in mouse testis. Western
blot analysis of aurora B protein in mouse adult testis (lane 1),
interstitium (lane 2), normal mouse testis germ cells (lane 3–6),
and NIH-3T3 cells as a positive control (lane 7) (40 g/lane).
Whole lysates were detected by Western blotting with anti-Aurora
B polyclonal serum. The specific band of about 41 kDa was
identified by comparison with comigrating size markers (Bio-Rad,
Melville, NY, USA). -Tubulin (Sigma) was used to assess the equal
amounts of protein. The blots are representative of three separate
experiments.
Figure 3 (A) Localisation of the Aurora B protein in sections of
adult mouse testis by immunocytochemistry. Representative
seminiferous tubules show staining in the spermatogonia (spg) and
spermatocytes (spc). ser, Sertoli cells. Bar=100 m. (B) Higher
magnification showing specific staining for Aurora B in spg, spc
and Sertoli cells (ser). Bar=50 m. Lower panel: spg in mitotic
metaphase showing Aurora B immunostaining. Bar=25 m.
(C) Control section using the antibody preabsorbed with the cognate
peptide (106 M); symbols are as indicated above. Bar=50 m.
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A topological regular expression of Aurora B was observed
in seminiferous tubules with complete spermatogenesis
(Fig. 3A). The protein was found in the spg and occasion-
ally in spc (pachytene stage) and Sertoli cells (ser, Fig. 3B).
In particular, immunoreactive spg showed intense meta-
phase mitotic figures (Fig. 3B, lower panel). On the other
hand, Aurora B expression was not detectable in maturing
germ cells. In fact, no labelling was seen in many primary
and secondary spc, spt and spz (Fig. 3B).
The antiserum used in this study fulfils the criteria of
specificity. In particular, immunoabsorption tests revealed
that the labelling was quenched by preincubating antibody
with 106 M of the cognate peptide (Fig. 3C).
Aurora B expression in the normal human testis and in
seminomas
The vast majority of testicular cancers arise from germ
cells. Premeiotic germ cells have been suggested to be the
precursor for male germ cell tumours; therefore Aurora B
expression was examined in a series of seminomas
(Chaganti et al. 1994). Immunohistochemical analysis was
performed in 10 cases of ‘classical type’ seminomas. In all
cases examined a variable percentage of the neoplastic
population was stained (range 29–55) as shown in Fig. 4A.
The pattern of Aurora B staining in seminomas diﬀered
significantly from the pattern observed in mouse testis.
Also, in the non neoplastic tissue adjacent to the neo-
plasia the staining pattern was limited to the basal spg
and a few spc, with maturing cells being devoid of signal
(Fig. 5A). As shown in Fig. 3, Aurora B-positive cells were
irregularly distributed throughout the neoplastic tissue
with a strong signal (Fig. 5B). Interestingly, individual
dividing cells showed the most intense signal (Fig. 5B,
insert).
We next compared the expression in seminomas of
Aurora B to Ki-67, a well known proliferation marker, by
using MIB-1 antibody. Similar to Aurora B, MIB-1
antibody was also more evident in tumours than in
adjacent areas, with the percentage of Ki-67 stained cells
ranging from 41–79 (Fig. 4A). Taking into account the
overall data, Aurora-B expression showed a highly statisti-
cal correlation with Ki-67 (R=0·816; P=0·004, Fig. 4B).
It is noteworthy that the percentage of Aurora-B-
positive cells was lower than the Ki-67-positive cell
population, indicating that a subset of Ki-67-positive cells
is also positive for Aurora B. In fact, Ki-67 was expressed
by the very large majority of tumour cells (median
percentage 66%), whereas the median percentage of
Aurora B-positive cells was 51% of the total tumour cells
(Fig. 4A).
Discussion
Spermatogenesis in mammals is characterised by a well-
defined sequence of mitotic and meiotic divisions that lead
to the production of mature spermatozoa. However,
testicular development and normal spermatogenesis
require specialised molecular mechanisms that ensure
stringent stage-specific gene expression (McCarrey 1993,
Chieﬃ et al. 2002).
Figure 4 (A) Analysis of Ki-67 and Aurora B expression in seminomas. Values are reported as percentage of immunopositive cells.
(B) Spearman analysis of the relationship between Ki-67 and Aurora B.
Aurora B gene and spermatogenesis · P CHIEFFI and others 267
www.endocrinology.org Journal of Endocrinology (2004) 181, 263–270
In this study we have characterised the expression
and the localisation of Aurora B in the testis and have
demonstrated that mRNA and protein are present strongly
and specifically in mitotic mouse germinal and inter-
stitial cells, and absent in the meiotic and post-meiotic
lineage cells.
Testicular tumours are rare, comprising 2% of all cancers
in men; however, testicular cancer is the most common
malignancy aﬀecting males aged 20–35 years (Senturia
1987, Leendert et al. 1999). Because the molecular basis of
these cancers needs to be elucidated, identification of
cellular genes involved in testicular tumorigenesis could
Figure 5 (A) Localisation of the Aurora B protein in sections of normal human testis by
immunocytochemistry. Representative seminiferous tubules show staining in the spg and spc
whereas stromal cells and fibromyocytes (fm) are devoid of signal. Bar=75 m. (B) Paraffin-
embedded section of seminoma (seminoma #6) showing extensive immunoreactivity for Aurora B
protein. Bar=75 m. Insert: at high magnification note the presence of a clear signal in neoplastic
germ cells. Bar=25 m.
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increase our understanding of the development of testicu-
lar tumours, thus providing the basis for new targeted
therapies.
There are at least three Aurora–related kinases in
mammals, Aurora A (STK-15), Aurora B (AIM-1), and
Aurora C (STK-13). All three mammalian members of this
family are overexpressed in human cancer cells. Aurora A
(STK-15) has been found to be overexpressed in half of all
colorectal and breast cancers (mapped to 20q13) and it is
highly expressed in the meiotic testicular cells. Aurora A
(STK-15) is predominantly localised to centrosomes and
its overexpression is supposed to be related to multiple
centrosome production (Yanai et al. 1997, Bischoﬀ et al.
1998, Giet & Prigent 1999, Zhou et al. 1998). Aurora C
(STK-13) is also overexpressed in colorectal cancers
(Takahashi et al. 2000).
Overexpression of Aurora B (AIM-1) has been observed
in human neoplastic cell lines and in colorectal tumours
(Tatsuka et al. 1998, Katayama et al. 1999). Recently,
Aurora B has been shown to phosphorylate histone H3 at
Ser-10 during mitosis in vivo (Ota et al. 2002). Expression
of a kinase-negative form of Aurora B in Chinese hamster
embryo cells (CHE) suppresses mitotic phosphorylation of
histone H3 at Ser-10 (Terada et al. 1998). Mitotic phos-
phorylation of histone H3 at Ser-10 is critical for proper
chromosome condensation and segregation (Terada et al.
1998). This has been demonstrated in Tetrahymena by
abnormal chromosome segregation in a histone H3 mutant
unable to undergo Ser-10 phosphorylation (Wei et al.
1999). Recent experiments performed by Sassoni-Corsi
and coworkers clearly showed that Aurora B physically
interacts with the H3 tail (Crosio et al. 2002); these data
are of particular interest since the amino-terminal tail of
histone H3 is able to bind its mitotic kinase from Xenopus
egg extract (de la Barre et al. 2000). It has been clearly
demonstrated that Aurora B overexpression induces in-
creased mitotic H3 phosphorylation at Ser-10 (Ota et al.
2002), and phosphorylation imbalance induced by Aurora
B overexpression might explain the errors in cytokinesis
responsible for the appearance of multinuclear cells
(Tatsuka et al. 1998). It is noteworthy that a significant
overexpression of Aurora B has been observed in human
cancer cell lines and in colorectal tumours in these lesions
elevated expression was clearly observed in the neoplastic
mitotic cells and Aurora B expression levels were increased
as a function of Dukes’ stage. (Tatsuka et al. 1998,
Katayama et al. 1999)
In the present study, we show that Aurora B expression
is a consistent feature of human seminomas, where its
topological staining pattern is lost. The increase in Aurora
B expression showed a positive correlation with the Ki-67
protein. It is important to note that Aurora B-positive
staining in human seminomas does not completely overlap
with the expression of Ki-67. The expression of Ki-67
occurs in all phases of the cell cycle excluding G0;
therefore, Ki-67 immunostaining identifies all proliferat-
ing cells. Conversely, immunostaining against Aurora B
may be capable of identifying, with more specificity, those
cells progressing to G2/M, beyond the restriction point,
indicating that Aurora B staining could provide diﬀer-
ent biological and clinical information. However, further
experiments are required to assess the diﬀerent expression
of Aurora B and other proliferative markers.
Aurora B expression levels are regulated at both the
mRNA and protein levels, with maximal mRNA and
protein levels occuring during the G2/M phases (Terada
et al. 1998). This cyclical pattern of regulation is conserved
in cancer cells (Tatsuka et al. 1998). This indicates that the
eﬀects of Aurora B overexpression may be of critical
importance during the G2/M phases of the cell cycle. The
sequence of these events is essential for normal mitotic cell
division in spermatogenesis and clearly overexpression of
Aurora B may have implications for the abnormalities in
germ cell maturation, such as those that occur in testicular
cancer. Taken together, our data support a role for Aurora
B in testicular mitotic germ cell maturation and, possibly,
in the initiation and/or progression of testicular cancers.
In conclusion, we have shown that Aurora B expression
occurs during spematogonial proliferation; in addition,
expression of Aurora B is a consistent feature of human
seminomas. This observation is of clinical interest since
Aurora B might be a target for cancer treatment and may
serve as a prognostic marker.
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ONYX-015 Enhances Radiation-Induced Death of Human
Anaplastic Thyroid Carcinoma Cells
GIUSEPPE PORTELLA, ROBERTO PACELLI, SILVANA LIBERTINI, LAURA CELLA,
GIANCARLO VECCHIO, MARCO SALVATORE, AND ALFREDO FUSCO
Dipartimento di Biologia e Patologia Cellulare e Molecolare (G.P., S.L., G.V., A.F.), Universita` di Napoli Federico II, Istituto
di Biostrutture e Bioimmagini Consiglio Nazionale delle Ricerche (R.P., L.C.), and Dipartimento di Diagnostica per
Immagini e Radioterapia (M.S.), Universita` di Napoli Federico II, 80131 Naples
ONYX-015 is a genetically modified adenovirus with a deletion
of the E1B early gene and therefore is designed to replicate
preferentially in p53-mutated cells causing their death. We
previously demonstrated that the ONYX-015 virus kills ana-
plastic thyroid carcinoma (ATC) cells and enhances the anti-
neoplastic effects of doxorubicin and paclitaxel. Here we
report that ONYX-015 increased the cytopathic effect of ra-
diotherapy in three ATC cell lines. In fact, ONYX-015 and
radiation induced a significant cytopathic effect on ATC cells.
DNA fragmentation analysis showed that ATC ONYX-015-
treated cells were very sensitive to radiation-induced apopto-
sis. In addition, low doses of ONYX-015 associated with a single
radiation dose of 10 Gy delayed the growth of a xenograft
tumor induced by ARO cells in athymic mice. Our results
suggest that the combination of ONYX-015 and radiotherapy
should be considered for experimental trials in patients with
anaplastic thyroid carcinoma. (J Clin Endocrinol Metab 88:
5027–5032, 2003)
ANAPLASTIC THYROID CARCINOMA (ATC) ac-counts for about 2% of all human thyroid neoplasias
(1, 2) and, being resistant to conventional antineoplastic ther-
apy (3), it is one of the most lethal human neoplasms. ONYX-
015 is an attenuated adenovirus that does not replicate ef-
ficiently in cells bearing a normal p53 gene; however, it
replicates efficiently in tumor cells that lack either functional
p53 or p14 Arf, so causing their death (4–6). Because mu-
tations in the p53 gene are a feature of ATC (7–12), ONYX-015
seems a prime candidate as an antineoplastic agent in this
type of tumor. The ONYX-015 virus has already been tested
in phase II and III clinical trials for the treatment of squamous
cell cancers of the head and neck (13, 14), in phase I and II
trials for primary and secondary liver tumors (15–17), and in
a phase I trial for primary carcinoma of the pancreas (18).
We previously showed that the ONYX-015 virus kills ATC
cells and reduces the growth of ATC tumor xenografts (19).
We also showed that ONYX-015 enhances the antineoplastic
effects of doxorubicin and paclitaxel in ATC cells. These
results suggested that ONYX-015 might be envisaged for the
treatment of ATC. However, although the ONYX-015 virus
has proven to be biologically active and safe in cancer pa-
tients (20), it is unlikely to be effective as monotherapy be-
cause few cancers are cured with a single agent. For example,
treatment with ONYX-015, cisplatin, and 5-fluorouracil re-
sulted in a higher number of complete responses vs. ONYX-
015 alone in patients with head and neck cancer (13). In
addition, ONYX-015 enhanced the effect of standard che-
motherapy in primary lung cancer cells and in nude mice
human tumor xenografts (21, 22).
The aim of our study was to investigate the effect of
ONYX-015 plus radiotherapy, which is frequently used to
control local tumor growth, on the proliferation of human
ATC cell lines. Here we report that ONYX-015 therapy en-
hanced radiation-induced cell death. The combination of
ONYX-015 and radiotherapy also significantly delayed the
growth of xenograft tumors induced in athymic mice by the
injection of ATC cells.
Materials and Methods
Viruses
ONYX-015 (a gift from Dr. A. Balmain, University of California San
Francisco Cancer Center and Cancer Research Institute, San Francisco,
California; and Dr. I. Ganly, Cancer Research UK Beatson Laboratories,
Bearsden, UK) is a chimeric human group C adenovirus (Ad2 and Ad5)
that has a deletion between nucleotides 2496 and 3323 in the E1B region
that encodes the 55-kDa protein. In addition, there is a C to T transition
at position 2022 in region E1B that generates a stop codon at the third
codon of the protein. These alterations prevent the expression of the
55-kDa protein in ONYX-015-infected cells (4).
Ad5 CMV lacZ (Quantum Biotechnology, Carlsbad, CA) is a non-
replicating E1-deleted adenovirus in which the reporter construct lacZ
has been inserted in the E1 region under the control of the cytomega-
lovirus (CMV) promoter. We used the Ad5 CMV lacZ adenovirus as a
control in clonogenic assays and in vivo experiments. Viral stocks were
expanded in the human embryonic kidney 293 cell line, which expresses
the E1 region of Ad2, and purified, as previously reported (19). Stocks
were stored at 70 C after the addition of glycerol to a concentration of
50% vol/vol. Virus titer was determined by plaque-forming units (pfu)
on the human embryonic kidney 293 cells.
Cell lines
ARO (23) and FRO (8), human thyroid anaplastic carcinoma cell
lines, were obtained by Dr. G. Juillard (University of California Los
Angeles); ARO and FRO cell lines are a kind gift of Prof. J. A. Fagin
(University of Cincinnati College of Medicine, Cincinnati, OH); and
KAT-4 (24) cells were obtained from Dr. K. B. Ain (University of
Kentucky, Lexington, KY). Cells were grown in DMEM supple-
mented with 10% fetal calf serum and ampicillin/streptomycin.
ARO and KAT-4 harbor a mutated p53 gene, i.e. 273 Arg-His,
Abbreviations: ATC, Anaplastic thyroid carcinoma; CMV, cytomeg-
alovirus; MOI, multiplicity of infection; pfu, plaque-forming units.
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whereas FRO cells express very low levels of p53 but do not have a p53
gene mutation (19).
Clonogenic assay
Cells were seeded at a density of 2 105 in 60-mm plates and infected
with ONYX-015 or with a nonreplicating E1-deleted adenovirus with the
lac Z reporter construct (Ad5 CMV lacZ virus) at multiplicity of infection
(MOI) of 0.1 and 0.5 per cell for ARO, 0.5 and 1 per cell for KAT-4 cell
line. FRO cell line was infected with a MOI of 0.5 and 2.5. An uninfected
dish was used as a control. Cells were harvested 24 h later, plated at a
density of 200 cells/plate (three replicates), and irradiated at a dose of
2, 4, or 6 Gy. Cells were incubated for 12 d to allow colony formation
to occur. The colonies were stained with crystal violet, and colonies
constituted by more than 40 cells were counted. The mean colony count
in the three different plates per MOI, Gy dose, and both was calculated
and expressed relative to the uninfected and untreated control. The
results shown are the average of three different experiments
DNA fragmentation
To analyze the time dependency of apoptotic DNA fragmentation,
ARO cells were plated in 96-well plates (1 103 in 100-l medium) and
treated with ONYX-015 (0.1 or 0.5 pfu/cell), radiation, or both. Cells
were left for 48 h and then lysed. Apoptosis was measured in triplicate
samples using the Cell Death Detection ELISA plus kit (Roche, Mann-
heim, Germany). This photometric sandwich enzyme-immunoassay de-
termines cytoplasmic histone-associated DNA fragments (mono and
oligo nucleosomes) upon induction of cell death. Briefly, a mixture of
biotin-labeled antihistone and peroxidase-conjugated anti-DNA anti-
bodies was added to the cell lysates and placed in a streptavidin-coated
microtiter plate. During incubation, the antihistone antibody binds to the
histone-competent apoptotic nucleosomes and links the immunocom-
plex to the streptavidin-coated plates via its biotinylation. The amount
of nucleosomes by peroxidase activity was determined spectrophoto-
metrically at 405 nm with 2,2-azino-bis(3-ethylbenzthiazoline-6-sulfonic
acid) as a substrate (Microplate reader, Bio-Rad, Munich, Germany).
Results were expressed as relative amounts of apoptosis, being the
results of the negative control equalized to 1.
Tumorigenicity assay
All experiments were performed with 6-wk-old male athymic mice
(Charles River, Calco, Lecco, Italy). ARO cells (5 105) were injected into
the right flank of 60 athymic mice. After 15 d, the animals were divided
into four groups (15 animals/group), and tumor volume was evaluated.
ONYX-015 (5  106 pfu) was injected in the peritumoral area in two
groups for a consecutive 4 d. On d 5, at the end of viral treatment, a
control group and a virus-treated group were anesthetized, and a single
radiation dose of 10 Gy was administered on the tumor volume at a
distance of 80 cm with a bolus interposition to avoid lower doses at the
tumor external edge. Tumor diameters were measured with calipers
every second day by two blind and neutral observers until the animals
were killed. No mouse showed signs of wasting or other indications of
toxicity.
Tumor volumes (V) were calculated with the rotational ellipsoid
formula: V  A  B2/2 (A, axial diameter; B, rotational diameter).
The same schedule was used for a control experiment with the rep-
lication-defective virus Ad5 CMV lacZ virus. Briefly, 40 athymic mice
were inoculated sc with 1 106 ARO cells, and 15 d later, when tumors
became detectable, 5  106 pfu of Ad5 CMV lacZ virus were injected
peritumorally for a consecutive 4 d in 20 animals. Ten animals treated
with Ad5 CMV lacZ virus and 10 untreated animals were then irradiated
with a single dose of 10 Gy.
All mice were maintained at the Dipartimento di Biologia e Patologia
Animal Facility. The animal experimentations described herein were
conducted in accordance with accepted standards of animal care and in
accordance with the Italian regulations for the welfare of animals used
in studies of experimental neoplasia, and the study was approved by our
institutional committee on animal care.
FIG. 1. ONYX-015 and radiation induced cell killing of human ana-
plastic thyroid carcinoma cell lines. ARO cells were infected with a
MOI of 0.1 and 0.5 per cell, KAT-4 with a MOI of 0.5 and 1 per cell.
FRO cell line was infected with a MOI of 0.5 and 2.5 per cell. After 24 h
cells were irradiated with 2, 4, or 6 Gy. Control cells were irradiated
at the indicated doses. Cells were incubated for 12 d to allow colony
formation to occur, and colonies greater than 40 cells were counted.
A, Clonogenic survival of ARO cells treated with ONYX and radiation.
B, Clonogenic survival of FRO cells treated with ONYX and radiation.
C, Clonogenic survival of KAT-4 cells treated with ONYX and radi-
ation. Data are presented as mean  SE of three replicate cultures.
The lines are statistically significant bi-exponential fit.
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Statistical analysis
Comparison among different treatment groups in the experiments
was made by the ANOVA method and the Dunnett’s post hoc test using
a commercial software (SPSS Inc., Chicago, IL). For each cell line, com-
parison among cell survivals at different doses was made using ONYX-
015 concentration as the grouping variable. Assessment of differences
among rate of tumor growth in mice was made for each time point of
the observation period; treatment groups were control, ONYX-015, ra-
diotherapy, and ONYX-015  radiotherapy.
Results
ONYX-015 increases the radiation-induced death of human
thyroid anaplastic carcinoma cells
To evaluate the efficacy of ONYX-015 combined with ra-
diation treatment, three ATC-derived human cell lines (ARO,
KAT-4, and FRO) were used. ARO cells were infected with
a MOI of 0.1 and 0.5 per cell, KAT-4 with a MOI of 0.5 and
1 per cell. FRO cell line was infected with a MOI of 0.5 and
2.5 per cell.
Twenty-four hours later, cells were irradiated with differ-
ent doses (2, 4, or 6 Gy), and the cytotoxicity and the syn-
ergistic effects were evaluated. At these doses, radiation does
not affect ONYX-015 DNA replication or DNA integrity. In
fact, even a dose as high as 20 Gy does not alter virus integrity
(25). A MOI of 1 or 2.5 was required to obtain an adjuvant
effect of ONYX-015 on FRO cells. This is consistent with our
previous finding that FRO cells are more resistant than ARO
cells to adenovirus infection (19). However, in this previous
study FRO cells were treated with 10 pfu/cell of ONYX-015
for 7 d, and a viability assay was used to assess the effects of
the treatment yielding a survival fraction of about 90%. In the
present study, FRO cells yield a survival fraction 55% at 2.5
pfu/cell of ONYX-015. The different treatment time and the
different methods used to assess the effect of the replicating
virus ONYX-015 can explain the discrepancy between these
studies.
ONYX-015 enhanced the cytopathic effects of radiother-
apy in all cell lines tested (Fig. 1). This enhancement was
statistically significant at the doses of 2, 4, and 6 Gy for ARO
cells (Dunnett’s post hoc test, P 0.01) with a MOI of 0.5, and
for FRO cells (Dunnett’s post hoc test, P  0.05) with a MOI
of 2.5. For KAT-4 cells a significant effect (Dunnett’s post hoc
test, P  0.05) was observed at a dose of 6 Gy with a MOI of
1.0. In particular, the enhancement factor for a radiation-
induced clonogenic inhibition of 50% in ARO cells pretreated
with 0.1 pfu/cell of ONYX-015 was 1.55. Conversely, infec-
tion with a replication-defective virus bearing deletions of
E1A and E1B that contains a lacZ reporter gene does not
induce any significant additive or synergistic effects upon
radiation treatment (Table 1). These results indicate that
ONYX-015 could be used in association with radiotherapy to
treat ATC because low viral concentration results in signif-
icant cell killing upon radiation.
DNA fragmentation of human thyroid anaplastic carcinoma
cells infected with ONYX-015 and irradiated
We evaluated the capability of ONYX-015 to induce ap-
optosis in irradiated ATC cells using an ELISA-based assay
to measure cytosolic apoptotic nucleosomes. ARO cells were
infected with 0.1 or 0.5 pfu/cell of ONYX-015, and 24 h later
the cells were irradiated with 2 Gy. Cells were left for 48 h
and then lysed. The infection of ARO cells with 0.1 or 0.5
pfu/cell of ONYX-015 greatly increased the DNA fragmen-
tation of ARO with respect of untreated or not infected con-
trol cells (Fig. 2).
Reduced growth of tumor xenografts of ATC cells treated
with ONYX-015 and irradiated
To evaluate whether radiation treatment had a synergistic
effect with ONYX-015 also in vivo, we inoculated 60 athymic
mice sc with 5 105 ARO cells, and 15 d later, when tumors
became detectable, animals were randomly assigned to four
groups. Two groups were injected with 5 106 pfu of ONYX-
015 peritumorally for a consecutive 4 d. One group not
treated with ONYX-015 and one group treated with ONYX-
015 were then irradiated with a single dose of 10 Gy. Tumor
growth was then followed. In Fig. 3 tumor growth is ex-
pressed as a percentage of growth relative to the volume
observed at radiation (T 0). As expected, in the group that
received either ONYX-015 or radiation only, tumor growth
was not significantly inhibited compared with the control
group (Dunnett’s post hoc test, P 0.1). Only the combination
of ONYX-015 viral plus radiation therapy significantly de-
layed tumor growth compared with the control (Dunnett’s
post hoc test, P  0.05).Conversely, the combination of Ad5
CMV lacZ plus a single dose of 10 Gy did not significantly
delay tumor growth (Fig. 4).
Discussion
ATC is one of the most aggressive solid tumors, and pa-
tients with ATC have a very poor prognosis (3, 26). Conse-
quently, several novel therapeutic approaches have been
proposed. Manumycin, a farnesyl:protein transferase inhib-
itor, has proved to be effective against ATC cells alone and
in combination with paclitaxel (27, 28). Moreover, there is
evidence that suppression of HMGA1 protein synthesis leads
to ATC cell death (29). More recently, we found that the
replication defective ONYX-015 virus is highly efficient in
TABLE 1. Effects of infection of ATC cells with Ad5 CMV lacZ, an adenovirus lacking E1A and E1B regions, and radiation
Cell line Untreated Ad5 lacZ 2 Gy Ad5 lacZ/2 Gy 4 Gy Ad5 lacZ/4 Gy 6 Gy Ad5 lacZ/6 Gy
ARO 285  21 267  27 215  26 204  31 175  28 160  19 110  13 94  11
KAT-4 305  32 292  28 273  33 280  27 215  31 196  25 138  17 125  23
FRO 324  35 305  28 286  29 295  32 210  22 219  28 157  21 146  19
ARO and KAT-4 cells were infected with a replication-defective virus at an MOI of 0.5 pfu/cell, whereas FRO cells were infected at an MOI
of 2.5 pfu/cell. After 24 h, cells were irradiated with 2, 4, or 6 Gy and incubated for 12 d to allow colony formation to occur. Control cells were
irradiated at the indicated doses. The total number of colonies obtained are indicated. No additive or synergistic effects of Ad5 CMV lacZ virus
and radiation were observed on the different cell lines.
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killing human ATC cell lines either alone or in combination
with doxorubicin and paclitaxel (19), and that this effect
results from impairment of p53 function, which is a general
feature of ATC cells (7–11).
The ONYX-015 plus radiation combination was used in a
human colon carcinoma cell line carrying a wt p53 gene
(RKO) and in a subclone that expresses an inactivating mu-
tation of p53 gene (RKO p53.13). In this study, the authors
have shown that ONYX-015 exerted a neoadjuvant effect to
radiation against xenograft induced by the cell line carrying
a mutant p53 gene (25). These findings prompted us to eval-
uate the effects of combined ONYX-015/radiation treatment
on ATC cells.
Here, we report that ONYX-015 at a low MOI is an effective
neoadjuvant to radiotherapy in ATC treatment. Our finding
confirms that ONYX-015 could be beneficial in the treatment
of this very aggressive disease. We found that very low viral
concentrations (from 0.1–2.5 MOI), which are suitable for the
clinical setting, enhanced the radiation-induced killing of
ATC cells. Moreover, low doses of ONYX-015 associated
FIG. 2. DNA fragmentation of ARO
thyroid anaplastic carcinoma cells in-
fected with ONYX-015 and irradiated.
ARO carcinoma cells were treated with
ONYX-015 (0.1 or 0.5 pfu/cell) and ir-
radiated. DNA fragmentation was mea-
sured after 48 h. Results are the
means  SD of duplicate determina-
tions of three independent experi-
ments. Results were expressed as rel-
ative amounts of apoptosis, being the
results of the negative control equal-
ized to 1.
FIG. 3. Tumor growth delay induced by ONYX-015 and
radiation. A, Relative tumor growth of animals treated with
ONYX-015 and radiation, and control groups. Data are
presented as mean SE. B, Representative tumors excised
from mice after treatment: 1) control; 2) 5 106 pfu ONYX-
015; 3) 10 Gy radiotherapy; and 4) 5 106 pfu of ONYX-015
and 10 Gy radiotherapy. RT, Radiotherapy.
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with a single 10 Gy dose of radiation drastically delayed the
growth of established xenograft tumors in athymic mice.
Conversely, infection of ATC cells with Ad5 CMV lacZ virus,
a replication-defective virus bearing deleted E1A and E1B
sequences and treated with various doses of radiation, did
not have any additive or synergistic cell killing; furthermore
Ad5 CMV lacZ virus associated with a single 10 Gy dose of
radiation was not able to delay the growth of established
xenograft tumors in athymic mice. Consequently, the anti-
neoplastic effects reported herein are specific for ONYX-015.
A DNA fragmentation assay showed that ATC ONYX-
015-treated cells were very sensitive to radiation-induced
apoptosis, which explains the synergistic effects observed in
this study. The enhanced sensitivity to antineoplastic drugs
or radiation observed in ONYX-015-infected cells has been
attributed to the expression of E1A (30). Ad5 E1A expression
has been shown to sensitize cells to radiotherapy and anti-
cancer agents by inducing apoptosis (31–34), and E1A me-
diates apoptosis by inducing p53 accumulation (35, 36).
However, E1A per se is sufficient to induce apoptosis regard-
less of p53 (36). Further experiments are required to elucidate
how ONYX-015 and radiation activate apoptosis in ATC
cells.
The necessity for p53 pathways to be nonfunctional in
order for ONYX-015 replication to occur is an ongoing con-
troversy. Despite the original design of the virus as selec-
tively replication-competent only in p53-deficient cells, there
are several reports indicating that the ONYX-015 virus is
capable of replicating in p53 wild-type cells (37, 38). How-
ever, inactivation of the p53 pathway can be induced by
changes in other components of the pathway, such as
p14ARF or MDM2, and these alterations are functional sur-
rogates for p53 mutation. Recently, in abdominal wall im-
plants from a primary gall bladder carcinoma injected with
ONYX-015, replication of the virus has been observed, not
only in tumor cells, but in adjacent stromal cells presumably
normal and bearing 53 wild type (39). Further studies are
required to clarify whether these cells represented tumor cell
variants or normal stromal cells, and the p53 status of these
cells needs to be assessed.
The treatment of advanced or recurrent ATC is complex
because the tumor invades the trachea and causes death by
asphyxiation. Monotherapy usually fails to control local and
regional ATC, and a multidisciplinary strategy consisting of
surgery, chemotherapy, and radiotherapy is preferred (26).
Clinical trials indicate that treatment with ONYX-015 helps
to control locally aggressive neoplasms. Moreover, ONYX-
015 administered iv has been found to be clinically safe and
effective (20). Therefore, we propose that our results indicate
that ONYX-015 plus radiation should be attempted to control
local and regional ATC without increasing the toxic effects
of radiation.
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